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 This pilot study assessed tolerance of different volumes of processed 
tomato juice consumed daily and its impact on serum lycopene, selected serum 
inflammatory mediator levels and radiation-induced side effects in men with 
localized prostate cancer undergoing radiation therapy. Participants (n = 17) 
were randomized into control group or one of three intervention groups (4 oz, 8 
oz or 12 oz of processed tomato juice daily). Non-Hispanic Whites comprised 
71% of study participants. Tumor staging ranged from T1c-2cN0M0, with 71% of 
participant tumors in the T1cN0M0 stage.  
Participants tolerated daily tomato juice supplementation without any 
adverse gastrointestinal (GI) effects. Serum lycopene decreased in control group 
participants, while increasing from 0.33±0.11 μg/mL (baseline) to 0.41± 0.12 
μg/mL (endpoint) in the intervention group.  No correlation between serum and 
dietary lycopene was detected. Control group participants lost weight, while 
participants in the intervention groups did not. Not surprisingly, participants 
exhibited systemic inflammation at baseline. Overtime, increased c-reactive 
protein (CRP) and interleukin-6 (IL-6) was observed in control group, while 
decreases in serum CRP, IL-6 and prostaglandin E2 (PGE2) levels were 
observed in intervention groups (p>0.05). No statistically significant within group 
differences were detected for CRP.  Within group differences were statistically 
significant for 12 oz group only, when comparing baseline and endpoint with 
midpoint levels (p = 0.014) for IL-6, and when comparing PGE2 baseline levels 
with midpoint and endpoint (p = 0.003).  
We observed no statistical correlation between inflammatory markers, 
cancer characteristics and dietary or serum lycopene, or acute side effects of 
treatment. Lower performance score was observed in intervention group 
participants. Daily tomato juice intake appeared to offer a GI protective effect 
during the first three weeks of treatment. Based on the results of this study, daily 
consumption of processed tomato juice (at least 8-12 oz) may decrease serum 
levels of CRP, IL-6 and PGE2; lower performance status score; and offer a 
protective GI effect during radiotherapy for prostate cancer. This information may 
assist in improving patient tolerance and minimize acute side-effects of radiation 
therapy in men with localized prostate cancer undergoing intensity modulated 
radiation therapy. 
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CHAPTER I 
 
INTRODUCTION 
 
 
 Chronic inflammation is now recognized as one causative mechanism in 
carcinogenesis (Colotta, Allavena, Sica, Garlanda, & Mantovani, 2009; 
Mantovani, Allavena, Sica, & Balkwill, 2008), contributing to about 20% of all 
cancers (De Marzo et al., 2007). The presence of inflammatory cells and 
mediators such as cytokines and prostaglandins in tumor tissue is considered a 
“hallmark” of cancer-related inflammation (Mantovani, et al., 2008). In addition to 
generating reactive oxygen (ROS) and nitrogen species (RNS), inflammation 
also activates several pro-inflammatory cytokines (such as tumor necrosis factor-
α (TNF- α), interleukin-6 (IL-6), IL-1β) which further increase cancer risk by 
inducing enzymes that produce more ROS/RNS (Ohshima, Tatemichi, & Sawa, 
2003). Additionally, cancer treatments, specifically radiation therapy may also 
induce inflammation (McBride et al., 2004). Researchers have reported 
upregulation of proinflammatory cytokines (TNF- α, IL-6, IL-1β) during and after 
treatment, contributing to fatigue (Bower, 2007) and impacting quality of life.  
 Prostate cancer is the most commonly diagnosed cancer among men 
("Cancer Facts and Figures 2010," 2010), and inflammation has been identified 
as one causative factor (De Marzo, et al., 2007; Wong, Bray, & Ho, 2009). Cell 
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and animal studies have demonstrated upregulation of several cytokines and 
inflammatory enzymes in prostate carcinogenesis (Fujita et al., 2002).   
Researchers have also documented upregulation of several inflammatory 
mediators during radiation therapy for prostate cancer in men (Christensen et al., 
2009; Johnke et al., 2009).  
 Nutritional modulation for chemoprevention is not a new concept. 
Consumption of phytonutrients such as lycopene, have been associated with a 
decreased incidence of prostate cancer in epidemiological studies (Giovannucci, 
1999, 2002). Several cell (Hwang & Bowen, 2004; Ivanov et al., 2007; Kanagaraj 
et al., 2007; L. Kim, Rao, & Rao, 2002) and animal studies (Guttenplan et al., 
2001; Konijeti et al., 2010) and clinical trials in men at risk for developing prostate 
cancer (Bunker et al., 2007; Edinger & Koff, 2006; Mohanty, Saxena, Singh, 
Goyal, & Arora, 2005; Schwarz et al., 2008) have demonstrated a 
chemopreventive role of lycopene. Researchers have also evaluated the benefits 
of lycopene in prostate cancer patients prior to initiating treatment (Jatoi et al., 
2007; H. Kim et al., 2003; Kucuk et al., 2001) or after failure of treatment (Clark 
et al., 2006). Clinical trials have demonstrated a decline in serum prostate 
specific antigen (PSA) level, tumor bulk, and inflammation, and an increase in 
serum lycopene levels with lycopene supplementation. However, the impact of 
lycopene supplementation during radiation treatment for prostate cancer and its 
impact on biomarkers, physical side effects and quality of life remain unknown. 
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 The long-term goal of this project was to increase our understanding of 
lycopene supplementation during radiotherapy for prostate cancer, to minimize 
side effects, evaluate biomarker responses, and develop specific guidelines for 
lycopene intake during radiation therapy. The objectives of this project were to 
assess tolerance of an orally ingested food source of lycopene (tomato juice) 
during radiotherapy for prostate cancer, impact of lycopene supplementation on 
serum lycopene levels, radiotherapy-related side effects, and select inflammatory 
markers. The patient population for this study was newly diagnosed patients with 
non-metastasized prostate cancer who had not received prior treatment and who 
were scheduled to receive radiotherapy to the prostate gland (treatment volume 
to include prostate and seminal vesicles). The central hypothesis was that tomato 
juice supplementation during radiotherapy will increase serum lycopene levels 
and minimize inflammatory response and radiation therapy-related side effects.  
The dissertation design is presented in Figure 1.1.  
 The rationale for this project was that knowledge of the impact of lycopene 
supplementation during radiation treatment in prostate cancer patients will 
provide important insights about a potential method to reduce side effects 
associated with radiotherapy in prostate cancer patients. Overall this project had 
the following three specific aims.  
Aim 1 
  To examine the impact of supplementing three different volumes (4 oz, 8 
oz, 12 oz) of tomato juice on serum lycopene levels in men with prostate cancer 
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undergoing radiation therapy. We also quantified dietary lycopene intake using a 
validated food frequency questionnaire (National Cancer Institute’s Diet History 
Questionnaire (NCI-DHQ)).  
Hypothesis: A dose-dependent response will be observed with tomato juice 
supplementation, with an increase in serum lycopene levels in the intervention 
groups. To test this hypothesis, we evaluated the effectiveness of three different 
doses of tomato juice on serum lycopene levels, which were measured using a 
liquid chromatography-mass spectrometry (LC-MS) analysis at Dr. Wei Jia’s 
laboratory in Kannapolis, NC. We administered the NCI-DHQ once during this 
study to determine frequency of consumption of lycopene rich foods among the 
participants. We also used the NCI-common toxicity criteria (CTC) to evaluate if 
any participants suffered from gastro-intestinal (nausea, vomiting, heartburn) side 
effects as a result of tomato juice consumption. 
Aim 2 
 Evaluate serum levels of select inflammatory mediators (c-reactive protein 
(CRP), prostaglandin E2 (PGE2), TNF-α, and IL-6) in men with prostate cancer 
prior to initiating radiation therapy and then at midpoint and endpoints along with 
supplementation of three different volumes of tomato juice.  
Hypothesis: A dose-dependent decrease in serum inflammatory biomarkers will 
be observed with tomato juice supplementation.  
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To test this hypothesis, we evaluated the impact of three different doses of 
tomato juice on serum CRP, TNF-α, IL-6 and PGE2 levels. Traditional enzyme-
linked immunosorbent assay (ELISA) tests were conducted to analyze the serum 
for the presence of CRP, TNF-α, IL-6 and PGE2 at three different time points. 
Aim 3 
 Evaluate the time of onset and severity of select side effects (urinary 
frequency and urgency, proctitis, and diarrhea) of radiation therapy in the control 
group and three treatment groups. We also wanted to evaluate if the cytokine 
response was predictive of radiation therapy symptoms. 
Hypothesis: A dose-dependent response will be observed with tomato juice 
supplementation, with delayed onset and decreased severity of side effects, and 
improvement or maintenance of the patient’s performance score. To test this 
hypothesis, we evaluated the effectiveness of three different doses of tomato 
juice on performance status (measured using the Eastern Cooperative Oncology 
Group (ECOG) Scoring), the time of onset and severity of urinary frequency and 
urgency, proctitis, and diarrhea. The symptom severity was measured using the 
NCI common terminology criteria for adverse events (CTCAE). 
 The research population (men with prostate cancer undergoing radiation 
therapy) and phytonutrient (lycopene/tomato juice) supplementation were based 
on the identified research gaps (Davis et al., 2005). However, the implication of 
inflammatory mediator involvement was extrapolated from literature reviews of 
6 
 
patients undergoing radiation therapy to the pelvis and lungs. Researchers have 
since demonstrated serum/plasma cytokine expression in men with prostate 
cancer undergoing radiation therapy (Christensen, et al., 2009; Johnke, et al., 
2009). 
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Figure 1.1. Flow diagram representing recruitment and randomization of study 
participants 
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CHAPTER II 
 
REVIEW OF THE LITERATURE 
 
 
Prostate Cancer 
 Prostate cancer has the dubious distinction of being the most commonly 
diagnosed cancer among men in the United States.  In 2010, the American 
Cancer Society projected 217,730 new cases and of these, 6910 new cases 
were expected in North Carolina. Incidence of prostate cancer is highest among 
African American men. Prostate cancer is detected by PSA blood test and digital 
rectal exam, with final confirmation obtained with a prostate biopsy ("Cancer 
Facts and Figures 2010," 2010).  In addition to ethnicity, age and family history 
(De Marzo et al., 2007), patients with high-grade prostatic intraepithelial 
neoplasia (HGPIN), genetic variants (such as SNP, CYP3A4, ELAC2, SRD5A2, 
etc), and elevated biochemical risk factors (e.g., Prostate Specific Antigen (PSA) 
and/or Insulin like Growth Factor-1) are also considered at a higher risk for 
developing prostate cancer (Lieberman, 2001).  Chronic inflammation has also 
been implicated in the development of prostate cancer (De Marzo, et al., 2007; 
Rebbeck et al., 2008).  
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Inflammation and Prostate Cancer 
 Inflammation, a natural physiological process, initiated in response to 
injury as a result of infections (Philip, Rowley, & Schreiber, 2004; Sgambato & 
Cittadini, 2010) and environmental factors (Grivennikov, Greten, & Karin, 2010), 
has been implicated in the development of more than 20% of all human cancers, 
including prostate cancer (Bardia, Platz, Yegnasubramanian, De Marzo, & 
Nelson, 2009; De Marzo, et al., 2007; Kirschenbaum, Liu, Yao, & Levine, 2001).  
Epidemiologic, histopathologic and molecular pathological studies have provided 
evidence to implicate inflammation in prostate carcinogenesis (De Marzo, et al., 
2007). Intraprostatic inflammation may be caused by infection, cellular injury, 
hormonal exposure and/or dietary factors, and direct injury to the prostate 
epithelium from chronic exposure to these noxious stimuli may lead to 
proliferative inflammatory atrophy (PIA) or proliferative atrophy (De Marzo, et al., 
2007). PIA lesions may transition to PIN, and HGPIN is considered a precursor 
for prostate carcinogenesis (Wagenlehner et al., 2007). Tissue samples obtained 
from patients with benign prostate hyperplasia (BPH) have shown the presence 
of significantly high chronic inflammatory cells and atrophic epithelium indicating 
the presence of PIA (De Marzo, et al., 2007).  A higher risk of developing 
prostate cancer has been reported in the presence of increased levels of 
inflammatory cytokines and chemokines in the prostate (Haverkamp, 
Charbonneau, & Ratliff, 2008). Researchers have demonstrated a decreased risk 
(21% lower) of developing prostate cancer in current and long-term users of 
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asprin, further linking inflammation in the development of prostate cancer 
(Salinas et al., 2010).  Tables 2.1 - 2.3 summarize the cell/animal studies and 
human clinical trials documenting the association of inflammation in prostate 
pathologies. 
Inflammatory Markers:  
 Key mediators of inflammation that were investigated in this study are 
briefly reviewed below: 
 Interleukin-6: Interleukin-6 (IL-6) is a plieotropic pro-inflammatory 
cytokine produced by leukocytes, fibroblasts and endothelial cells (Lamprecht, 
Oettl, Schwaberger, Hofmann, & Greilberger, 2007). IL-6 is involved in regulating 
several key cellular functions such as immune function, acute phase response, 
inflammation, oncogenesis (Song & Kellum, 2005), proliferation, differentiation, 
apoptosis and angiogenesis (Culig, Steiner, Bartsch, & Hobisch, 2005). IL-6 is 
considered a prognostic indicator for prostate cancer development and has been 
shown to correlate with stages of prostate cancer (Wertz, Siler, & Goralczyk, 
2004).  While IL-6 is localized to the basal epithelial cells in the normal prostate, 
in BPH it has been reported to be localized in the stromal and luminal epithelial 
cells (Royuela et al., 2004). Acting as an autocrine growth factor, IL-6 has been 
reported to be a key player in the stromal growth in BPH (Kramer, Mitteregger, & 
Marberger, 2007). Poor outcomes have been reported with elevated IL-6 levels in 
patients with prostate and other cancers (König, Senge, Allhoff, & König, 2004).   
16 
 
Researchers hypothesize that IL-6 may stimulate the growth of prostate 
cancer cells and cause progression of the disease through increased IL-6 
production (Nakashima et al., 2000).  An 18 fold increase in the concentration of 
IL-6 has been reported in localized prostate cancer compared to normal prostate 
tissue (Steiner et al., 2004). IL-6 has also been reported to upregulate the 
expression of COX-2 and PGE2 in a human PIN cell line and has a reciprocal 
and synergistic effect with COX-2/PGE2 on the growth of human PIN cells (X.-H. 
Liu et al., 2002). More recently researchers have demonstrated upregulation of 
IL-6 in men with prostate cancer undergoing radiation therapy (Christensen et al., 
2009; Johnke et al., 2009). Diminished IL-6 expression has been reported in 
prostate tumors with lycopene supplementation (Wertz, et al., 2004). Figure 2.1 
illustrates the cascade of events ascribed to IL-6 as discussed by several 
researchers (Christensen, et al., 2009; Helzlsouer, Erlinger, & Platz, 2006; 
Kuroda et al., 2007; Nakashima, et al., 2000; Steuber, Helo, & Lilja, 2007; Twillie 
et al., 1995).   
 C-Reactive Protein:  C-reactive protein (CRP), an acute phase protein 
(Ford, Liu, Mannino, Giles, & Smith, 2003; Helzlsouer, et al., 2006; Lehrer et al., 
2005), is a sensitive, yet non-specific marker of inflammation and is elevated in 
several diseases and disorders such as obesity, trauma, infection, diabetes and 
cancer (Walsh, Mahmoud, & Barna, 2003). CRP elevation in cancer patients may 
signify disease progression or recurrence (Walsh, et al., 2003).  Two of the most 
commonly measured biomarkers of inflammation in prostate cancer are IL-6 and 
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CRP (Bowen, 2005).  CRP levels are inversely associated with circulating levels 
of lycopene along with other carotenoids, retinoids and antioxidants (Ford, et al., 
2003; McMillan et al., 2002). 
 Tumor Necrosis Factor-α: Tumor necrosis factor-α (TNF-α), a pro-
inflammatory cytokine, is a paracrine and autocrine mediator (Danilko et al., 
2007) of systemic inflammatory and immune reactions, and is produced by 
leukocytes, endothelia and adipocytes (Lamprecht, et al., 2007). Normal serum 
values are reported to be between 0-8.1 pg/mL (Akmansu, Unsal, Bora, & Elbeg, 
2005). Chronic production of TNF may contribute to tumor promotion, leading to 
tissue remodeling and stromal development, ultimately contributing to tumor 
growth and metastasis (Wilson & Balkwill, 2002). TNF- α may trigger the 
inflammatory process by inducing the acute phase response along with 
increasing prostaglandin, leukotriene and collegenase synthesis (Huang, Ghai, & 
Ho, 2004). Acting as a macrophage and neutrophil activating factor, TNF- α 
triggers the synthesis of interleukin cascade, especially IL-1, IL-6, IL-8 and IL-10 
(Danilko, et al., 2007). Loss of androgen responsiveness has been linked with 
tumor cell TNF production in patients with prostate cancer (Balkwill & Mantovani, 
2001).  
 Prostaglandin: Prostaglandins (PGs) are lipid derivatives and regulate 
several physiological processes such as immune response, clotting, and platelet 
aggregation (Dubois et al., 1998; Williams, Mann, & DuBois, 1999). Action of 
cyclooxygenase (COX) enzyme on arachidonic acid leads to the production of 
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PGs (Keskek et al., 2006; Smyth, Grosser, Wang, Yu, & FitzGerald, 2009). COX-
1 and COX-2 , the two isoforms of COX are involved in PG synthesis (Keskek, et 
al., 2006).  While COX-1 is the constitutive isoform, COX-2 is the inducible form 
whose expression is induced by proinflammatory cytokines such as IL-1 and 
TNF-α (Keskek, et al., 2006).  PGs (PGE2, PGI2) generated via COX-2 are 
reported to be immunosuppressive (Williams, et al., 1999) and a key source of 
inflammation and inflammation related cancers (Smyth, et al., 2009). COX-2 is 
over expressed in several malignant conditions and may also be induced by 
radiation and chemotherapies. Therefore, decreasing expression of COX-2 may 
be potentially important in the prevention and treatment of these malignant 
conditions (Dorai & Aggarwal, 2004).  
 PGE2 is a key player in the immune suppression associated with 
inflammation and is secreted by several different cells including tumor cells, 
macrophages and monocytes (Ben-Baruch, 2006).  It is synthesized by 
cyclooxygenase -2 (COX-2), and together they show great potential as targets for 
cancer therapy (Ben-Baruch, 2006). COX-2 and PGE2 are over-expressed in 
both PIN and prostate cancer (Kirschenbaum, et al., 2001).  Liu et al (2002) 
demonstrated in a human PIN cell line that COX-2, PGE2 and IL-6 have a 
reciprocal and synergistic effect. PGE2 stimulates the release of soluble IL-6 
receptor and activates the STAT-3 signaling (X.-H. Liu, et al., 2002). 
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Radiation Therapy for Prostate Cancer  
 In prostate cancer, radiotherapy may be used as an independent therapy 
or in conjunction with surgery, chemotherapy, or hormone therapy (Samant & 
Gooi, 2005).  Radiotherapy is generally administered in small daily doses 
(fractions), five days a week over a period of several weeks (Samant & Gooi, 
2005; Withers, 1992). The number of treatments may vary based on factors such 
as organ being treated, patient condition, and size of the tumor (personal 
communication with radiation oncologist BF on September 12, 2007).  
Conventional radiation therapy has been available since the 1960’s and with the 
advent of technology, treatment dose has increased while the exposure to the 
normal tissue in close proximity to the tumor has decreased considerably 
(Duchesne, 2001). Intensity modulated radiation therapy (IMRT) can conform 
higher dose volumes as close to the tumor as possible (Duchesne, 2001). 
Despite this specificity of IMRT, non-cancerous tissues still get irradiated and 
physiological changes noted in patients are related to this low dose exposure 
(Okunieff, Chen, Maguire, & Huser, 2008). Thus, patients may develop acute or 
late intestinal radiation toxicity depending on the radiation dose, fractions and 
treatment time frame (Hovdenak, Fajardo, & Hauer-Jensen, 2000). 
 Radiation therapy leads to ionization of intracellular water, producing free 
radicals (Lewanski & Gullick, 2001; Prasad, Cole, Kumar, & Prasad, 2002), which 
results in DNA strand breaks and plasma membrane damage ultimately leading 
to cell death (Lewanski & Gullick, 2001). In addition to DNA damage, apoptosis, 
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necrosis and inactivation of the cell cycle are additional mechanisms through 
which radiation may cause cell death (Okunieff, et al., 2008).  While total body 
irradiation can have a significant immunosuppressive effect, loco-regional 
radiation therapy can also have a suppressive effect on the immune system 
(McBride et al., 2004).  Radiation therapy treatment has also been shown to 
induce inflammation and up-regulate PGE2 (Milas & Hanson, 1995; Steinauer et 
al., 2000).   
 Acute Side Effects During Pelvic Radiation Therapy: Radiation 
treatment related adverse effects occurring during or within three months of 
radiation treatment are considered acute and impact a patient’s quality of life 
(Hauer-Jensen, Wang, Boerma, Fu, & Denham, 2007).  Acute toxicity is 
observed frequently in tissues such as the skin and the gastrointestinal (GI) tract, 
that experience rapid cell proliferation (Mollà & Panés, 2007).  Radiation therapy 
destroys stem cells which prevents the functional cells lost during normal tissue 
turnover from being replaced (Mollà & Panés, 2007).  In addition to the GI 
toxicities, genitourinary (GU) toxicities are still the most commonly observed 
treatment related side effects among patients receiving pelvic radiation, and are 
dependent on the dose and volume of radiation delivered (Hovdenak, et al., 
2000; Teh et al., 2004), along with treatment time (Hovdenak et al., 2003) and its 
process of dissipation through the tissues (Andreyev, 2007).   
 Andreyev (2007) proposed that radiotherapy induced damage to the blood 
vessels may lead to ischemia and fibrosis, thus altering GI function by either 
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worsening pre-existing GI problems or creating new GI dysfunction depending on 
the affected site. Other researchers have proposed that acute toxicity in the 
intestines is secondary to damage to the epithelial cells leading to the breakdown 
of mucosal barrier and causing mucosal inflammation (Hauer-Jensen, et al., 
2007). Radiation-induced bowel damage may be evident in > 75% patients 
receiving pelvic radiotherapy (Cole, Slater, Sokal, & Hawkey, 1993).  Cole et. al 
(1993) demonstrated a significant increase in eicosanoid inflammatory mediators 
(such as leukotriene B4, thromboxane B2 and PGE2), implicating them in 
radiation-induced bowel inflammatory changes in patients receiving pelvis 
radiotherapy. Table 2.4 summarizes some of the cell and animal research 
studies reporting the upregulation of COX-2 in radiation induced bowel injury. 
Figure 2.2 represents the cascade of events reported during radiation therapy 
(Ben-Baruch, 2006; Cole, et al., 1993; Dorai & Aggarwal, 2004; Dubois, et al., 
1998; Kurzrock, 2001; Larsen et al., 2007; Steinauer, et al., 2000; Steuber, et al., 
2007; Wang, Bergh, & Damber, 2005; Williams, et al., 1999). 
Lycopene 
 
 Lycopene is a 40 carbon, lipid soluble, highly conjugated aliphatic 
hydrocarbon carotenoid responsible for the red color of some fruits and 
vegetables (Kun, Lule, & Xiao-Lin, 2006; A V Rao & Agarwal, 1999, 2000; A V 
Rao & Ali, 2007). Lycopene is not synthesized by animals, only microorganisms 
and plants (Agarwal & Rao, 2000).  The molecular formula for lycopene is C40H56, 
its molecular weight is 536.85 Daltons (Kun, et al., 2006; A V Rao & Agarwal, 
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1999; Shi & Maguer, 2000) and its melting point is 172-1750C (Shi & Maguer, 
2000).  Lycopene resides primarily within cell membranes and is hydrophobic 
(Clinton, 1998). It contains 11 conjugated and two nonconjugated double bonds 
(A. Liu et al., 2006) and has a half life of 2-3 days in the serum (Stahl & Sies, 
1992), and reaches maximum serum concentration within 15-48 hours of 
consuming lycopene rich foods (Gustin et al., 2004; Stahl & Sies, 1992). 
Lycopene is devoid of vitamin A activity due to the absence of the β-ionone ring 
(Clinton, 1998; Heber, 2004; Shi & Maguer, 2000).  
 Lycopene exists in a variety of geometric isomers like all-trans, mono-cis, 
and poly-cis form (Shi & Maguer, 2000). The trans configuration is the most 
common form of lycopene and is the form found in most plants (Kun, et al., 
2006), while in the human plasma 50% lycopene exists as cis isomers (A V Rao 
& Agarwal, 2000; Shi & Maguer, 2000).  The all-trans isomer of lycopene is the 
most thermodynamically stable form of the commonly identified isomers –5-cis, 
7-cis, 9-cis, 11-cis, 13-cis and 15-cis (Shi & Maguer, 2000).  The structural 
differences among some of the geometrical isomers of lycopene are presented in 
Figure 2.3. 
 Food sources of lycopene include tomatoes and tomato products, papaya, 
pink grapefruit, watermelon, and guava (Clinton, 1998; Kun, et al., 2006; A V Rao 
& Ali, 2007). Tomato and tomato products contribute more than 85% of dietary 
lycopene consumed in the North American diet (A V Rao & Agarwal, 2000).  
Tomato variety and the stage of ripening are key determinants of the lycopene 
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content of tomatoes (Clinton, 1998; Hadley, Miller, Schwartz, & Clinton, 2002).  
Tomato products may also contain polyphenols like quercetin, naringenin and 
chlorogenic acid along with small amounts of glucosinolates, tomatine and 
cyclolycopene (Bowen, 2005). More than 21 carotenoid pigments have been 
identified in tomatoes (Shi & Maguer, 2000).  Some of these include phytoene, 
phytofluene, δ-carotene, γ-carotene, β-carotene, neurosporene (Khachik et al., 
2002) and lutein (Shi, Kakuda, & Yeung, 2004).  The highest concentration of 
lycopene is found in the liver, adrenal glands, testes and the prostate (Kun, et al., 
2006; Wertz, et al., 2004), while the lowest concentrations are noted in the 
kidney, lung and  ovaries (Kun, et al., 2006). This variation in deposition of 
lycopene may be indicative of specific mechanisms involved in this process 
(Bramley, 2000). Tissue lycopene concentration in the prostate is reported to be 
0-1.8 nM/gm (Clinton, 1998), and mean plasma lycopene concentrations ranging 
from 50-900 nM have been reported (Bramley, 2000).  Concentration of lycopene 
in tissues, blood and other body secretions (seminal fluid, breast milk) is 
dependent on several factors such as food preparation practices, composition of 
the meal, diet composition, lipoprotein metabolism, and factors affecting lipid 
metabolism (Clinton, 1998). 
 Lycopene, a potent antioxidant and anti-inflammatory agent (Huang, et al., 
2004; Rafi, Yadav, & Reyes, 2007), protects cells against ROS induced damage 
(Ford, et al., 2003; Neill & Fleshner, 2006; A V Rao & Shen, 2002). In addition to 
its role as an antioxidant, lycopene can influence several biological processes to 
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regulate cell cycle progression, gap junction communication and cytokine and 
growth factor signaling (Wertz, 2009). Some of the other mechanisms of action 
for lycopene include induction of phase II enzymes, inhibition of insulin like 
growth factor 1 (IGF-1) signal transduction, apoptosis induction, inhibition of IL-6 
expression, inhibition of androgen activation and signaling, (Wertz, 2009) and 
modulation of the cyclo-oxygenase pathway (De Stefano et al., 2007; Sengupta, 
Ghosh, Das, Bhattacharjee, & Bhattacharya, 2006). 
 Recommended Intake of Lycopene: While researchers have recognized 
the health benefits of lycopene for some time now, it is still not recognized as an 
essential nutrient (A V Rao & Rao, 2007).  No actual Dietary Reference Intake 
(DRI) levels currently exist for lycopene. Mean per capita intake of lycopene in 
the US has been reported to be about 8.2 (Matulka, Hood, & Griffiths, 2004) to 
10.9 mg/day (McClain & Bausch, 2003). Clinical trials have been conducted 
using lycopene supplements (both food-based and pills) ranging from 5-120 
mg/day, but a consensus is yet to be reached on the optimal daily dose. While 
Gustin et al., (2004) recommend daily ingestion of lycopene due to its short half 
life, they do not advocate more than 30 mg lycopene for chronic consumption. 
  Bioavailability of Lycopene: Lycopene absorption in humans is reported 
to be only about 10-30% of amount consumed (A V Rao, Ray, & Rao, 2006; Shi, 
Qu, Kakuda, Yeung, & Jiang, 2005). Lycopene in raw tomatoes is attached to the 
membranes which weaken during cooking, making lycopene more available from 
cooked tomato products  (A V Rao & Agarwal, 2000; Weisburger, 2002).  In 
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addition to heat, other factors that affect the bioavailability of lycopene include 
presence of dietary fiber (Kun, et al., 2006) , and amount and type of fat (Kun, et 
al., 2006; Lee, Thurnham, & Chopra, 2000; A V Rao & Ali, 2007; Stahl & Sies, 
1992). Other factors such as age, gender, hormonal status, smoking, alcohol 
consumption, body mass and composition may also affect bioavailability of 
lycopene (A V Rao, et al., 2006; Stahl & Sies, 1992). In addition, dietary 
components and drugs affecting lipid metabolism may impact serum lycopene 
concentration (Hadley, et al., 2002). During digestion lycopene is incorporated 
into micelles and through passive diffusion is absorbed by the intestinal epithelial 
cells (Shi, et al., 2005). Chylomicrons carry lycopene into the portal circulation, 
and after being repackaged, lycopene is released into the blood bound to low 
density lipoprotein (LDL) (Shi, et al., 2005).  
 Safety/Toxicity Evaluation of Lycopene: Upon reviewing lycopene 
supplementation studies, McClain and Bausch (2003) reported no systemic 
toxicity, genotoxicity, or adverse effects on reproductive parameters.  No adverse 
effects were noted in toxicology studies conducted in rats with intakes up to 3 
gm/kg/day (Trumbo, 2005). Safety of food based lycopene supplementation in 
humans has been established by virtue of its unrestricted use (McClain & 
Bausch, 2003). While no upper tolerable limit has been established for lycopene 
consumption, synthetic lycopene, lycopene extracts and crystallized lycopene 
extracts are generally regarded as safe (GRAS) in foods at levels ranging from 
0.5 to 7% (Trumbo, 2005). After reviewing published data on lycopene 
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supplementation, Shao and Hathcock (2006) recommend 75 mg per day as the 
upper limit for supplementation in humans. Astley and Elliott (2005) propose that 
15 mg of lycopene obtained from supplements is equivalent to the addition of 
approximately 150 gm of lycopene-rich foods in the diet. 
 Some side effects of lycopene supplementation have been reported in 
clinical trials. These include nausea and vomiting (Bunker et al., 2007; Jatoi et 
al., 2007), diarrhea (Clark et al., 2006; Jatoi, et al., 2007), abdominal distention 
(Jatoi, et al., 2007), flatulence (Edinger & Koff, 2006; Jatoi, et al., 2007), anorexia 
(Jatoi, et al., 2007) and dyspepsia (Jatoi, et al., 2007). Edinger and Koff (2006) 
reported heartburn, skin itching and flatulence among some study participants 
fed 50 grams tomato paste daily for 10 consecutive weeks. Jatoi et al., (2007) 
also reported occurrence of severe hypotension, prostatic hemorrhage, diarrhea, 
and anemia. While Jatoi et al., (2007) raise cautious concern about mild adverse 
reactions to lycopene supplementation, they do not preclude future clinical trials, 
but instead stress the importance of patient education about any potential side 
effects.   
Prostate Cancer, Inflammation and Lycopene 
  Epidemiological studies (Giovannucci, 1999, 2002)  have documented an 
inverse relationship between intake of lycopene rich foods and the development 
of prostate cancer. Several cell (Hwang & Bowen, 2004; Ivanov et al., 2007; 
Kanagaraj et al., 2007; L. Kim, Rao, & Rao, 2002) and animal studies 
(Guttenplan et al., 2001; Konijeti et al., 2010), and clinical trials in men at risk for 
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developing prostate cancer (Bunker, et al., 2007; Edinger & Koff, 2006; Mohanty, 
Saxena, Singh, Goyal, & Arora, 2005; Schwarz et al., 2008) have demonstrated 
the chemopreventive role of lycopene. Researchers have also evaluated the 
benefits of lycopene in prostate cancer patients prior to initiating treatment (Jatoi, 
et al., 2007; H. Kim et al., 2003; Kucuk et al., 2001) or after failure of treatment 
(Clark, et al., 2006).  Despite the presence of several carotenoids and 
polyphenols, the chemoprotective effect of tomatoes on prostate cancer has 
been attributed to lycopene (Hwang & Bowen, 2004). Researchers have even 
demonstrated a stronger anti-mutagenic effect of food-based lycopene (tomato 
puree) compared with pure lycopene. This stronger effect was attributed to the 
likely synergistic effect of all bioactive compounds found in tomatoes (Polívková, 
Šmerák, Demová, & Houška, 2010). A summary of some of the key trials/studies 
are provided in Tables 2.5-2.7. 
 Despite several clinical trials evaluating the role of lycopene in patients 
with BPH and prostate cancer, data on the efficacy of lycopene supplementation 
in prostate cancer patients during radiation therapy are lacking. Based on the 
existing evidence, while some researchers have advocated for the inclusion of 
tomato extracts/products in prostate cancer treatment and prevention (Guns & 
Cowell, 2005), others have proposed urgency in evaluating the effectiveness of 
lycopene supplementation in prostate cancer patients undergoing radiation and 
androgen oblation therapies (Clinton, 2005; Davis et al., 2005), in order to 
formulate evidence-based recommendations for this population.  
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 Lycopene Use During Radiation Therapy: Lycopene and other 
antioxidants have been proposed to resolve free radical induced oxidative 
damage produced during radiation therapy (Simone, Simone, Simone, & Simone, 
2007).  Researchers have demonstrated a beneficial effect of lycopene 
supplementation during radiation therapy to reduce the associated 
gastrointestinal (GI) side effects in rats (Andic, Garipagaoglu, Yurdakonar, 
Tuncel, & Kucuk, 2009). Clinical trials evaluating the impact of lycopene 
supplementation during radiotherapy are limited. The only documentation in the 
literature of lycopene supplementation during radiotherapy was found in patients 
with high grade gliomas undergoing radiotherapy and chemotherapy (Puri et al., 
2005).  Puri et al., (2005) reported a significant increase in serum lycopene 
levels, no adverse effects and positive, but not statistically significant (p = 0.1), 
outcomes in the lycopene (8 mg supplement) treated group compared to the 
control group. A summary of some of the studies evaluating the effectiveness of 
lycopene supplementation during radiation therapy are provided in Table 2.8. 
Summary 
 Despite several clinical trials evaluating the role of lycopene in patients 
with BPH (Edinger & Koff, 2006; Schwarz, et al., 2008) and prostate cancer 
(Bowen et al., 2002; Chen et al., 2001; Jatoi et al., 2007; Kim et al., 2003; Kucuk 
et al., 2001; Rao et al., 1999), data on the efficacy of lycopene supplementation 
in prostate cancer patients during radiation therapy are lacking. To our 
knowledge, no studies have examined the effects of lycopene supplementation in 
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men undergoing radiation therapy for the treatment of prostate cancer.  Several 
researchers have proposed the urgency in evaluating the effectiveness of 
lycopene supplementation in prostate cancer patients undergoing radiation and 
androgen oblation therapy (Bowen, 2005; Davis, et al., 2005).  Thus, the 
proposed study evaluated the impact of daily supplementation of three different 
doses of lycopene on serum lycopene levels, PSA, and select markers of 
inflammation, and on the onset and severity of specific physical side effects 
(urinary frequency and urgency, proctitis, and diarrhea) and performance status 
in patients with localized prostate cancer during radiotherapy. 
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Figure 2.1. Cascade of events reported with increased IL-6 expression. IL-6 = 
interleukin-6, CRP = c-reactive protein, ESR = erythrocyte sedimentation rate, 
RBC = red blood cells, Hgb = hemoglobin, Hct = hematocrit, WBC = white blood 
count, XRT = radiation therapy, QOL = quality of life 
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Figure 2.2. Radiation therapy related cascade. XRT = radiation therapy, COX-2 = 
cyclooxygenase-2, PGE2 = prostaglandin E2, CRP = c-reactive protein, ESR = 
erythrocyte sedimentation rate, IL-1 = interleukin-1, TNF-α = tumor necrosis 
factor- α, IL-6 = interleukin-6 
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Figure 2.3: All-trans and cis isomers of lycopene (Source – (Rao & Rao, 2007)). 
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TABLE 2.1. Cell and animal research studies implicating inflammation in prostate tumorigenesis 
 
 
Study 
Animal/
cell line 
Tests/Assays Results 
(Quintar 
et al., 
2010) 
Rat 
model 
Prostatic tissues immuno- 
stained for PBP, ACTA2, 
ErbB1, & ErbB2 receptors, 
TUNEL, & cell proliferation 
markers. Dot & Western 
blots for PBP, ACTA2, 
ErbB1, ErbB2, & TGFb1  
Post infection prostatic epithelium hypertrophied with  PBP, 
ErbB1 & ErbB2 in a time dependent fashion. @ 72 hrs post 
infection, the epithelium showed apoptosis & atrophy with  in 
PBP & ErbB receptors.  in ACTA2 at 72 hr post infection 
indicating atrophic & proliferative changes promoted by even early 
stage prostatic inflammation 
(Wong, 
Bray, & 
Ho, 2009) 
LNCaP 
prostate 
cancer 
epithelial 
cells 
Western blots, RNA 
isolation, cDNA synthesis, 
& real time quantitative 
PCR, ELISA, Flow 
cytometry   
LNCaP cells show local proinflam response (NF-kB activation, &  
TNFa, IL-1b, & IL-6 expr. in activated macrophage conditioned 
media). Sig.  VCAM-1 & nuclear estrogen receptor-a indicating 
potential link between chronic inflam. & its involvement in PC 
(Fujita et 
al., 2002) 
LNCaP 
cells 
RNA Extraction and RT-
PCR,  Quantitative Real-
Time PCR, western blot, 
COX assay, luciferase 
assay, ELISA  
COX-2 mRNA & protein & COX activity in LNCaPCOX-2 cells sig. 
 compared with parent and control-transfected cells &  both 
proliferation in vitro & tumor growth rate in vivo. But pro-tumor 
effect not associated with androgen receptor level/activity.  VEGF 
seen in LNCaP-COX-2 cells suggesting tumor growth in vivo 
stimulated by angiogenesis induced by COX-2. 
(X.-H. Liu, 
et al., 
2002) 
Human 
PIN cell 
line 
immunoprecipitation, 
immunoblotting, ELISA, 
nuclear extract 
preparation & 
electrophoretic mobility 
shift assay 
PGE2 demonstrates autocrine upregulation by stimulating soluble 
IL-6 receptor release, gp130 dimerization, Stat-3 protein 
phosphorylation, & DNA binding activity, leading to  PIN cell 
growth. COX-2 inhibitor  cell growth. IL-6 neutralizing antibodies 
diminished PGE2-stimulated PIN cell growth indicating that  COX-
2/PGE2 leads to PC dev. thru activation IL-6 signaling pathway 
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TABLE 2.2. Human tissue studies implicating inflammation in prostate tumorigenesis  
Study 
n Study Design & 
Population 
Tests/Assays Results 
(Ravenna 
et al., 
2009) 
20 
pairs 
human normal  
and primary 
prostate tissue 
real-time PCR and 
Western blot analysis 
in prostate samples 
RAGE, P2X7R, COX2, NOS2, PTX3, EGFR, ERa, 
(but not ERb) up-regulated in tumor samples. 
Western blot analysis showed nuclear translocation 
of the NF-kB subunit p65.  
(Bouraoui 
et al., 
2008) 
47 Tissues from 5 
normal, 25 BPH 
and 17 human  
PC 
Western blot & 
immune-histochemistry 
of IL-1, IL-6 & TNF-α, 
PSA 
in BPH, IL-1α, IL-6 and TNF expressed in pts with 
PSA levels of 0–4 or 4–20 only, but not >20 ng/ml 
In PC these cytokines only expressed in patients 
with PSA serum  levels > 4 ng/ml. 
(Khor et 
al., 2007) 
586 Prostate tissue 
from men treated 
with radiation 
(XRT) and both 
short (STAD)or 
long term 
androgen 
deprivation 
(LTAD) 
Immunohistochemical 
staining; any failure, 
local failure, distant 
metastasis, 
biochemical failure, 
overall mortality, cause 
specific mortality 
intensity of COX-2 staining an indep. predictor of 
distant mets (p=0·0004); biochem. failure (p=0·008); 
& any failure (p=0·011). higher the expression of 
COX-2, greater the chance of failure. COX-2 over-
expression most discriminating for those receiving 
STAD vs LTAD.  COX-2 expr. sig.  associated with 
biochemical failure, distant mets & any failure.  LTAD 
might overcome effects of COX-2 overexpr. COX-2 
expr. may be useful in selecting pts needing LTAD. 
(Cohen et 
al., 2006) 
60 Prostate cancer 
specimens from 
men post radical 
prostatectomy 
immune-
histochemistry, slide 
grading; preoperative 
PSA, stage, Gleason 
sum (GS), margin, 
extraprostatic 
extension (EPE); 
seminal vesicle (SV) 
invasion 
At 62-mths follow-up, COX-2 staining predicted 
progression with 82.4% sensitivity & 81.3% 
specificity. Sensitivity (86.4%) & specificity (86.7%) 
improved at ≥100-months follow-up., preop. PSA, 
EPE, margin, SV invasion & high COX-2 expr. were 
sig. predictors of biochemical recurrence (p < 0.05). 
In multivariate analysis, preop PSA & COX-2 were 
indep. prognostic indicators. Pts with PSA > 7 ng/ml 
&  COX-2 expr. had highest prob. of recurrence.  
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TABLE 2.2. Human tissue studies implicating inflammation in prostate tumorigenesis, cont’d 
Study 
n Study Design 
& Population 
Tests/Assays Results 
(Wang, Bergh, & 
Damber, 2004) 
45 BPH samples. immunohistochemist
ry; double staining; 
 COX-2 expression seen in all prostate 
luminal epithelial samples; highest proliferation 
index found in COX-2 +ve stained 
epithelium.COX-2 expression associated with 
Bcl-2 immunostaining in atrophic lesions 
(P<0.0001). T lymphocytes & macrophages 
predominant inflammatory cells related to the 
COX-2 expression in prostate epithelium. 
(Hughes et al., 
2002) 
106 PC pts taking 
part in the 
Phase III 
RTOG 86-10 
trial 
Immunohistochemic
al staining for COX-
2 
99% of slides expressed COX-2, samples with 
GS 7-10 had 81% COX-2 expression, GS 2-6 
had only 69% 
(Gupta, 
Srivastava, 
Ahmad, Bostwick, 
& Mukhtar, 2000) 
12 PC 
tissue 
samples 
12 
control 
Diagnosis of 
PC 
semi-quanti. reverse 
transcription-PCR, 
immunoblotting, & 
immunohistochemist
ry 
Mean COX-2 mRNA levels 3.4-x  in PC tissue 
compared with the paired benign tissue. COX-2 
protein over- expressed in 10 of 12 samples;  
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TABLE 2.3. Clinical trials implicating inflammation in prostate tumorigenesis 
Study n 
Study Design 
& Population 
Tests/Assays Results 
(Salinas, 
et al., 
2010) 
1001 
PC 
cases, 
942 age 
matched 
controls 
Case control 
study 
Assessment of 
aspirin and other 
NSAID use, 
Genotyping 
Significant   (21%) in PC risk seen among current 
users of aspirin compared with nonusers. Long-term 
use of aspirin & daily use of low-dose aspirin also 
associated with  risk. no evidence that the association 
with aspirin use varied by disease aggressiveness, but 
there was effect modification. PC risk not related to use 
of non aspirin NSAIDs or acetaminophen.  
(Schenk 
et al., 
2010) 
676 
cases 
683 
control 
Nested case-
control study 
from placebo 
arm of the PC 
Prevention Trial  
Baseline serum was 
analyzed for CRP, 
TNF-a, sTNF-RI & 
sTNF-RII, IL-6, & 
interferon c 
 CRP associated with  BPH risk (for quartile 4 vs. 
quartile 1, OR =1.40, 95% CI: 1.04, 1.88; which 
attenuated after control for BMI (OR = 1.30, 95% CI: 
0.95, 1.75). Low sTNFRII &  IL-6 associated with  
BPH risk; associations only in men aged <65 years. 
(Rebbeck, 
et al., 
2008) 
1090 Caucasian PC 
cases, history 
of BPH  
Genotype analysis only remaining significant associations involved 
CYP3A43 P340A genotypes & history of BPH on both 
Gleason grade (interaction p-value = 0.026) and tumor 
stage (interaction p-value = 0.017). 
(Di 
Silverio et 
al., 2003) 
3942 
case 
Retrospective 
histopathology 
examination  
Histopathology 
examination  
% of pts with inflammation associated with BPH. FAA 
(p = 0.027), PIN (p = 0.036) & incidental PC  sig. with 
age. Distribution on inflammatory aspects and AAH 
varied sig. (p = 0.002) based on prostate volume.  
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TABLE 2.3. Clinical trials implicating inflammation in prostate tumorigenesis, cont’d 
Study n 
Study Design 
& Population 
Tests/Assays Results 
(Nickel, 
Downey, 
Young, & 
Boag, 
1999) 
80 diagnosis of 
BPH 
immunostained for 
leukocyte common 
antigen; computerized 
image-analysis system.  
Inflammation present in all pts but only 1.1% of mean 
tissue surface area involved, 44% prostate specimens 
showed bacterial growth. no sig. diff. between 
inflammation pattern, volume or grade of inflammation in 
those catheterized or not (P=0.15) or culture +ve 
(pathogenic or not) & culture-negative cases (P=0.06). 
amount, degree or distribution of inflammation didn’t sig. 
correlate with total PSA or PSA density  
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Table 2.4. Cell and animal research studies implicating COX-2 upregulation in radiation therapy of the prostate 
Study 
Animal/
cell line 
Tests/Assays Results 
(Keskek, 
et al., 
2006) 
Sprague
-Dawley 
rats 
abdominal irradiation, 
Cyclooxygenase-2 
Immunostaining, 
Myeloperoxidase Activity, 
Malondialdehyde Assay, 
Histopathology 
COX-2  sig. in vascular endothelial cells on days 4 & 14 post 
exposure. COX-2  in fibroblasts immediately post irradiation & 
remained sig.  during the entire study (P < 0.001), there was a 
peak COX-2 expression on day 14 similar to that observed in 
endothelial cells. Irradiation significantly  intestinal epithelial 
damage, MPO activity, & MDA levels compared to the control 
group in a time-dependent fashion. Treatment with rofecoxib 
significantly  these  except on day 4  
(Li et al., 
2003) 
PC3 cell 
line 
Glutathione Assay, DCF, 
ROS assay, PGE2 
monoclonal Immunoassay 
Kit 
L-Buthionine sulfoximin  cellular GSH &  cellular ROS in PC-3 
cells, whereas lipoic acid & NAC  GSH level &  cellular ROS. 
Both radiation & H202 similarly up-regulated COX-2 & PGE2 in PC-
3 cells.  greater when PC-3 cells pretreated with BSO. 
Pretreatment with a-lipoic acid or NAC for 24 h, up-regulated both 
radiation- & H202-induced COX2 &  PGE2 production.  
(Steinauer
, et al., 
2000) 
PC3 cell 
line 
Western blot analysis for 
COX-2 protein expression. 
PGE2 measured using 
Monoclonal Immunoassay 
Kit.  flow cytometry. 
dose-dependent  in COX-2 of 37.0%, 79.7%, & 97.5% post 
irradiation with 5, 10, and 15 Gy, respectively. PGE2  in irradiated 
cells than controls;  PGE2 levels in cells irradiated in the 
presence of NS-398. no differences in cell cycle distribution or 
 apoptosis  between cells irradiated in the presence or absence 
of NS-398. 
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TABLE 2.5.  Summary of lycopene research in cell/animal studies 
 
 
  
Study Methods Lycopene dose 
animal/Cell 
line 
Results 
(Polívková, 
et al., 2010) 
AMES test, bone 
marrow micronucleus 
test 
(30 mg and 300 
mg per plate)  
 
0, 25 or 50 
mg/kg for 
animal study 
TA98, 
TA100, 
BALB/c 
mice 
Sig., dose dependent, antimutagenic effects of 
lycopene noted at various conc. Of AFB1 & IQ in 
TA98 & TA100.  protective effects seen in AFB1 & 
IQ compared to MNU. Mice treated for 3 days with 25 
or 50 mg/kg of lycopene prior to mutagen admin. 
show a sig.  micronuclei numbers & tomato puree 
showed a stronger, dose-depend.  antimutagenic 
effect compared with similar doses of pure lycopene 
(Konijeti, et 
al., 2010) 
Serum IGF-I, IGFBP-
3 measured by 
ELISA, serum & 
prostate lycopene & 
α-tocopherol  & liver 
tissue deoxy-
guanosine & 8-
hydroxydeoxyguanosi
ne measured by 
HPLC 
28 mg/kg 
lycopene from 
tomato paste 
(TP) or 
lycopene 
beadlets (LB) 
TRAMP 
mice 
PC incidence sig.  in LB group compared to 
controls (60% vs. 95%, P=0.0197) but not between 
TP & control groups (80% vs. 95%, P=0.34). no diff 
in prostate wts seen between groups. Both total 
serum & prostate lycopene levels in LB & TP 
groups but not control group. ratio of 5-cis-lycopene 
to trans-lycopene in serum was sig.  in LB group 
compared to TP group (P=0.0001). sig.  oxidative 
DNA damage in livers of mice fed LB & TP diets but 
not control group. 
(Kanagaraj, 
et al., 2007) 
IGF-I, IGFBP-3 and 
IGF-I receptors in 
lycopene-treated cells, 
Annexin V & PI 
binding studies 
20, 40 & 60 μM 
lycopene 
treated for 24, 
48, 72 
& 96 hrs 
PC-3 cells lycopene treatment showed a sig.  in cell 
proliferation. 40 μM lycopene sig.  IGFBP-3. 
Lycopene induced apoptosis; & DNA fragmentation 
absent after 24 hrs but not after 48 hrs. sig. in the 
IGF-IR post cell treatment with lycopene, IGF-I 
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TABLE 2.5.  Summary of lycopene research in cell/animal studies, cont’d 
Study Methods 
Lycopene 
dose 
animal/Cel
l line 
Results 
(Ivanov, 
et al., 
2007) 
Proliferation assay, 
bromodeoxyuridine 
incorporation and flow 
cytometric analysis of 
cellular DNA content 
0-100µM LNCaP, 
PC3  
LNCaP & PC-3 cells undergo mitotic arrest 
accumulating in G0/G1 phase - block in G1/S 
transition due to  cyclin D1 & E, CDK4 & Rb 
phosphorylation. Corresponding with  IGF-1 
receptor expression & activation,  IGFBP-2 
expression & AKT activation  
(Srinivas
an et al., 
2007) 
TBARS, single cell gel 
electrophoresis;levels of 
SOD, catalase, 
glutathione peroxidase 
ceruloplasmin, vitamin A, 
C, E & urinc acid 
1.86, 9.31, 
18.62 µM 
hepatocyte
s isolated 
from rat 
(Sprague-
Dawley) 
liver 
pretreatment with lycopene demonstrated a sig.  in 
TBARS and DNA damage and a sig.  in glutathione, 
vitamin A, C, E, uric acid and ceruloplasmin. Max 
protection to hepatocytes noted at 9.31 µM lycopene 
(Gunasek
era et al., 
2007) 
Inhibition of cell growth, 
time course studies, 
Mitogenic assays for 
growth factor studies 
0, 0.04, 0.4, 
5, 10, 20 µM 
Dunning 
R3327AT3 
or AT3 
cells and 
DTE  
both lycopene & lutein inhibited malignant AT3 cells in 
a dose and time-dep. manner, but not DTE cells. 
Lycopene showed more robust response than lutein & 
no synergistic or additive effect observed with both. 
(Gitenay 
et al., 
2007) 
Mass Spec, RNA 
extravtion, real time 
PCR, western blot 
50 mg/kg Male 
Wistar 
rats,PC3A
R human 
cell line 
 Cx43 expression sig.  post exposure to RTS or 
YTS for 48 hrs compared to control, LBS effect not 
sig. diff. similar lycopene levels in cells incubated with 
RTS & LBS, while YTS contained no lycopene.  
(Limpens 
et al., 
2006) 
HPLC-prostate and liver  
to detect lycopene and 
a,G, D tocopherol 
Ly/Vit E-5 or 
50 mg/kg; 
Ly+E - 5 
mg/kg 
PC-346C none of the treatments sig.  tumor vol., Lycopene+vit 
E @5 mg/kg sig.  tumor growth,  median survival 
by 40%. Lycopene levels  in a dose dep.manner 
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TABLE 2.5.  Summary of lycopene research in cell/animal studies, cont’d 
 
 
Study 
Methods 
Lycopen
e dose 
animal/Cell 
line 
Results 
(A. Liu, et 
al., 2006) 
subcellular fractionation 
of LNCaP cells using 
centrifugation and liquid 
chromatography-tandem 
mass spectrometry  
 
1.48 
Mmol/L 
LNCaP, PC-
3, and 
DU145 
After 24 hrs of incubation with 1.48 Mmol/L lycopene, 
LNCaP cells accumulated most lycopene & only one 
to express PSA. Levels of PSA  55% in LNCaP 
cells after 1.48 Mmol/L lycopene. lycopene not found 
to be a ligand for ligand-binding domain of the human 
androgen receptor. majority of lycopene (55%) 
localized in the nuclear membranes, followed by 
nuclear matrix (26%), & then microsomes (19%) & 
none in the cytosol. 
(Hwang & 
Bowen, 
2004) 
effects of lycopene on 
cell growth or survival, 
cell cycle progression, 
and apoptosis 
0, 0.1, 1, 
and 5 µM 
LNCaP Lycopene at 1 µM inhibited cell growth by 31% 
compared to placebo post 48-hr incubation. 
Lycopene at 5 µM  number of cells in G2/M phase 
of cell cycle from 13% to 28% & S-phase cells from 
45% to 29%, no shifts in cell cycle seen in placebo-
treated groups. Apoptosis observed at 5 µM 
lycopene @ late stages during 24 &48 hour 
treatments. 
(Obermuller-
Jevic et al., 
2003) 
Cellular uptake, 
thymidine assay, flow 
cytometry, western blot 
0.1-
5.0µM 
PrEC 
(Human 
prostate 
epithelial 
cells) 
Dose dependent inhibition of cell proliferation noted; 
synchronized cells treated with 0.5µM lycopene 
showed minimal change, but cells treated with 5.0µM 
showed a significant accumulation in G0/G1 with no 
expression of cyclin D1, cyclin E was unaffected. 
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TABLE 2.5.  Summary of lycopene research in cell/animal studies, cont’d 
Study Methods 
Lycope
ne dose 
animal/Cell 
line 
Results 
(Yaping, 
Wenli, 
Weile, & 
Ying, 2003) 
croton oil-induced mouse 
ear edema model, & glass 
slide method  
0.1, 0.5, 
1, 2 g/kg 
body wt 
3-4 week 
old male 
mice 
Administration of lycopene for four days was 
associated with  swelling of the treated ear 
similar to amoxycillin. Lycopene also  coagulation 
time 
(Guttenplan
, et al., 
2001) 
DNA isolation, 
mutagenesis assay, 
lycopene assay 
0.5, 1 
mmol/kg 
LacZ male 
mice 
inhibition of spontaneous mutagenesis in prostate 
and colon observed at 1 mmol/kg of lycopene-
rich tomato oleoresin (LTO), benzo[a]pyrene 
(BaP)-induced mutagenesis inhibited by LTO in 
prostate.  
(Forssberg, 
Lingen, 
Ernster, & 
Lindberg, 
1959) 
lycopene administered pre 
48-12 hrs) & post (7-24 
hrs) treatment 
0.5-2 mg 
inj. 
Intraperit
oneally 
159 - lycop; 
190 - 
control 
lycopene improves survival when given before 
irradiation & at certain time after. females tolerated 
 lycopene dose in combination with radiation 
better than males (males did better at smaller 
doses); radiation tolerance varies in different 
stages of menstrual cycle;  
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TABLE 2.6. Summary of lycopene trials in healthy subjects 
study n 
Lyco 
dose 
food vs 
pill 
duratio
n 
Participg 
Populat. 
end point Results 
(Talvas et 
al., 2010) 
30 0, 16 
mg 
Tomato 
paste, 
purified 
lycopen
e 
1 wk 
supplem
entation, 
2 wk 
washout 
period 
Health 
men, 50-
70 yrs 
Differentiat
e the effect 
of tomato 
matrix from 
tomato 
paste or 
purified 
lycopene 
serum lycopene  after consuming red 
tomato paste & purified lycopene. No 
change in lipid profile, antioxidant status, 
PSA & IGF-I after consumption of tomato 
paste & lycopene. Sig. in IGFBP-3 & 
Bax:Bcl-2 ratio & of cyclin-D1, p53, & 
Nrf-2 in men consuming red tomato paste 
compared with serum collected after first 
washout period. Sig.  of IGFBP-3, c-fos, 
& uPAR in men consuming purified 
lycopene compared with placebo 
(Graydon 
et al., 
2007) 
20 15 mg pill 4 weeks healthy 
men 18-
60 yrs 
Serum 
IGF-1, 
IGFBP-3 & 
lycopene 
pre & post 
supplemnt 
 change in serum lycopene in 
treatment group compared to control. no 
diff in median change in IGF-1 or IGFBP-
3 between treatment & control groups. 
Change in lycopene corresponded with 
the change in IGFBP-3 in treatment 
group (r=0.78; P=0.008; n=10) 
(Goyal, 
Chopra, 
Lwaleed, 
Birch, & 
Cooper, 
2007) 
6 22.8 
mg 
Cream 
of 
tomato 
soup 
2 weeks Healthy 
men 
Blood/ 
seminal 
lycopene & 
antioxidant 
capacity pre 
& post 
supplemt 
statistically sig.  in blood & seminal 
plasma lycopene levels post 
supplementation, with a strong +ve 
correlation (r=0.84,P<0.05). no 
measurable  in total radical scavenging 
capacity of semen.  
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TABLE 2.6. Summary of lycopene trials in healthy subjects, cont’d 
study n 
Lyco
pene 
dose 
food vs 
pill 
duration 
Participg 
Populat. 
end point Results 
(Riso, 
Brusamol
ino, 
Martinetti
, & 
Porrini, 
2006) 
20 5.7 
mg 
Lyc-o-
mato 
drink 
26 days Healthy 
young 
men and 
women 
Blood 
carotenoid, 
IGF-1 and 
IGFBP-3 
estimation 
tomato drink  plasma lycopene, 
phytoene, phytofluene, & bcarotene (P 
< 0.05). No sig. effect of tomato drink 
on IGF-1. changes in lycopene pre & 
post each experimt period inversely & 
sig. correlated with IGF-1 (r = –0.33, P 
< 0.05). No correlation with other 
carotenoids. sig.  serum IGF-1 (–
5.7%) with highest plasma lycopene 
(P<0.05). No change with placebo  
(Gustin, 
et al., 
2004) 
25  10, 
30, 
60, 
90, 
120 
mg 
30 gm 
tomato 
paste + 
5 ml 
olive oil 
28 days healthy 
men 18-
45 yrs  
3 parameters 
of lycopene & 
isomers after 
single dose of 
lycopene; 
toxicity profile 
headache, nausea, diarrhea most 
common adverse events, toxicity grade 
2 or less; max serum lycopene reached 
in 15-32.6 hrs; half life 28-61.6 hrs; 
lower doses (10, 30) had the largest  
in systemic exposure parameters 
(Allen et 
al., 2003) 
36 21 
mg, 
12 
mg, 
17 mg 
sauce, 
soup, 
juice (v8 
tomato 
or 
veggie) 
6 week 
lycopene 
free diet- 
2 wk 
washout+ 
4 week 
Tx  
healthy 
men and 
women; 
18-65 yr 
impact of single 
daily svgs of 3 
tomato prod. 
on blood & 
BMC conc. of 
carotenoid & 
lycopene 
isomer 
serum & BMC lycopene  with all three 
(sauce, soup, juice); lycopene 
plateaued after 2 weeks.  
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TABLE 2.6. Summary of lycopene trials in healthy subjects, cont’d 
study n 
Lyco
pene 
dose 
food vs 
pill 
duration 
Particip 
Populat. 
end point Results 
(Hadle
y, et 
al., 
2002) 
60 35 
mg, 
23 
mg, 
25 mg 
cond. 
soup (35 
mg), 
RTS 
soup (23 
mg), V8 
veg juice 
(25 mg) 
1 wk 
lycopene 
free diet, 
15 day 
lycopene 
suppleme
ntation 
healthy 
>40 yr old 
men & 
women 
rate & magnitude 
of plasma 
lycopene after 1 
wk of lycopene 
free diet & then 
with 3 diff food 
sources of 
lycopene; assess 
impact on 
biomarkers of 
oxidative damage 
plasma conc of lycopene  35% 
(p<0.0001) during washout period, 
lycopene   123% cond. soup, 57% 
RTS soup, 112% V8. No significant 
change seen in urinary 8-OH-2’-dG & 
8-epi-PGF2α, but ex-vivo lipoprotein 
oxidation lag period (measure of 
antiox. capacity)  significantly 
(A V 
Rao & 
Shen, 
2002) 
12 5, 10, 
20 mg 
ketchup 
& lyc-o-
mato 
2 week 
washout, 
then 2 
week 
interventio
n  
healthy  
men & 
women, 
non-
smokers, 
no MVI 
serum lycopene, 
oxidative 
biomarkers 
(MDA) 
dose dependent  in serum lycopene 
with both pill and food, levels slightly 
higher with pill but diff not stat. Sig. 
MDA  & reduced thiols  with both 
pill and food all doses. 
(Porrini 
& Riso, 
2000) 
9 7 mg  25 gm 
tomato 
paste + 
 
carotene 
diet  
14 days healthy 
women 
plasma and 
lymphocyte 
carotenoid conc.; 
lymphocyte 
resistance to 
oxidative stress 
Inverse relationship between plasma 
lycopene conc. and lymphocyte 
lycopene conc.and oxidative DNA 
damage…small amts of lycopene over 
short duration can  carotenoid conc 
and resistance of lymphocytes to 
oxidative stress. 
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TABLE 2.6. Summary of lycopene trials in healthy subjects, cont’d 
study n 
Lyco
pene 
dose 
food vs 
pill 
duration 
Particip 
Populat. 
end point Results 
(Bohm 
& 
Bitsch, 
1999) 
22 5 mg tomatoe
s, 
tomato 
juice 
and pill  
2 wks of 
washout, 
6 weeks 
of 
supplemt 
adult 
females 
(20-27 
yrs) 
serum lycopene, 
lipid panel, 
antioxidant 
capacity of 
plasma 
no change with tomato intake, but TJ 
(0.22) and oleoresin (0.25)  serum 
lycopene conc. No affect on the lipid 
status or antioxidant capacity in any of 
the 3 groups 
(Paeta
u et 
al., 
1998) 
15 70-75 
mg 
tomato 
juice, 
and 
lycopen
e 
oleoresi
n & 
beadlets 
4 weeks 
each, 6 
week 
washout 
period 
between 
Tx 
healthy 
men and 
women 
33-61 yr 
lycopene plasma 
response from 
food and 
supplements; 
changes in 
lycopene 
oxidation 
products  
lycopene level  with all 3 Tx, no stat 
significant diff among the three; levels 
plateaued after 1 wk for supplements 
and after 2 wks for TJ. TJ  other 
tomato carotenoids (phytofluene, 
phytoene). Cyclolycopene (lycopene 
metabolite)  most with TJ. 
(Stahl 
& Sies, 
1992) 
6 0.35, 
1.25, 
2.5µmol
/kg  
tomato 
juice - 
heated 
and 
unheate
d 
single dose 
(absorption
, dose 
dep), once 
a day x 4 
days)  
healthy 
22-36 yr 
old (5) 
male & (1) 
females 
absorption 
studies, dose 
dependent 
response, 
accumulation 
Absorption: Peak conc seen within 
24-48 hrs post consumption of heated 
TJ; 1/2 life 2-3 days; Dose Dep: 
lycopene uptake was dose dep, but 
not very linear; higher absorption with 
smaller amounts. Accumulation: of 
lycopene & its isomers very linear 
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TABLE 2.7. Summary of lycopene trials in subjects with prostate involvement 
study N 
Lycopene 
dose (mg) 
food vs 
pill 
durati
on 
patient 
population 
end point results 
(Barber et 
al., 2006) 
37 10 mg lycoplus 
(with vit 
C, E etc) 
1 year PC pts; 
confirm with 
biopsy, no 
Tx, watchful 
waiting 
change in 
PSA velocity 
with lycopene 
supplementat
ion 
lycopene inhibits DNA synthesis in 
PEC, results inconclusive!! Large  
in PSA doubling time but not stat. 
sig. Data skewed since some pts 
eliminated had sig.  in PSA 
(Edinger & 
Koff, 
2006) 
43 13 mg 50 gm T 
paste 
10 wks BPH, PSA PSA Significant  in PSA 
(Mohanty, 
et al., 
2005) 
40 0, 4 mg 
BID 
Lyc-o-
mato 
1 year  HGPIN PSA, serum 
lycopene, 
prostate 
biopsy, DRE 
lycopene can delay or prevent 
HGPIN from progressing to PC, 
inverse relationship between 
lycopene and PSA  
(Chang et 
al., 2005) 
118 
cases 
52 
contrl 
NA NA 2 
years 
Cases-
histologically 
confirmed 
localized PC 
Controls-
PSA<4ng/ml
, -ve DRE 
Plasma 
carotenoid 
50% less risk for men with 
plasma levels of α-carotene, 
trans-β-carotene, β-cryptoxanthin, 
lutein & zeaxanthin. No Sig. 
associations for total lycopene, all-
trans lycopene,& cis-lycopene 
isomer peaks 2, 3,& 5, high levels 
of cis-lycopene isomer peak 
inversely associated with risk.  
(Jian, Du, 
Lee, & 
Binns, 
2005) 
cases
-130, 
274 
contrl  
5 mg lycoplus 
(5 mg 
lycopene 
+ other 
antox 
I year  Cases- PC  
controls- 
hospital inpts 
without 
cancer 
prostate 
cancer dev 
prostate risk  with ing intake of 
lycopene, α & β-carotene, β-
cryptoxanthine, lutein,& 
zeaxanthine 
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TABLE 2.7. Summary of lycopene trials in subjects with prostate involvement, cont’d 
 
  
study N 
Lycopene 
dose 
(mg) 
food vs 
pill 
duration 
patient 
population 
end point Results 
(Ansari & 
Gupta, 
2004) 
20 10 mg pill 3 mths Metastatic 
hormone 
refractory 
PC 
ECOG, Dz 
response 
(complete or 
partial  vs 
stable or prog. 
dz), bone pain, 
LUTS 
complete response-5%, partial 
-30%, stable dz -50%) & dz 
prog.-15%. ECOG Grade 0-
25%, Grade I-50% & Grade II-
25%.  ECOG from Grade I-
0-35% & Grade II-I-15%,  in 
15% & unchanged – 35%.  
LUTS improved in 61% of pts. 
No supplmt related intol./ 
toxicity seen. 
(H. Kim, et 
al., 2003) 
32-tx; 
34-ct 
30 mg 3 pasta 
dishes  
3 weeks prostate 
cancer, BPH 
PSA, 
lycopene, bax, 
bcl-2,  
no change in bcl-2, but bax  
in cancer,  in apoptotic cells 
in BPH & cancer; PSA  
(Bowen et 
al., 2002) 
32 30 mg 3 pasta 
dishes  
3 weeks localized PC 
awaiting 
prostatectom
y 
PSA, leukocyte 
oxidative DNA 
damage 
Sig.  in serum & prostate 
lycopene; leukocyte oxidative 
DNA & PSA sig.  with 
lycopene;  
(Kucuk et 
al., 2002) 
26 30 mg lyc-o-
mato 
3 weeks PC PSA, IGF-1, 
IGFBP-3, 
prostate tissue 
Tx group pts had smaller 
tumors,  involvement of 
surgical margins, PSA  18%; 
IGF-1 & IGFBP-3  sig. 
  
 
49 
TABLE 2.7. Summary of lycopene trials in subjects with prostate involvement, cont’d 
study N 
Lycop
ene 
dose 
(mg) 
food vs 
pill 
durati
on 
patient 
population 
end point Results 
(van 
Breemen 
et al., 
2002) 
32 30 mg Tomato 
sauce 
based 
pasta 
dishes 
3 
weeks 
T1/T2 PC 
patients  
waiting 
prostatectomy 
Cis & trans 
lycopene in 
serum & 
prostate 
tissue 
Total lycopene  2.0-fold in 
serum & 3.0-fold in prostate 
tissue post suppl. Mean all-
trans-lycopene in prostate 
tissue  to 22.7% (from 12.4%) 
of total lycopene post suppl., 
serum only a 2.8% but 
statistically sig.  
(Chen et 
al., 2001) 
32 30 mg 3 pasta 
dishes 
3 
weeks 
PC pts waiting 
prostatectomy 
PSA, 
leukocyte 
oxidative 
DNA damage 
Sig. in serum & prostate 
lycopene; leukocyte oxidative 
DNA & PSA sig.  with 
lycopene  
(Kucuk, et 
al., 2001) 
26 30 mg lyc-o-
mato 
3 
weeks 
localized PC 
patients waiting 
prostatectomy 
PSA, 
connexin43, 
bax, bcl-2 
serum lycopene  post 
intervention. Lycopene suppl. 
may  PC growth; bcl-2, bax 
same between groups, IGF-1 
  in both groups 
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TABLE 2.7. Summary of lycopene trials in subjects with prostate involvement, cont’d 
study N 
Lycop
ene 
dose 
(mg) 
food vs 
pill 
durati
on 
patient 
population 
end point Results 
(Lu et al., 
2001) 
65 
cases 
132 
contro
l 
NA NA 4 
years 
Cases-
pathologically 
confirmed PC 
Control – 
healthy cancer 
free men 
Plasma 
tocopherols, 
retinol & 
carotenoids, 
NCI FFQ 
Sig. inverse associations with 
PC observed with plasma 
lycopene [OR, 0.17; 95% CI, 
0.04–0.78; P for trend, 0.0052] 
and zeaxanthin (OR,0.22; 95% 
CI, 0.06–0.83; P for trend, 
0.0028) Borderline associations 
found for lutein (OR, 0.30; 95% 
CI, 0.09 –1.03; P for trend, 
0.0064) & b-cryptoxanthin (OR, 
0.31; 95% CI, 0.08 –1.24; P for 
trend, 0.0666).  
(A Venket 
Rao, 
Fleshner, 
& 
Agarwal, 
1999) 
12 
cases 
12 
age 
match
edcon
trols 
NA NA NA Cases - 
Histologically 
conformed & 
untreated PC 
Controls- 
untreated 
muscle 
invasive 
bladder 
cancer, but no 
BPH or PC 
Serum & 
tissue 
lycopene, 
lutein, 
cryptoxanthin
, β-carotene, 
lipid and 
protein 
oxidation 
Sig  serum & tissue lycopene 
but not other carotenoids noted 
in cases; while no diff in serum 
lipid peroxidation noted, serum 
protein thiol sig  in cases. 
Role of lycopene in preventing 
oxidative damage and  risk of 
PC should be evaluated further. 
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TABLE 2.8. Cell and animal research studies investigating lycopene and radiation 
Study 
animal/
Cell 
line 
Test/Assays 
Lycope
ne dose 
Results 
(Saada, 
Rezk, & 
Eltahaw
y, 2010) 
Male 
albino 
rats  
6 Gy γ-radiation (XRT); Ileum 
tissues for xanthine oxidase; 
thiobarbituric acid reactive 
substances (TBARS); xanthine 
dehydrogenase; Superoxide 
dismutase (SOD), catalase 
(CAT), serotonin (5-HT), 
dopamine (DA), glutathione 
(GSH); norepinephrine (NE), 
epinephrine (EPI); 
monoamine-oxidase (MAO) 
5 mg/kg 
body 
weight 
Irradiated animals showed sloughing villi, ulcers, & 
ruptured goblet cells, shrinkage of submucosa 
layers & fibroblasts. Histopathological changes 
associated with sig.  in TBARS & change in 
xanthine oxidoreductase system (XOR). sig.  in 
reduced GSH, SOD & CAT seen. XRT also 
induced a sig.  in level of: 5-HT, DA, NE, & EPI 
associated with an  in MAO activity. Lycopene 
pretreatment sig.  the oxidant/antioxidant status, 
associated with sig. regeneration of small intestine, 
& improved monoamines levels. Thus, lycopene 
may protect small intestine against radiation-
induced damage. 
(Andic, 
et al., 
2009) 
Wistar 
albino 
rats 
8 Gy abdominal and pelvic 
radiation; Study endpoints: 
weight loss, diarrhea, duration 
of diarrhea, survival, & plasma 
level of TBARS. 
5 mg/kg 
body 
wt/day 
Rats receiving RT only had sig.  wt. loss rate 
compared to the lycopene + RT group (P = 0.001). 
Plasma TBARS levels after RT were also sig.  in 
the RT only group compared to lycopene + RT 
group (P = 0.001). Lycopene supplementation sig. 
 wt. loss & prevented oxidative stress in rats 
treated with abdomino-pelvic radiation. 
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TABLE 2.8. Cell and animal research studies investigating lycopene and radiation, cont’d 
Study 
animal/
Cell 
line 
Test/Assays 
Lycope
ne dose 
Results 
(Srinivas
an, 
Devipriy
a, 
Kalpana, 
& 
Menon, 
2009) 
Culture
d 
human 
lympho
cytes 
γ-radiation at 1, 2 and 4 Gy. 
The cellular changes were 
estimated by using TBARS, 
hydroperoxides (HP), the 
antioxidants SOD, CAT, 
GPx & GSH. The DNA 
damage was analyzed by 
cytokinesis blocked 
micronucleus assay 
(CBMN), dicentric 
aberration (DC) and 
translocation frequency.  
1, 5 & 
10μg/ml 
Diff. doses of γ-radiation led to sig.  in # of DC, 
micronuclei (MN), translocation frequency, TBARS & HP 
level, but levels of GSH & antiox. enzymes sig.  
compared with control. Max. damage to lymphocytes @ 
4Gy. Lycopene pretreatment (1, 5 &10μg/ml) sig.  
frequency of MN, DC & translocation when compared 
with control. level of TBARS, HP were also  & activities 
of SOD, CAT & GPx were sig.  along with GSH levels 
when compared with control. 5μg/ml lycopene more 
effective than other two doses-offering protection to 
normal lymphocytes against γ-radiation-induced cellular 
damage. 
(Srinivas
an, et 
al., 
2007) 
cultured 
rat 
hepatoc
ytes 
Cellular changes estimated 
using TBARS, SOD, CAT, 
glutathione peroxidase 
(GPx), GSH, ceruloplasmin, 
vitamins A, E, C and uric 
acid. DNA damage 
analysed by single cell gel 
electrophoresis (comet 
assay).  
1.86, 
9.31 & 
18.62 
μM 
 severity of DNA damage observed with  in γ-
radiation dose (1, 2 & 4 Gy) in cultured rat hepatocytes. 
TBARS  sig. while levels of GSH, vitamins C, E and A, 
ceruloplasmin, uric acid & antiox.enzymes sig.in γ-
irradiated groups. Max. damage to hepatocytes 
observed at 4 Gy irradiation. Pretreatment with lycopene 
(1.86, 9.31& 18.62 μM) showed a sig.  in levels of 
TBARS & DNA damage. Antiox.enzymes  sig. along 
with the levels of GSH, vitamins A, E, C, uric acid & 
ceruloplasmin. Max. protection of hepatocytes observed 
at 9.31 μM lycopene pretreatment. 
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Abstract  
 
 
Objectives: To determine the effect of radiotherapy and supplementing three 
different amounts of tomato juice on serum lycopene levels in men with prostate 
cancer.  
Methods: Dietary lycopene intake was calculated using the National Cancer 
Institute (NCI) Diet History Questionnaire. Gastrointestinal (GI) tolerance of 
tomato juice was evaluated using the NCI Cancer Therapy Evaluation Program: 
Common Toxicity Criteria v 2.0. Serum lycopene levels were determined using 
liquid chromatography-mass spectrometry. Both serum and dietary lycopene 
were used as covariates in data analysis. 
Results: Daily tomato juice supplementation (4, 8 or 12 oz) was tolerated without 
any adverse GI effects. Serum lycopene decreased in control group participants, 
while increasing from 0.33±0.11 μg/mL to 0.41± 0.12 μg/ in the intervention 
group.  No correlation between serum and dietary lycopene was observed. 
Control group participants lost weight, while participants in the intervention group 
did not. 
Major conclusions: Tomato juice, a food source of lycopene (a potent 
antioxidant) is well tolerated and does increase serum lycopene levels in men 
with prostate cancer undergoing radiotherapy.  Weight change should be 
monitored and evaluated in prostate cancer patients during radiotherapy. Larger 
clinical trials are needed to validate tomato juice use as a way to increase 
serum/dietary lycopene intake during radiotherapy in men with prostate cancer.   
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Introduction 
Dietary phytochemicals (such as lycopene) may halt carcinogenesis by 
suppressing the initiating transforming and inflammatory processes (Dorai & 
Aggarwal, 2004). Epidemiological studies (Gann et al., 1999; Giovannucci, 1999, 
2005; Vogt et al., 2002) have documented an inverse relationship between intake 
of lycopene rich foods and the development of prostate cancer. Researchers 
have also evaluated the impact of lycopene in patients with benign prostate 
hypertrophy (Edinger & Koff, 2006; Schwarz et al., 2008), and prostate cancer 
patients prior to initiating treatment (Bowen et al., 2002; Chen et al., 2001; Jatoi 
et al., 2007; Kim et al., 2003; Kucuk et al., 2001; Rao, Fleshner, & Agarwal, 
1999) and after failure of treatment (Clark et al., 2006). Data on the effectiveness 
of lycopene supplementation during radiation therapy are lacking and 
researchers have proposed an urgency in evaluating the effectiveness of 
lycopene supplementation in prostate cancer patients undergoing radiation and 
androgen oblation therapies (Clinton, 2005; Davis et al., 2005), in order to 
formulate evidence-based recommendations for this population.  
Serum antioxidant levels have been used to evaluate nutritional status and 
oxidative stress, since many of these antioxidants are essential and are utilized 
in physiological defense mechanisms (Polidori, Stahl, Eichler, Niestroj, & Sies, 
2001). Oxidative stress generated secondary to chemotherapy and radiotherapy 
may further decrease tissue antioxidant levels, thereby increasing oxidative 
stress (Simone, Simone, Simone, & Simone, 2007), and may worsen cancer 
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treatment related side effects and existing subclinical or clinical nutrient 
deficiencies (Kucuk, 2002). A relatively new trend in cancer research is utilizing 
chemopreventive agents either by themselves or as adjuncts to halt disease 
progression, prevent secondary cancers or reduce treatment toxicities (Kucuk, 
2002). In a case-controlled study, researchers demonstrated that prostate cancer 
patients have significantly lower (44%; p < 0.004) serum lycopene levels 
compared to matched controls (Rao, et al., 1999). Clinical trials evaluating the 
impact of lycopene supplementation during radiotherapy are limited, and since 
carotenoids have been reported to be preferentially utilized in oxidative states 
(Polidori, et al., 2001), we were interested in determining the level of serum 
lycopene in prostate cancer patients undergoing radiation therapy, and further 
evaluating the impact of tomato juice supplementation on serum lycopene levels. 
Consequently, we conducted this randomized controlled trial to evaluate the 
impact of three different volumes of tomato juice on serum lycopene levels during 
radiation therapy in men with localized prostate cancer. We also obtained diet 
history information to evaluate routine dietary lycopene intake among participants 
of this study. This study was part of a Phase I clinical trial evaluating the impact 
of three different volumes of tomato juice on various inflammatory markers and 
selected side effects of radiation therapy. 
Materials and Methods 
 This randomized controlled trial conducted in men newly diagnosed with 
localized prostate cancer consisted of four study arms (control group participants 
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consumed their normal diets, and three intervention groups who received 4, 8 or 
12 ounces (oz) of tomato juice in addition to their routine dietary intake). 
Participants were instructed to refrain from making any changes to their diet or 
consuming any nutritional (vitamin, mineral or other nutraceutical) supplements 
for the duration of the study. All participants received image guided intensity 
modulated radiation therapy (IMRT) to the prostate gland (treatment volume 
included prostate alone or prostate and seminal vesicles). In order to minimize 
time spent at the cancer center and avoid unnecessary follow-up visits, all 
assessments, blood draws and tomato juice administration (intervention groups 
only) were scheduled to coincide with each patient’s physician, procedure 
planning or radiation therapy appointment times. 
Seventeen men with newly diagnosed localized prostate cancer, receiving 
≥ 72 Gray (Gy) of external radiation to the prostate alone or prostate and seminal 
vesicles completed this pilot study. Sample recruitment was consecutive and 
nonprobabilistic, since we included all patients meeting the eligibility criteria who 
were referred to the Hayworth Cancer Center at High Point Regional Health 
System (HPRHS) between April 2009 and October 2010. Participant screening 
was conducted in two stages: a preliminary screening was conducted by the 
radiation oncologist (BF) at the time of initial consult based on treatment area, 
type and dose. Patients meeting preliminary screening criteria signed a Health 
Insurance Portability and Accountability Act (HIPAA) form granting access to 
their medical information for detailed medical record review. In addition, patient 
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interviews were also conducted (MD) to thoroughly screen potential participants 
based on the study eligibility criteria.  The Institutional Review Boards at the 
University of North Carolina Greensboro (UNCG) and HPRHS approved the 
study protocol. All participants provided written informed consent prior to 
enrolling in the study. 
The eligibility criteria included – histologically confirmed localized prostate 
adenocarcinoma with no lymph node involvement or metastasis; normal immune, 
liver and renal function; and Eastern Cooperative Oncology Group (ECOG) 
performance score of 0 or 1. Exclusion criteria included: post prostatectomy, 
chemotherapy or other prior treatment for prostate cancer. Patients who received 
hormone therapy or participated in other treatment based clinical trials 
concurrently while receiving radiation therapy were also not eligible to participate 
in this study. Patients who were allergic to tomato products or red dye; had pre-
existing uncontrolled gastro-esophageal reflux disease and other malabsorptive 
disorders, or hyperkalemia; or routinely consumed (and unwilling to stop these 
supplements during treatment) fiber, saw palmetto, lycopene, omega-3 fatty 
acids/fish oil, EPA/DHA, vitamin C, E, A; β-carotene, flaxseeds and flaxseed oil 
supplements were also ineligible to participate in this study. Any potential 
participants consuming these specified supplements at the time of the initial 
interview were asked to discontinue these supplements until the end of 
treatment. This allowed for a wash-out period of several weeks before radiation 
treatment commenced. Verbal confirmation was obtained on the first day of 
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treatment to insure that the participants had discontinued use of supplements as 
previously instructed.  
Names of each group (control, 4, 8, or 12 oz) and the participant number 
for that group were written on a piece of folded paper. The patient or 
accompanying family member then picked one of the folded pieces of paper and 
handed it to the investigator (MD) who transcribed the group assignment, writing 
it on the participant screening form and informing the participant and family 
members.  
Assigned volume of tomato juice (4, 8 or 12 oz) was initiated two days 
prior to participants receiving the first dose of radiation therapy and continued 
daily until the last day of treatment. Participants in the intervention groups were 
provided with the measured amount of their assigned volume of tomato juice for 
consumption over the weekend and on holidays. Verbal confirmation of tomato 
juice consumption was obtained at the subsequent treatment day. Participants 
were instructed to consume tomato juice with either a meal or a snack with at 
least five grams of fat to facilitate lycopene absorption. During treatment days, 
participants were asked to consume their assigned volume of tomato juice and 
crackers (providing at least five grams of fat) after their radiation treatment, prior 
to leaving the cancer center, which was observed by the researcher (MD). 
Caloric contribution of the tomato juice and crackers was 121 kcal (4 oz), 146 
kcal (8 oz) and 171 kcal (12 oz) daily (Table 3.3). Participants were asked to 
maintain their normal diets during the study. We used the National Cancer 
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Institute (NCI) Diet History Questionnaire (DHQ) ("Diet History Questionnaire,") to 
obtain participant’s diet history and routine dietary lycopene intake once during 
the study period. The DHQ was given to the participants prior to starting radiation 
therapy and all participants except one returned the completed DHQ within two 
weeks of starting treatment. Participants were weighed by the nursing staff on 
the first day of treatment (baseline) and then once a week during treatment on a 
stationary platform scale in the radiation therapy department at HPRHS. 
In order to evaluate (gastrointestinal) tolerance of tomato juice 
supplementation, the NCI Cancer Therapy Evaluation Program: Common 
Toxicity Criteria (CTC) v 2.0 ("Cancer therapy evaluation program. Common 
Toxicity Criteria, v2.0," 1999) was used. The CTC evaluates adverse events on a 
scale of 0-5 (TABLE 3.1) and any participant exhibiting toxicity grade ≥3 would 
have been withdrawn from the study by the researchers.   
Standardized planning and filming protocol was followed, and participants 
were treated on a Linear Accelerator 2100 iX (Varian Medical Systems, CA). A 
diagnostic image obtained prior to each treatment was approved by the treating 
Radiation Oncologist. The prescribed radiation dose ranged between 72.50-
79.20 Gy and treatment days varied between 29-44 days. Consequently, daily 
fractions ranged from 1.8-2.5 Gy. 
 Participants provided blood samples at baseline, midpoint (end of three 
weeks of treatment) and on the last day of treatment. Whole blood was collected 
in aluminum foil wrapped vacutainer tubes, and transported on ice to the 
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laboratory at UNCG. In order to minimize loss of lycopene, tubes were wrapped 
in aluminum foil immediately after collection and blood samples were processed 
under a yellow light. After centrifuging (3000 rpm x 20 min at 40C) whole blood, 
the separated serum was divided into aliquot tubes labeled with patient ID, time 
point of blood draw (baseline, midpoint or endpoint) and stored at -800C until 
analyzed. Serum and tomato juice samples were shipped under dry ice to Dr. 
Wei Jia’s laboratory at the Kannapolis Research Campus, NC, for lycopene 
analysis using liquid chromatography-mass spectrometry (LC-MS). 
 Stock solution for lycopene standard was prepared by dissolving ~1 mg of 
the standard in 1 mL of chloroform followed by storage at -80 °C. Fresh 
calibration solutions were prepared each day from the stock solution. Calibration 
curves were obtained using freshly prepared lycopene standard solutions in the 
range of 0.005-10 μg/mL in acetonitrile/methyl tert-butyl ether (MTBE) (1:1, v/v).  
Aliquots of 10 μL of each standard solution were injected onto the column for LC 
analysis, and calibration curves were constructed by linear regression analysis of 
the area versus the concentration of lycopene.  
Lycopene from tomato juice was extracted with an extraction mixture 
(hexane, methanol, acetone, 2:1:1, v/v/v, containing 2.5% butylated 
hydroxytoluen (BHT)). Tomato juice (200 μL) was extracted with the extraction 
mixture (600 μL). Samples were vortexed for one min and then centrifuged for 5 
min at 13,000 rpm at 40C. Aliquots of 10 μL of the supernatant were diluted to 1 
mL with the mobile phase for the HPLC injection. To prepare serum for lycopene 
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analysis, 300 μL serum was mixed with same amount of ethanol.  The mixture 
was extracted twice with 600 μL of hexane containing 100mg/L BHT. The hexane 
extracts were collected after being centrifuged at 13,000 rpm for 5 min (40C), 
combined, and evaporated to dryness under vacuum.  The extract was 
reconstituted in 100 μL of acetonitrile/MTBE (1:1, v/v). An aliquot of 10 μL was 
injected onto the LC for lycopene measurement.  An Agilent HPLC 1200 system 
equipped with a binary solvent delivery manager and a sample manager (Agilent 
Corporation, Santa Clara, CA, USA) is used with chromatographic separations 
performed on a 4.6 × 150 mm 5 μm Agilent ZORBAX Eclipse XDB-C18 
chromatography column. The flow rate was 1 mL/min. Elution solvent A was 
acetonitrile and solvent B was MTBE. The LC elution conditions are optimized 
with isocratic acetonitrile/MTBE (45:55, v/v). The column is maintained at 200C. 
The detection wavelength was set at 472 nm. A 10 μL aliquot reference 
standards and 10 μL samples were injected onto the column, respectively. 
 On the last day of treatment, the researcher (MD) asked each participant 
about his reasons for participating in the study, whether he was glad to have 
participated, and if he would recommend any changes to the study protocol. 
 Descriptive statistics were used to analyze key participant and cancer 
related characteristics. Between group differences were detected using the non-
parametric Wilcoxon Rank Sum analysis. We also conducted Spearman’s 
correlation to determine any associations between dietary and serum lycopene 
levels and select lifestyle characteristics, and stepwise regression to detect the 
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strength of this relationship. Repeated measures were used to evaluate within 
group change over time. One-sided level of significance was established at p ≤ 
0.05. Between-group comparisons with p between 0.051-0.10 were identified as 
demonstrating a trend towards significance. 
Results 
The flow diagram describes participant screening, final enrollment, attrition 
and reasons for participant exclusion (Figure 3.1). Seventeen men between the 
ages of 61 and 77 years completed this pilot study. Seventy-one percent of 
participants had clinical stage T1c prostate adenocarcinoma, followed by 18% 
with stage T2a and 6% each with stage T2b and T2c (data not shown). The 
largest proportion of our participants was non-Hispanic Whites (71%), followed 
by African-Americans (24%) and 6% of Peruvian descent. Despite a higher 
prevalence of prostate cancer reported among African-Americans ("Cancer Facts 
and Figures 2010," 2010), only 24% of our participants were African-American. 
This may be due to poor/limited access to health care and/or poor likelihood of 
localized prostate cancer diagnosis in African-Americans ("Cancer Facts and 
Figures 2010," 2010; Jemal, Siegel, Xu, & Ward, 2010). Height was statistically 
different between the control group and 12 oz group participants (p = 0.026); 
however, no differences were detected among groups for weight or body mass 
index (BMI). A majority (82%) of study participants in our study were married, 
and 71% reported less than or equivalent to a high school education (Table 3.2).  
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The most frequently (88%) observed medical diagnoses among study 
participants were hypercholesterolemia and hypertension. Thirty-five percent of 
participants had a diagnosis of diabetes but did not report following a “strict” diet 
for diabetes management/control. Only about 6% of participants reported still 
smoking compared with 65% of participants who reported consuming alcohol. 
One participant in the 4 oz treatment group reported changing his diet and 
activity significantly in the months prior to starting radiation therapy, but this was 
unrelated to his cancer diagnosis (data not shown). Overall, 71% of participants 
reported consuming one or more over-the-counter herbal/nutritional supplements 
at the time of enrollment. A multivitamin was the most commonly consumed 
(47%) supplement followed by fish oil/omega-3 fatty acid (29%). Other nutritional 
supplements consumed included vitamin D (18%), fiber (12%), vitamin C (12%), 
and 6% reported consuming either vitamin E, flax seeds, saw palmetto or 
coenzyme Q10 (Table 3.2). Twelve percent of the participants also reported 
using “eye” vitamin drops. Participants discontinued use of all supplements for 
the duration of the study. No statistically significant differences were detected 
between groups for supplement use. We did, however, find a significant positive 
correlation between supplement use and diagnosis of hypertension (r = 0.556, p 
= 0.009, n = 17) and observed a significant trend between supplement use and 
education level (r = 0.337, p = 0.093, n = 17). 
Participants in all three treatment groups tolerated the tomato juice well 
with no reported gastrointestinal side effects (nausea, vomiting, or heartburn) 
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(data not shown). Participants in the intervention groups received 121 kcal (4 oz), 
146 kcal (8 oz) and 171 kcal (12 oz) daily from the tomato juice and crackers 
(Table 3.3). When asked, some participants reported changes in their daily meal 
pattern or quantity of food intake in the meal closest to the time they received 
their tomato juice supplement at the cancer center. Not surprisingly, lycopene 
from tomato juice was statistically different between groups (Table 3.3).  Macro 
and select micro nutrient analysis obtained from participant-reported DHQs are 
reported in Table 3.4.  While a large variation was noted in energy intakes 
reported by participants among the four groups, caloric intake between only the 
control group and 8 oz group was statistically significant (p = 0.0476). Calculated 
dietary lycopene intake between the control group and 12 oz group (p = 0.0357) 
and 4 and 12 oz groups (p = 0.0286) were statistically significant.  Intervention 
group participants received an estimated additional 8 mg, 18 mg, or 28 mg daily 
dose of lycopene from their assigned volume (4, 8 or 12 oz per day) of tomato 
juice. Total dietary lycopene (diet+supplemetal) intake was also statistically 
significantly different between groups (Table 3.4). We found a significant positive 
correlation (r = 0.517; p = 0.017; n = 17) with education level and reported dietary 
lycopene intake and a significant trend between hypertension and reported 
dietary lycopene intake (r = 0.335, p = 0.094, n = 17), indicating that participants 
with higher education and a diagnosis of hypertension reported higher intake of 
dietary lycopene.  
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No significant differences in body weight were detected among 
participants in any group at the beginning of the study. While very little variation 
in body weight was observed among the 4 oz and the 12 oz intervention group 
participants from the beginning to the end of the study, participants in the control 
group lost nine pounds while participants in the 8 oz group gained about eight 
pounds (Table 3.5). 
 Mean serum lycopene level for all study participants at baseline was 0.30 
μg/mL and ranged between 0 to 1.04 μg/mL.  When baseline levels were 
evaluated by study group, participants in the 8 oz group had the highest baseline 
lycopene level (0.51±0.17 μg/mL). Two participants in both 4 and 12 oz groups 
had no detectable serum lycopene at baseline.  We detected a significant 
decrease (p = 0.009) in serum lycopene levels among control group participants 
over time, but not any of the intervention groups.  However, overall serum 
lycopene levels increased with daily tomato juice supplementation.  Intervention 
group mean serum lycopene increased from 0.33±0.11 μg/mL at baseline to 
0.41± 0.12 μg/mL at endpoint. Participants in the 4 oz group demonstrated a 
progressive, yet non-significant decrease, while 8 oz group participants 
demonstrated a significant increase (p = 0.056 comparing percent change from 
baseline to midpoint and p = 0.095 comparing percent change from baseline to 
endpoint) in serum lycopene throughout treatment. All participants in the 12 oz 
group had measureable levels at midpoint and endpoint versus only one at 
baseline. We detected significant between-group differences in serum lycopene 
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levels at various time points (Table 3.4). Total lycopene intake per kilogram of 
body weight varied considerably: 0.07 mg/Kg (control group), 0.14 mg/Kg (4 oz), 
0.27 mg/kg (8oz) and 0.53 mg/kg (12 oz group). These values were statistically 
significantly different (p < 0.01) between groups.  
 A significant positive correlation was detected between serum lycopene, 
weight (r = 0.525; p = 0.015; n = 17) and BMI (r = 0.541; p = 0.012; n = 17), and 
a negative correlation between serum lycopene and prior nutritional supplement 
use (r = -0.464; p = 0.030; n = 17). While not statistically significant, we also 
observed a negative trend between serum lycopene, smoking (r = -0.359; p = 
0.078; n = 17) and diagnosis of hypertension (r = -0.356; p = 0.080; n = 17).  
However, in the final stepwise regression model, BMI (but not weight) and 
smoking were the two variables that explained 56% of the variance [F(2, 14) = 
8.833, p = 0.003] in serum lycopene level. 
 The majority of participants (65%) reported taking part in the study 
because they “liked the idea of tomato juice helping reduce side effects of 
treatment.” Forty seven percent of the participants also reported participating in 
the hopes that the results of the study would “help other people.” Ninety-four 
percent of participants reported being glad that they participated in our clinical 
trial. Only one participant was dissatisfied, primarily because he was randomized 
into the control group and he wanted to participate in one of the intervention 
groups. While several participants remarked on the length of the DHQ while 
92 
 
completing the questionnaire, only one participant suggested shortening the 
DHQ during the exit interviews. 
Discussion 
We evaluated food based lycopene (tomato juice) supplementation in this 
randomized control trial in men undergoing radiation therapy for localized 
prostate cancer. The primary goal of this study was to evaluate serum lycopene 
levels during prostate radiation therapy and the impact of three different volumes 
of tomato juice administered daily on serum lycopene levels during radiation 
therapy. Secondary goals were to determine reported dietary lycopene intake in 
participants enrolled in our study and their reasons for participating in this clinical 
trial.  We were able to demonstrate an increase in serum lycopene levels with 
daily tomato juice supplementation in men with prostate cancer undergoing 
radiation therapy. Serum lycopene levels ranging from 0.43 μmol/L in BPH 
(Schwarz, et al., 2008) to 0.64 μmol/L in prostate cancer patients (Bowen, et al., 
2002) have been reported, similar to levels (0.55 μmol/L or 0.30 μg/mL) that we 
obtained at baseline. While Mayne et al (Mayne et al., 1999) have reported an 
association between serum and dietary lycopene intake, we did not observe this 
association. Inaccurate reporting of dietary lycopene, inconsistent digestion and 
absorption have been postulated as some of the reason why a  poor correlation 
between dietary intake and serum levels of lycopene may be observed (Hadley, 
Miller, Schwartz, & Clinton, 2002) . We also did not detect an association 
between alcohol intake, ethnicity, marital status or age as reported by Porrini and 
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Riso (Porrini & Riso, 2005). While an optimum time (before or after radiation 
exposure) for initiating an antioxidant supplement has not been identified (S. L. 
Brown et al., 2010), we choose to initiate tomato juice supplement two days 
before radiation therapy started. Researchers have reported that lycopene 
reaches maximum concentration in the serum 15-48 hours after consumption 
(Gustin et al., 2004; Stahl & Sies, 1992), and our goal was to insure the presence 
of lycopene in the serum of participants at the commencement of radiation 
therapy, to evaluate the impact of radiation induced oxidative stress on serum 
lycopene levels with daily tomato juice intake during radiation treatment. 
 Dietary lycopene intake was estimated once using the DHQ. Mean 
reported dietary lycopene intake among participants was 7.24±1.48 mg/day 
(range 1.56-23.59 mg/day).  Matulka et al (Matulka, Hood, & Griffiths, 2004) 
reported mean daily intake of lycopene to be about 8.2 mg/day, and lycopene 
intake ranging between 0.32-15.03 mg/d (Yong et al., 1994) has also been 
reported. We observed great variability among our participants in the reported 
consumption of lycopene. We found significant differences in reported dietary 
lycopene intake between the 12 oz group and 4 oz and control groups. Since 
most participants completed the DHQ within the first few weeks of treatment, we 
do not believe that the tomato juice supplement accounts for any of the 
differences in calculated dietary lycopene consumption. We found a positive 
correlation between education and dietary lycopene intake, perhaps indicating 
that participants with higher education included more variety (higher fruits and 
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vegetables) in their diet. While we did not find a correlation between education 
and dietary supplement use, a positive trend was observed, indicating that these 
men may be trying to lead a more “healthier” lifestyle, as reported by Wiygul et al 
who also reported similar supplement use in men diagnosed with prostate cancer 
(Wiygul et al., 2005). 
We observed some weight loss in control group participants, while 
intervention group participants either maintained or gained weight (Table 3.5). 
Participants in the intervention groups received additional 121 kcal (4 oz), 146 
kcal (8 oz) and 171 kcal (12 oz) daily (Table 3.4), which may account for perhaps 
1.47 pounds weight gain in the 4 oz group, 1.61 pounds in the 8 oz group and 
1.89 pounds in the 12 oz group if they maintained their usual dietary intake. 
Since we did not routinely monitor dietary intake beyond verbally ascertaining 
several times during the study that participants were maintaining their usual diet 
intake, we are unable to quantify whether any change in weight was related to 
the calories provided by the tomato juice and crackers or to other factors (such 
as fluid shifts/changes). In future studies, an isocaloric beverage with same 
amount of crackers should be provided to the control group participants to insure 
no discrepancies in caloric and volumetric intake. Similar trends in weight change 
have been reported in animal studies. Andic et al (Andic, Garipagaoglu, 
Yurdakonar, Tuncel, & Kucuk, 2009) reported weight loss in rats receiving 
radiation therapy without supplemental lycopene, and speculated that this may 
be a result of radiation induced anorexia and nausea. While control group 
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participants did not report any changes in appetite, other factors such as fatigue 
or biochemical changes (cytokine expression) may have contributed to their 
weight loss and should be monitored in these patients (Plata-Salamán, 1996). 
Participants in our study tolerated the tomato juice supplemented daily 
during radiation therapy, as evidenced by no reported GI side effects (heartburn, 
nausea, or vomiting).  Based on the responses received during the exit interview, 
our participants were enthusiastic about participating in a food-based trial, in 
order to reduce side effects of treatment. Reasons for participation  were similar 
to those reported by Jatoi et al (Jatoi, et al., 2007), however, our participants did 
not report any adverse effects with daily tomato juice supplementation. Our 
participants had received no prior treatment for prostate cancer, and their 
disease was also localized, unlike the participant demographics reported by Jatoi 
et al (Jatoi, et al., 2007).  Reasons for differences in tomato juice tolerance 
remain unclear. 
This study has several strengths. To our knowledge, this is the first clinical 
trial to evaluate serum lycopene levels, tolerance of food-based lycopene 
supplementation and its impact on serum lycopene levels in men with localized 
prostate cancer undergoing radiation therapy. Lycopene intake was estimated 
using the DHQ. The DHQ was selected for estimating lycopene rich foods since it 
has been tested with older adults (Subar et al., 2001) and because it would 
require less work for the participants as compared to other available methods 
such as maintaining a food diary.  It calculates average intake over a 12 month 
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period so that day-to-day or seasonal variations in dietary intake are included in 
the estimated amounts. Since we used a whole food approach instead of an 
isolated nutrient, there is a potential for greater beneficial effects due to the 
synergistic effect of all nutrients present (Norman et al., 2003) in tomato juice. 
We chose tomato juice as a vehicle for lycopene delivery because it is a 
processed tomato product, convenient to administer and consume. Additionally, 
this is a safe and effective way to increase consumption of vegetable intake 
among a population of men who typically have poor reported intake of fruits and 
vegetables.  
This study had several limitations as well. These include a small sample 
size, which may have prevented us from detecting statistical significance and 
limits generalizability of these results.  Due to variations in scheduling radiation 
treatments, blood was also not drawn from participants after an overnight fast. 
Serum lycopene levels may be influenced by any lycopene intake in a recent 
meal, however, researchers have demonstrated that the serum concentration of 
carotenoids does not change significantly for up to four hours after a meal (E. D. 
Brown, Rose, Craft, Seidel, & Smith, 1989; Mejia & Arroyave, 1983; Mejia, 
Pineda, Noriega, Benitez, & Falla, 1984). Additionally, we only measured total 
lycopene content in the serum.  Cis and trans isomers of lycopene should also be 
evaluated to determine clinical correlates. 
To conclude, tomato juice supplementation to increase dietary lycopene 
intake as a means to improve serum lycopene is feasible and easily accepted 
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among this sample of prostate cancer patients undergoing radiation therapy.  
Since lower serum lycopene levels have been reported in prostate cancer 
patients (Rao, et al., 1999) and antioxidants may decrease due to oxidative 
stress generated by radiation therapy, processed tomato juice supplementation 
can be used to increase serum lycopene levels in men with prostate cancer 
undergoing radiation therapy. While we did not observe a dose-dependent 
response to tomato juice supplementation, we did observe a variable response to 
increased intake of tomato juice.  Although we did not detect an association 
between dietary and serum lycopene, this lack of association may perhaps be 
explained by tissue lycopene uptake which we did not measure. These biomarker 
results need to be validated in larger clinical trials. 
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Table 3.1. Supplement (tomato juice) toxicity evaluation ("Cancer therapy 
evaluation program. Common Toxicity Criteria, v2.0," 1999) 
Criteria Grade 
0 
Grade 1 Grade 2 Grade 3 Grade 4 
Weight loss None 
(<5%) 
5-<10% of 
baseline, 
intervention not 
indicated 
10-<20% of 
baseline; 
nutrition 
support 
indicated 
 
> 20% of 
baseline; TF 
or TPN 
indicated 
--- 
Nausea None Able to eat 
reasonable 
intake 
Intake 
significantly 
decreased but 
can eat 
 
No significant 
intake 
----- 
Vomiting None 1 episode in 24 
hours over 
pretreatment 
2-5 episodes 
in 24 hours; IV 
fluids 
indicated < 24 
hrs 
≥ 6 episodes 
in 24 hours,  
IV fluids or 
TPN 
indicated > 
24 hrs 
 
Life 
threatenin
g 
conseque
nces 
Heartburn None  Mild  Moderate Severe - 
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Figure 3.1: Flow diagram representing recruitment and randomization of study 
participants 
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Table 3.2. Participant characteristics. Data are reported as mean ± standard 
error of the mean or number (%).   
 Control 
(n = 5) 
4 Oz 
(n = 4) 
8 Oz 
(n = 5) 
12 Oz 
(n = 3) 
Age 69.40±1.91 66.25±1.89 68.20±2.22 72.33±3.28 
Height* 66.40± 0.87* 70.50±1.44 70.60±1.36 71.17±0.93* 
Weight 167±13.11 193±14.61 221±30.74 168±28.41 
BMI (kg/m2) 27±1.97 27±1.30 30±3.22 23±4.10 
Ethnicity     
African American 2 (40) 1 (25) 1 (20) 0 
Caucasian 2 (40) 3 (75) 4 (80) 3 (100) 
Other 1 (20) 0 0 0 
Education     
< High School 1 (20) 2 (50) 2 (40) 0 
High School 3 (60) 1 (25) 1 (20) 2 (67) 
> High School 1 (20) 1 (25) 2 (40) 1 (33) 
Marital Status     
Married 4 (80) 4 (100) 4 (80) 2 (67) 
Divorced 1 (20) 0 1 (20) 1 (33) 
Diabetes     
Yes 2 (40) 2 (50) 1 (20) 1 (33) 
No 3 (60) 2 (50) 4 (80) 2 (67) 
Hypertension     
Yes 5 (100) 4 (100) 4 (80) 2 (67) 
No 0 0 1 (20) 1 (33) 
Hypercholesterolemia     
Yes 4 (80) 4 (100) 4 (80) 3 (100) 
No 1 (20) 0 1 (20) 0 
Routine use of supplements     
Yes 4 (80) 3 (75) 4 (80) 1 (33) 
No 1 (20) 1 (25) 1 (20) 2 (67) 
Supplements Evaluated     
Fiber† 0 0 2 (40) 0 
Multivitamin† 3 (60) 1 (25) 4 (80) 1 (33) 
Saw Palmetto† 0 0 1 (20) 0 
Vitamin C† 0 1 (25) 1 (20) 0 
Vitamin D† 2 (40) 0 1 (20) 0 
Vitamin E†  0 0 1 (20) 0 
Omega-3 Fatty acids/Fish oil† 1 (20) 1 (25) 3 (60) 0 
Flax seeds OR flaxseed oil† 0 1 (25) 0 0 
Coenzyme Q10† 0 1 (25) 0 0 
Eye Vitamin† 0 0 2 (40) 0 
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† Data reported indicate affirmative responses from participants using these 
supplements.          *p < 0.05 (one sided) 
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Table 3.3: Nutritional contribution from crackers and tomato juice provided to 
participants daily during IMRT  
 4 Oz 
(n = 4) 
8 Oz 
(n = 5) 
12 Oz 
(n = 3) 
6 crackers    
Calories (kcal) 96 96 96 
Fat (gm) 5.4 5.4 5.4 
Sodium (mg) 162 162 162 
Potassium (mg)  12 12 12 
Tomato Juice    
Calories (kcal) 25 50 75 
Sodium (mg) 340 680 1020 
Potassium (mg)  215 430 645 
Lycopene (mg) 7.85ab 17.52ac 28.09bc 
 
ac; p = 0.011 (between group differences) 
b; p < 0.001 (between group differences) 
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Table 3.4: Reported nutritional information obtained using the Diet History 
Questionnaire ("Diet History Questionnaire,"), measured and percent change in 
serum lycopene levels. Data are reported as mean ± standard error of the mean. 
Nutrients Control 
(n = 5) 
4 Oz 
(n = 4) 
8 Oz 
(n = 5) 
12 Oz 
(n = 3) 
Energy (Kcal) 1634±276.8a 2202±496.3 3015±668.2a 2296±969.4 
Protein (gm) 56±7.3 89±25.0 84±21.01 72±31.2 
Total Fat (gm) 63±10.9 81±18.8 88±16.0 86±45.7 
Saturated fat (gm) 17±3.42 25±6.75 27±4.82 23±10.1 
Monounsaturated fat 
(gm) 
24±4.02 32±6.84 38±8.20 34±18.5 
Polyunsaturated fat 
(gm) 
17±3.36 18±3.75 17±2.90 23±14.6 
Cholesterol (mg) 187±39.95 278±110.50 306±63.48 160±56.4 
Dietary Fiber 19±8.16 21±2.89 20±3.08 23±8.9 
Dietary Lycopene 
(mg) 
4.77±1.31b 4.00±1.23c 9.35±3.88 12.19±3.58bc 
Total (diet+TJ) 
dietary lycopene 
(mg)  
4.77de 11.85fg 26.87dfh 40.27egh 
Measured Serum 
Lycopene (μg/mL) 
    
Baseline 0.209±0.07 0.295±0.21 0.514±0.17i 0.082±0.08i 
Midpoint 0.137±0.05j 0.272±0.08k 0.534±0.09jkl 0.069±0.01l 
Endpoint  0.167±0.07m 0.257±0.07 0.622±0.25m 0.253±0.20 
Percent Change 
Serum lycopene 
    
Midpoint-Baseline -135.21 -572.15 8.83 -30.74 
Midpoint-Endpoint -21.87 -3.34 -53.33 3.15 
Endpoint-Baseline -151.29 -97.79 -47.15 -15.21 
p<0.05 (one sided) 
Between group differences  
abchilp< 0.05  degp≤ 0.001 fmp< 0.03  jp< 0.005  kp< 0.01  
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Table 3.5: Measured weekly weight of participants undergoing IMRT. Data are 
reported as mean ± standard error of the mean. 
 Control 
(n = 5) 
4 Oz 
(n = 4) 
8 Oz 
(n = 5) 
12 Oz 
(n = 3) 
Starting Weight (lbs) 167±13.11 193±14.61 221±30.74 168±28.42 
Week 1 (lbs) 167±12.94 195±14.01 220±29.75 168±26.82 
Week 2 (lbs) 167±13.09 194±13.81 221±30.42 168±26.39 
Week 3 (lbs) 168±13.52 194±14.08 221±30.10 169±27.02 
Week 4 (lbs) 166±13.00 195±14.60 223±30.46 168±26.91 
Week 5 (lbs) 167±13.37 195±13.91 222±30.48 168±27.06 
Week 6 (lbs) 158±17.33 195±13.67 224±38.66 168±27.15 
Week 7 (lbs) 158±17.19 195±13.74 229±38.20 168±26.24 
Weight Change (lbs) -9 lbs +2 lbs +8 lbs None 
One sided level of significance (p<0.05). No significant between group 
differences detected. 
Lbs = pounds 
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Abstract 
 
  
Purpose: Evaluate selected inflammatory mediator levels in serum and the 
impact of different volumes of tomato juice on these, in prostate cancer patients 
undergoing radiotherapy.  
Principle results: All participants exhibited inflammation at baseline. Increased 
c-reactive protein (CRP) and interleukin-6 (IL-6) was observed in control group, 
while decreases in serum CRP, IL-6 and prostaglandin E2 (PGE2) levels were 
observed in intervention groups. Serum tumor necrosis factor-α was not detected 
in these participants at any time point.  
Major Conclusions: Systemic inflammation was observed pretreatment and 
tomato juice supplementation appears to decrease serum CRP, IL-6 and PGE2 
levels in localized prostate cancer patients undergoing radiotherapy.  
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Introduction 
Inflammation is now one of the acknowledged causes of carcinogenesis 
(Baniyash, 2006). However, the link between prostate cancer and inflammation is 
still considered “suggestive” (De Marzo, Marchi, Epstein, & Nelson, 1999; De 
Marzo et al., 2007; Palapattu et al., 2005; Schottenfeld & Beebe-Dimmer, 2006; 
Sciarra et al., 2008; Wagenlehner et al., 2007) since a direct causal relationship 
has not yet been demonstrated (Haverkamp, Charbonneau, & Ratliff, 2008). 
Biopsies obtained from patients with benign prostate hypertrophy and prostate 
cancer (Lehrer et al., 2005) do provide evidence of the presence of chronic 
inflammation in prostate carcinogenesis. Several pro-inflammatory mediators 
such as cytokines, chemokines, inflammatory enzymes, etc., have been 
implicated in fostering chronic inflammation (Aggarwal, Shishodia, Sandur, 
Pandey, & Sethi, 2006). Increased levels of c-reactive protein (CRP), interleukin-
6 (IL-6), cyclooxygenase-2 (COX-2) and other inflammatory markers have been 
reported in various stages of prostate carcinogenesis (McArdle, McMillan, Sattar, 
Wallace, & Underwood, 2004; Pfitzenmaier et al., 2003).  Researchers have 
recently also reported the up-regulation of several inflammatory markers in men 
with prostate cancer undergoing radiation therapy (Christensen et al., 2009; 
Johnke et al., 2009).   
CRP, an acute phase protein (Ford, Liu, Mannino, Giles, & Smith, 2003; 
Helzlsouer, Erlinger, & Platz, 2006; Lehrer, et al., 2005), is a sensitive, yet non-
specific marker of inflammation and is reported to be elevated in cancer patients 
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(Walsh, Mahmoud, & Barna, 2003).  Radiation therapy has also been proposed 
as an independent cause of CRP elevation (Cengiz, Akbulut, Atahan, & Grigsby, 
2001). CRP levels are inversely associated with circulating levels of lycopene 
along with other carotenoids, retinoids and antioxidants (Ford, et al., 2003; 
McMillan et al., 2002). 
Tumor necrosis factor- α (TNF-α) is a key player in the body’s 
inflammatory response, and can promote carcinogenesis by facilitating the 
growth of initiated cancer cells and by involving surrounding inflammatory cells 
(Balkwill, 2006). TNF-α is recognized not only for its role in carcinogenesis, but 
also for its ability to induce other inflammatory mediators such as NF-kB 
(Balkwill, 2006), and ultimately the acute phase response along with increasing 
prostaglandin, leukotriene and collegenase synthesis (Huang, Ghai, & Ho, 2004). 
TNF-α may induce a cascade of secondary mediators such as IL-1 that may be 
responsible for some of the physiological effects observed in various 
inflammatory conditions, independent of serum TNF-α levels (Kevin J. Tracey & 
Cerami, 1994).  
IL-6 is a pleiotropic cytokine (Song & Kellum, 2005) that is involved in 
several key cellular functions such as proliferation, differentiation, angiogenesis 
and apoptosis (Culig, Steiner, Bartsch, & Hobisch, 2005), and has also been 
implicated in the development and progression of several tumors including the 
prostate (Culig, et al., 2005; Stark et al., 2009). Researchers have reported 
higher IL-6 levels in patients with prostate cancer, and have linked IL-6 along 
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with TNF-α and IL-1 with cancer progression (Bouraoui et al., 2008). While TNF-
α and IL-1 stimulate the release of IL-6, it remains in the plasma longer than 
TNF-α and IL-1 and, consequently, is considered a key indicator of the activation 
of pro-inflammatory cytokines (Song & Kellum, 2005). Researchers have also 
recently demonstrated that IL-6 is upregulated in the plasma of men with prostate 
cancer undergoing radiation therapy (Christensen, et al., 2009; Johnke, et al., 
2009).  
Prostaglandin E2 (PGE2) is a key player in the immune suppression 
associated with inflammation (Ben-Baruch, 2006).  It is synthesized by COX-2 
and together they have demonstrated great potential as targets for cancer 
therapy (Ben-Baruch, 2006). COX-2 and PGE2 are over-expressed in both 
prostate intraepithelial neoplasia and prostate cancer (Kirschenbaum, Liu, Yao, & 
Levine, 2001).  Radiation therapy may also induce inflammation and up-regulate 
PGE2 (Dorai & Aggarwal, 2004; Milas & Hanson, 1995; Steinauer et al., 2000) 
and other inflammatory markers. COX-2 can be induced by other pro-
inflammatory cytokines such as TNF-α and IL-1 (Keskek et al., 2006). Sustained 
levels of COX-2 may play a key role in radiation-induced intestinal side 
effects/toxicities, by amplifying toxicities and by increasing their duration and 
severity (Keskek, et al., 2006). Upregulation of PGE2 has been implicated in 
radiation induced inflammatory changes in the bowel (Cole, Slater, Sokal, & 
Hawkey, 1993). Enhanced patient response to radiation therapy has been 
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proposed with the inhibition of COX-2 levels in prostate cancer patients (Khor et 
al., 2007). 
Radiotherapy targets normal tissues and organs along with the cancer 
tissues by generating free radicals (Prasad, Cole, Kumar, & Prasad, 2002), 
inducing oxidative stress through generation of reactive oxygen species (ROS) 
and subsequent imbalance between pro-oxidants and antioxidants in the cell 
(Srinivasan et al., 2007). Tissue antioxidant levels can become depleted as a 
result of oxidative stress generated secondary to chemotherapy and 
radiotherapy, thereby increasing the level of oxidative stress (Simone, Simone, 
Simone, & Simone, 2007). Radiation therapy has been reported to induce 
cytokine expression (Friedman, 2002) along with triggering the acute phase 
response (Cengiz, et al., 2001; Koc, Taysi, Sezen, & Bakan, 2003).  Researchers 
hypothesize that expression of radiation induced cytokines may be tissue specific 
(Stone, Coleman, Anscher, & McBride, 2003) and that these may serve as useful 
indicators of toxicity to the cells and tissues during radiation therapy for prostate 
cancer (Christensen, et al., 2009). Antioxidants can modulate cytokine levels in 
tissues, consequently reducing the inflammatory response (Okunieff et al., 2008). 
Several mechanisms have been proposed to explain the anti-inflammatory 
actions of tomato products/lycopene. These include antioxidative action, 
inhibition of IL-6, induction of phase II enzymes (Wertz, 2009), and modulation of 
the cyclo-oxygenase pathway (De Stefano et al., 2007; Sengupta, Ghosh, Das, 
Bhattacharjee, & Bhattacharya, 2006). We conducted this randomized controlled 
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trial to evaluate the levels of select serum markers of inflammation (CRP, TNF-α, 
IL-6 and PGE2) in men with localized prostate cancer undergoing radiation 
therapy. We were also interested in determining the impact of different volumes 
of tomato juice, dietary and serum lycopene on these select serum markers of 
inflammation during radiation therapy in this patient population.  
Materials and Methods 
Seventeen of 20 eligible patients with localized prostate cancer recruited 
between April 2009 and October 2010 completed the study. Participants were 
recruited consecutively at High Point Regional Health System’s (HPRHS) 
Hayworth Cancer Center in High Point, North Carolina. Preliminary screening 
based on treatment area, type and dose was performed by the Radiation 
Oncologist (BF) at the time of initial consult. Participants meeting these criteria 
were referred to the primary investigator (MD) for detailed medical record review 
and patient interviews. Health Insurance Portability and Accountability Act and 
informed consent forms were obtained from participants. Institutional Review 
Board approvals for the study protocol were obtained at the University of North 
Carolina at Greensboro (UNCG) and HPRHS.  
Patients were eligible for this study if they had a new diagnosis of 
localized prostate cancer and were scheduled to receive ≥ 72 Gray (Gy) external 
image guided intensity modulated radiation therapy (IMRT) to the prostate alone 
or prostate and seminal vesicles included in the treatment volume. Patients were 
ineligible to participate in this study if they had received prior treatment for 
119 
 
prostate cancer or were scheduled to receive other treatments concurrently with 
IMRT; or if they had abnormal liver, renal or immune function; hyperkalemia; 
uncontrolled gastro-esophageal reflux disease and other malabsorptive 
disorders; allergy to tomato products or red dye; ECOG score > 1; continued use 
of fiber supplements and other nutraceuticals with antioxidant properties 
(multivitamin, omega-3 fatty acids/fish oil, EPA/DHA, lycopene, vitamin C, E, A; 
B-carotene, flaxseeds and flaxseed oil) or action on the prostate (saw palmetto), 
and unwillingness to discontinue these for the study duration. Participant 
assessments, blood draws and tomato juice administration were scheduled 
during each patient’s planning procedure and radiation therapy appointment time. 
Potential participants picked one out of four folded pieces of paper with different 
group name printed on each.  The investigator (MD) recorded the group and 
individual participant ID on the participant screening form and informed the 
participant and family members of group assignment.  
We used the National Cancer Institute (NCI) Diet History Questionnaire 
(DHQ) to obtain participant diet information and estimate dietary lycopene intake. 
The DHQ is a 124 item questionnaire that has been tested for reliability and 
validity. It is easy to use, takes about an hour to complete and includes questions 
on food portion sizes as well as dietary supplements ("Diet History 
Questionnaire,").  
 Tomato juice supplementation commenced two days before the first dose 
of radiation therapy and continued daily till the last day of treatment. During 
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treatment days, participants consumed tomato juice and crackers (providing at 
least five grams of fat, to facilitate lycopene absorption) prior to leaving the 
cancer center, in the presence of the researcher (MD). Tomato juice was 
provided to participants for consumption over weekends and holidays with the 
instruction to consume it with food providing at least five grams of fat. 
Suggestions for snack and meals containing at least five grams of fat were 
discussed with participants. Verbal verification of tomato juice consumption was 
obtained from participants at their subsequent treatment day. 
Blood samples were collected at baseline, at the end of three weeks of 
treatment (midpoint) and on the last day of treatment (endpoint). In order to 
protect serum lycopene from light, serum tubes for whole blood collection were 
wrapped in aluminum foil. Due to the length of transport time (20 min) from 
collection site to processing site at UNCG, collected blood was transported on 
ice. Blood samples were processed (centrifuged at 3000 rpm x 20 min at 40C) 
under a yellow light to further minimize loss of lycopene. Separated serum, 
divided into aliquot tubes, was stored at -800C until analyzed.  Each aliquot tube 
was labeled with time point of blood draw (baseline, midpoint or endpoint) and 
patient ID. Standard Enzyme-Linked Immuno Sorbent Assay (ELISA) kits were 
used to test for serum PGE2, CRP, TNF- α, and IL-6 levels at the UNCG 
laboratory using the manufacturer’s (R&D) instructions.  We also used control 
samples for each kit to establish quantitative controls. Optical density was 
measured at 450nM using the SynergyTM HT (Bio-Tek Instrument, Inc) multi-
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detection microplate reader. The minimum detectable limits for PGE2, CRP, TNF- 
α, and IL-6 were 30.9 pg/mL, 0.010 ng/mL, 1.6 pg/mL and 0.70 pg/mL 
respectively. Since the CRP levels were not normally distributed, we log 
transformed the serum levels. We chose not to use PSA as an endpoint in this 
study, even though it has been used as an endpoint in several lycopene clinical 
trials (Ansari & Gupta, 2004; Barber et al., 2006; Edinger & Koff, 2006; 
Vaishampayan et al., 2007).  Since radiation therapy results in a decline in PSA 
levels post treatment, we would not be able to identify if the observed effect was 
due to radiation therapy or lycopene. 
Serum samples for lycopene analysis were packed in dry ice and 
transported to Dr. Wei Jia’s laboratory at the Kannapolis Research Campus, NC. 
Samples were analyzed for lycopene using high performance liquid 
chromatography and mass spectrometry (LC-MS).  
All study participants received image guided IMRT, on a Linear 
Accelerator 2100 iX (Varian Medical Systems, CA) following same standardized 
planning and filming protocol. For treatment, participants were placed supine on 
the treatment table with their head resting on a square sponge and legs placed in 
a “W” shaped cushion. Patients were instructed to keep hands away from the 
treatment area by placing their hands on their chest. Daily treatment fractions 
were delivered utilizing specified photons with a prescribed field treatment plan. 
Each treatment day a diagnostic image was obtained by radiation therapy staff 
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and approved by the treating radiation oncologist to verify proper positioning of 
the isocenters. 
 Key participant and cancer related characteristics were analyzed using 
descriptive statistics. Inflammatory mediator data are reported as mean±standard 
error of the mean. Between-group differences were examined using the Wilcoxon 
rank sum test, and within-group differences were detected with repeated 
measures. Spearman’s rho correlation was used to evaluate an association 
between the inflammatory mediators, serum lycopene and select lifestyle (weight, 
age) and cancer related characteristics (PSA, gleason sum (GS), treatment dose, 
daily fractions). One-sided level of significance was established at p ≤ 0.05, with 
significant trends observed between 0.051-0.10. 
Results 
Forty seven percent of participants had a GS score 7, and 71% 
participants had tumor stage T1cN0M0. The proportion of participants who 
received 2 Gy, 1.8 Gy and 2.5 Gy fractions daily were 53%, 29% and 18% 
respectively. Treatment dose ranged between 72.50-79.20 Gy (Table I). 
Serum lycopene levels during radiation therapy 
Overall serum lycopene at baseline was 0.30 μg/mL, and 0.33±0.11 μg/mL 
in the intervention group at baseline. We did observe a small non-significant 
increase in serum lycopene levels with daily tomato juice supplementation, in the 
intervention group towards the end of the study (0.41±0.12 μg/mL). A progressive 
statistically significant decrease (p = 0.009) in serum lycopene was observed in 
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control group participants (Table II). Participants with GS 6 had lower serum 
lycopene levels at baseline (0.21±0.11 μg/mL) compared to participants with GS 
7 (0.39±0.11 μg/mL). 
CRP was detected in the serum of all participants at baseline. Participants 
in the 12 oz group had the lowest CRP, while participants in the 8 oz group had 
the highest CRP levels at baseline (Table II). Additionally, participants with GS 6 
had higher CRP levels at baseline compared with participants with GS 7 
(8.24±0.59 vs 8.10±0.14). No statistically significant within group differences 
were detected. While an increase in CRP was observed in control group 
participants throughout treatment, CRP levels decreased in the intervention 
groups.   A statistically significant difference (p = 0.018) at midpoint was 
observed between control group and 12 oz group participants (Table II). While 
we did not detect a statistical significance, we did observe a trend towards 
significance (p = 0.071) in the baseline CRP levels between 8 and 12 oz groups, 
and midpoint levels (p = 0.057) between 4 and 12 oz groups. A statistically 
significant positive correlation was detected between serum IL-6 and CRP levels 
at baseline (r = 0.417, p = 0.048, n = 17) and endpoints (r = 0.566, p = 0.009, n = 
17).  
No TNF-α levels were detected in the sera of study participants. IL-6 was 
detected in the serum in all but two participants (n=1 each control group and 8 oz 
groups) at baseline. Overall baseline IL-6 among study participants was 2.15 
pg/mL. Unlike CRP, participants with GS 7 had higher IL-6 levels at baseline 
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(2.46±0.76 vs 1.87±0.54 pg/mL). Highest IL-6 level at baseline was observed in 
the 4 oz group. Interestingly, a progressive increase in IL-6 levels was observed 
in control group participants, while a progressive decrease was observed in the 4 
oz group means. While IL-6 levels in both 8 and 12 oz participants at end point 
were lower than baseline (Table II), the within group differences for 12 oz group 
only were statistically significant when comparing percent change at baseline and 
endpoint with midpoint (p = 0.014). While we did not detect a statistical 
significance, we did observe a trend towards significance (p = 0.0952) in the 
midpoint IL-6 levels between 4 and 8 oz groups.  
Control group participants had the highest level of PGE2 at all time points. 
No PGE2 was detected in the serum of two participants (n=1 each, 4 and 8 oz 
groups) at any time point. Participants with GS 6 had higher PGE2 levels at 
baseline compared with participants with GS 7 (514.56±120.26 vs 
440.08±217.68 pg/mL).  While PGE2 levels in the 4 oz group were lower at 
endpoint compared to baseline (Table II),  both 8 and 12 oz participants 
demonstrated a progressive decrease, but within group differences for only the 
12 oz group were statistically significant (p = 0.001) when comparing percent 
change at baseline with midpoint and endpoint (p = 0.003). We did observe a 
trend towards significance in the baseline PGE2 levels between 4 oz and control 
groups (p = 0.0952) and between 4 and 12 oz groups (p = 0.0857).  We detected 
no correlation between inflammatory markers, cancer characteristics (PSA, GS, 
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radiation dose or daily fractions) and dietary or serum lycopene (data not 
reported).  
Discussion 
This study evaluated the levels of selected inflammatory mediators during 
radiation therapy of the prostate and the impact of lycopene supplementation via 
tomato juice on these mediators of inflammation. Overall, control group 
participants demonstrated a progressive but non-significant increase in CRP and 
IL-6 levels and a slight non-significant decrease in PGE2 level throughout 
treatment.  High CRP levels in patients undergoing radiation therapy have been 
reported by other researchers (Cengiz, et al., 2001; Koc, et al., 2003). Since CRP 
is virtually undetectable in healthy adults the midpoint elevations observed in the 
4 oz group participants may also represent an increase in the acute phase 
response. A considerable decline in the endpoint CRP levels was observed in the 
8 oz group (percent change -2976% between baseline and endpoint), and a 
much lower magnitude of response was observed in the 4 (change -64%) and 12 
oz (change -70%) group CRP levels between baseline and endpoint. Daily 
lycopene consumed as tomato juice may explain these results. An inverse 
relationship has been previously been reported between CRP and serum 
lycopene by Ford et al (Ford, et al., 2003).  Participants with lower GS had higher 
CRP levels. The clinical implications of this remain unclear at the present time. 
Serum IL-6 levels mirrored CRP levels in all groups. A progressive, non-
significant increase in IL-6 levels was observed in control group and a non-
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significant decrease observed in the intervention group participants. Higher IL-6 
levels observed in participants with higher GS have also been reported by 
Alcover et al. (Alcover et al., 2010). Other researchers have also reported 
elevated IL-6 levels in prostate cancer patients undergoing IMRT (Christensen, et 
al., 2009; Johnke, et al., 2009). However, Johnke et al (Johnke, et al., 2009) 
reported normalization of IL-6 levels to pre-treatment levels after about two 
weeks of IMRT, results that we did not observed in this study. IL-6 levels 
increased progressively until the end in our control group participants. While we 
did observe an elevation at midpoint (end of 3 weeks of treatment) in the 8 and 
12 oz groups, endpoint levels were below baseline and we observed a 
progressive decline in 4 oz group participants, as well.  This may indicate a 
physiological role of tomato juice supplementation, even though we did not 
observe a dose dependent response. 
We observed high PGE2 levels at baseline prior to participants receiving 
radiation therapy, confirming role of inflammation in carcinogenesis 
(Kirschenbaum, et al., 2001). Baseline PGE2 levels were highest among control 
and 12 oz groups, almost four times higher than participants in the 4 oz group.  
The non-significant decrease observed in intervention group participants 
overtime, likely indicates a beneficial effect of tomato juice to these participants. 
Lack of PGE2 levels observed in two patients may be due to gene 
polymorphisms (Zhang, Dhakal, Lang, & Kadlubar, 2010).  
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While we did not detect any TNF-α in the serum of our participants, 
researchers have reported higher TNF-α levels in prostate cancer patients 
undergoing IMRT (Christensen, et al., 2009). However, some researchers have 
also reported that detecting serum TNF-α may be problematic, perhaps as a 
result of a short half-life or binding to its competitive inhibitor soluble receptor 
(Bossola et al., 2000). TNF-α levels may also be suppressed by non steroidal 
anti-inflammatory agents, production of TGF-β, IL-10 and PGE2 (K. J. Tracey & 
Cerami, 1993), and binding with receptors (Kevin J. Tracey & Cerami, 1994). 
Akimoto et al reported 85% of prostate cancer patients in their study had TNF-α 
levels below the detectable limit (Akimoto, Okumura, & Fuse, 1998). However, 
TNF-α may induce a cascade of secondary mediators such as IL-1, that may be 
responsible for some of the physiological effects observed in various 
inflammatory conditions, independent of the serum TNF-α levels (Kevin J. Tracey 
& Cerami, 1994). Researchers have also reported lower TNF-α levels in patients 
with localized disease compared with metastatic prostate cancer (Michalaki, 
Syrigos, Charles, & Waxman, 2004). Since we did not observe any TNF-α in the 
serum of our participants, we cannot conclusively state that TNF-α was not 
induced. Future studies may need to test TNF receptors, IL-1 and other 
downstream secondary inflammatory mediators.  
Increase in CRP at mid point may be reflective of acute radiation toxicity 
among those participants (data not reported). A progressive decline in CRP and 
PGE2 and a statistically significant within group differences when comparing 
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baseline and endpoint with midpoint (p = 0.014) for the 12 oz group may perhaps 
be a result of higher lycopene intake. This relationship needs to be evaluated 
further in prostate cancer patients undergoing radiation therapy.  We did not 
detect a correlation between the different volumes of tomato juice intake and the 
levels of specific inflammatory mediators in our study. As we did not exclude 
participants for using anti-inflammatory medication, future studies should control 
for this variable as has also been recommended by other researchers (Grainger 
et al., 2008).  
  While recent publications have demonstrated higher serum levels of 
different cytokines during radiation therapy, we believe this is the first study 
evaluating the impact of food-based lycopene supplementation on select 
inflammatory mediators (CRP, TNF-α, IL-6 and PGE2) during radiotherapy in 
prostate cancer patients. Impact of dietary lycopene supplementation on the level 
of inflammatory mediators during radiotherapy also needs to be evaluated in men 
with prostate cancer receiving hormone therapy along with more aggressive 
stages of cancer. 
  This study has several limitations. In order to minimize disruption of daily 
activities among the study participants, blood draws were scheduled around the 
time of their prescheduled radiation treatment appointment. Consequently, 
patients were not in a fasted state for the blood draws. The impact of non-fasted 
state on these test parameters remains unknown. A small sample size of this 
study limits generalization of these results and may have prevented us from 
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detecting statistical significance. Due to the emerging research interest in 
cytokine expression during radiation therapy in prostate cancer patients, specific 
reference values relating to the magnitude of increase that can be expected in 
this population are lacking. 
  In conclusion, as expected, systemic inflammation was observed in men 
with localized prostate cancer prior to treatment. Despite the small sample size 
and mixed inflammatory mediator levels observed among the treatment group, 
our findings suggest that 8-12 oz tomato juice may be helpful in blunting the 
inflammatory response during radiation therapy in this population. Larger clinical 
trials are needed to validate these results and to ascertain if food based lycopene 
supplementation is an acceptable adjunct during radiation therapy. 
Acknowledgements 
The authors would like to thank Paula Cooney for providing assistance in 
the laboratory, and Wei Jia, Ph.D and post-doctoral fellow Guoxiang Xie, Ph.D, 
for conducting the serum lycopene analysis. A University of North Carolina at 
Greensboro Faculty Grant supported this research. 
  
130 
 
Table 4.1. Participant cancer related characteristics. Data are reported as mean 
± standard error of the mean. 
 Control 
(n = 5) 
4 Oz 
(n = 4) 
8 Oz 
(n = 5) 
12 Oz 
(n = 3) 
PSA 7.33±1.83 5.97±0.88 7.09±0.94  7.79±1.27  
0-4.99 ng/mL 3 (60) 2 (50) 0 0 
5-9.99 ng/mL 1 (20) 2 (50) 4 (80) 3 (100) 
10-14.99 ng/mL 1 (20) 0 1 (20) 0 
Gleason Sum* 6.40±0.25 6.75±0.25 6.40±0.25  6.33±0.33  
6 3 (60) 1 (25) 3 (60) 2 (67) 
 7 2 (40) 3 (75) 2 (40) 1 (33) 
Tumor Stage     
T1cN0M0  4 (80)  3 (75)  3 (60)  2 (67)  
T2aN0M0  1 (20)  1 (25)  0  1 (33)  
T2bN0M0 0 0 1 (20) 0 
T2cN0M0  0  0  1 (20)  0  
Treatment Dose 
(Gy) 
74.60±0.86 
(72.50-76.00)  
78.40±0.80 
(76.00-79.20)  
76.58±1.25 
(72.50-79.20)  
77.33±0.67 
(76.00-78.00)  
Treatment Days 34±2.21  43±1.50  39±2.75  39±0.33  
Level of significance (p<0.05). No statistical significance detected. 
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Table 4.2. Serum lycopene and inflammatory markers at three time points in all 
participants. Data are reported as mean ± standard error of the mean 
 Baseline Midpoint Endpoint 
Lycopene (μg/mL)    
Control* 0.209±0.07 0.137±0.05b 0.167±0.07e 
4 oz 0.295±0.21 0.272±0.08c 0.257±0.07 
8 oz 0.514±0.17a 0.534±0.09bcd 0.622±0.25e 
12 oz 0.082±0.08a 0.069±0.01d 0.253±0.20 
Log CRP    
Control 7.65±0.49 8.57±0.51f 8.34±1.04 
4 oz 7.96±0.25 8.07±0.14 7.53±0.36 
8 oz 9.22±0.78 8.92±0.96 8.02±0.53 
12 oz 7.60±0.32 7.37±0.22f 7.18±0.10 
IL-6 (pg/mL)    
Control 1.433±0.517 1.911±0.406 2.655±1.383 
4 oz 3.442±1.263 1.844±0.891 1.580±0.586 
8 oz 2.289±0.909 5.888±3.181 1.914±0.519 
12 oz 1.374±0.619 2.094±0.398 1.073±0.171 
PGE2 (pg/mL)    
Control 707.47±307.80 684.81±428.24 664.58±428.64 
4 oz 188.03±78.42 277.21±185.76 170.40±98.38 
8 oz 351.13±176.75 183.79±162.06 98.31±40.99 
12 oz 702.16±221.48 510.71±101.29 244.56±69.61 
Statistical significance: p < 0.05 one-sided  
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*within group difference p = 0.009 
a p <0.05 (between group differences)      b p <0.005 (between group differences) 
c p <0.01 (between group differences)       def p <0.03 (between group differences) 
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Abstract  
 
 
Purpose: to evaluate the impact of three different volumes of tomato juice on 
several frequently reported acute side effects (diarrhea, proctitis and urinary 
urgency and frequency) of radiation therapy and performance status in men with 
localized prostate cancer.  
Materials and Methods: The National Cancer Institute’s Cancer Therapy 
Evaluation Program: Common Toxicity Criteria v 2.0 was used to evaluate 
tolerance of tomato juice; and Common Terminology Criteria for Adverse Events 
was used to evaluate severity of side effects related to radiation therapy. 
Performance status was assessed using the Eastern Cooperative Oncology 
Group scale.  
Results: Men with localized prostate cancer (tumor grade T1c-2cN0M0) scheduled 
to receive external radiation to the prostate alone or prostate and seminal 
vesicles were recruited between April 2009 and October 2010. Seventy one 
percent of participant tumors were staged T1cN0M0. Daily radiation fractions 
varied between 1.8-2.5 Gray. Control group participants reported higher (worse) 
performance status scores than participants in the intervention groups. A strong 
positive correlation was detected between performance status, reported alcohol 
intake and diagnosis of hypertension at baseline. No differences in urinary 
frequency and urgency were detected between control and intervention groups. 
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However, tomato juice supplementation (especially 12 oz tomato juice) appeared 
to have a protective effect on gastrointestinal acute toxicity (diarrhea and 
proctitis) for the first three weeks of treatment.  
Discussion: Daily tomato juice supplementation during intensity modulated 
radiation therapy in men with localized prostate cancer resulted in a 
gastrointestinal protective effect for the first three weeks of treatment and in 
performance status though out treatment. These results need to be validated in 
larger clinical trials using 12 ounce tomato juice or equivalent tomato products.  
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Introduction 
In 2010, 217,730 new cases of prostate cancer were projected in the US 
and more than 90% of these cases were expected to be loco-regional cases with 
100% five-year survival (Jemal, Siegel, Xu, & Ward, 2010). This is significant 
considering primary treatment strategies in addition to active surveillance include 
surgery and radiation therapy,("Cancer Facts and Figures 2010," 2010) and 
reducing side effects of therapy will enhance quality of life (Andic, Garipagaoglu, 
Yurdakonar, Tuncel, & Kucuk, 2009). Side effects of radiation therapy may be 
either acute or chronic. Acute side effects of radiation therapy are those 
observed during or within three months of radiation, while symptoms occurring 
after three months are classified as chronic(Hauer-Jensen, Wang, Boerma, Fu, & 
Denham, 2007) or late effects (Stone, Coleman, Anscher, & McBride, 2003). 
Despite improved biochemical control, intensity modulated radiation therapy 
(IMRT) may still cause toxicity (Christensen et al., 2009). While the timeliness, 
severity and type of expression is dependent on the site of the irradiated tissue 
and cytokine cascade activation (Bentzen, 2006; Stone, et al., 2003), rate of 
tissue renewal, presence of microvascular (diabetes, hypertension) auto-immune 
or collagen vascular diseases, and radiation dose (Andreyev, 2007; Okunieff, 
Chen, Maguire, & Huser, 2008) may also impact treatment tolerance. Pre-
existing medical conditions such as hypertension (HTN), coronary artery disease 
(CAD) and diabetes (DM) may actually increase the potential for higher toxicity 
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upon exposure to radiation therapy (Chon & Loeffler, 2002; Houterman, Janssen-
Heijnen, Hendrikx, Berg, & Coebergh, 2006; Okunieff, Chen, et al., 2008).   
The most common acute toxicity symptoms of pelvic radiation are 
gastrointestinal (GI) and genitourinary (GU) symptoms. De Meerleer et al 
reported that the incidence of acute GI toxicity was observed in about 37% of 
patients (Grade 1: 44% and Grade 2: 29%), while 38% patients reported mild to 
moderately severe GU toxicity (Grade 1: 47%, Grade 2: 36% and Grade 3: 7%) 
(De Meerleer et al., 2004). Other researchers (Fonteyne, Villeirs, Lumen, & De 
Meerleer, 2009; Lips et al., 2008) have reported similar incidence of acute toxicity 
in prostate cancer patients undergoing radiation therapy. Symptoms of early 
radiation toxicity may be subtle and transient, but they can impact quality of life 
and functional status of patients considerably during treatment (Hauer-Jensen, et 
al., 2007), even in patients with milder symptoms (Christiansen et al., 2007).  
While acute toxicities may be transient and of short duration, it is imperative to 
treat or minimize these, since acute toxicities have been reported to be one of 
the significant predictors of long term “chronic” toxicities (Denham et al., 1999; 
Hovdenak et al., 2003; O'Brien, 2001; Schultheiss et al., 1997). 
Researchers have proposed that various cytokines may be predictive, 
prognostic or diagnostic markers of radiation toxicity (Okunieff, Chen, et al., 
2008). The release of a “cytokine storm” has been suggested to occur 
immediately after tissue irradiation, and that the intensity of these cytokines may 
be a predictor of toxicities in patients (Okunieff, Chen, et al., 2008). Higher levels 
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of serum interleukin-6 (IL-6) has been reported in prostate cancer patients 
undergoing IMRT (Christensen, et al., 2009), and increased levels of IL-6 along 
with tumor necrosis factor-α (TNF-α) have been reported in men with prostate 
cancer who develop radiation-induced proctitis (Christiansen, et al., 2007). Other 
researchers have reported elevation of IL-6 and other cytokines in patients with 
radiation induced pathologies (Indaram, Visvalingam, Locke, & Bank, 2000; 
McBride, 1995). Prostaglandins have also been implicated in radiation induced 
enteritis, but the results are not conclusive (Lifshitz, Savage, Taylor, Tewfik, & 
Van Orden, 1982). 
 Antioxidants can modulate cytokine levels in tissues, consequently 
reducing the inflammatory response (Okunieff et al., 2008). The potential for 
using radioprotective compounds to limit radiation–induced toxicity by protecting 
normal tissues and enhancing the therapeutic benefits has been explored by 
researchers and clinicians (Grdina, Murley, & Kataoka, 2002; Weiss & Landauer, 
2003). Synthetic antioxidants such as amifostine have been successfully used in 
head and neck, ovarian, and non-small cell lung cancer patients to reduce 
treatment related toxicities (Grdina, et al., 2002). This radioprotective effect is not 
limited to synthetic antioxidants (Weiss & Landauer, 2003). Several 
phytochemicals (genistein, caffeine etc.) Have been identified that have both 
antioxidant as well as radioprotective effects in vivo (Weiss & Landauer, 2003). 
We limited our focus to lycopene which is a potent antioxidant and anti-
inflammatory agent (Huang, Ghai, & Ho, 2004; Rafi, Yadav, & Reyes, 2007). 
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Researchers (Saada, Rezk, & Eltahawy, 2010; Srinivasan, Devipriya, Kalpana, & 
Menon, 2009; Srinivasan et al., 2007) have demonstrated that lycopene can 
protect cells against γ-radiation induced cellular damage and decrease acute GI 
side effects (diarrhea) observed during pelvic radiation therapy (Andic, et al., 
2009). We undertook this study to evaluate the impact of a food based source of 
lycopene (tomato juice) on the frequently reported acute GI (diarrhea and 
proctitis) and GU (urinary urgency and frequency) side effects and performance 
status in men undergoing radiation therapy for localized prostate cancer.  
Materials and Methods 
 Participants were selected consecutively and non-probabilistically at High 
Point Regional Health System’s (HPRHS) Hayworth Cancer Center in High Point, 
NC between April 2009 and October 2010. Of the 154 new prostate cancer 
referrals to the cancer center, 40 participants met the preliminary screening 
criteria based on treatment area, type and dose. Eighteen participants did not 
meet the other eligibility criteria and two participants expressed no interest in 
participating in the study. Of the twenty participants who were randomized into 
four treatment arms (control, 4, 8 or 12 oz tomato juice), two dropped out due to 
inability to consume the assigned volume of tomato juice (n = 1 each from 8 and 
12 oz groups) and one participant (4 oz group) was withdrawn by the 
investigators due to inability to obtain access for blood draws. The study protocol 
was approved by the Institutional Review Boards at the University of North 
Carolina at Greensboro (UNCG) and HPRHS. All participants signed a Health 
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Insurance Portability and Accountability Act (HIPAA) and informed consent forms 
prior to study enrollment.  
The eligibility criteria included: newly diagnosed localized prostate cancer 
patients scheduled to receive ≥72 Gray (Gy) IMRT, treatment volume included 
prostate alone or prostate and seminal vesicles; no concurrent hormones, 
chemotherapy or other treatments for cancer; Eastern Cooperative Oncology 
Group (ECOG) performance score of 0 or 1. Patients were ineligible to 
participate in this study if they had pre-existing uncontrolled gastro-esophageal 
reflux disease and other malabsorptive disorders, renal or liver disease; 
compromised immune system; hyperkalemia; allergy to tomato products or red 
dye; or routinely used and unwilling to stop these supplements- fiber, saw 
palmetto, lycopene, omega-3 fatty acids/fish oil, EPA/DHA, vitamin C, E, A; β-
carotene, flaxseeds and flaxseed oil supplements. In order to minimize time 
spent at the cancer center and to avoid additional follow-up visits, assessments, 
blood draws and tomato juice administration were scheduled around each 
patient’s appointment times (planning, radiation therapy, etc.). 
A Linear Accelerator 2100 ix (Varian Medical Systems, CA) was used to 
provide image guided IMRT to all participants in the study. Standardized planning 
and treatment protocols were followed for radiation therapy delivery under close 
supervision of the treating radiation oncologist. Researchers (MD) assessed 
performance status weekly using the ECOG performance scale. The NCI Cancer 
Therapy Evaluation Program: Common Toxicity Criteria (CTC) v 2.0 was used to 
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assess any GI adverse effects (nausea, vomiting, heartburn) from tomato juice 
supplementation, and the NCI Common Terminology Criteria for Adverse Events 
(CTCAE) was used to evaluate severity of side effects (urinary frequency and 
urgency, diarrhea and proctitis) related to radiation therapy.  
 Participants in the three intervention groups commenced tomato juice 
consumption two days before treatment and continued drinking it daily until the 
last day of treatment. During week days, tomato juice and crackers containing 
five grams of fat (to aid in the absorption of lycopene) were provided at the 
cancer center. The researcher (MD) observed participants drinking the juice and 
eating the crackers each treatment day. Participants were provided containers of 
their assigned volume of tomato juice for weekends and holidays with the 
instructions to consume tomato juice with either a meal or a snack containing at 
least five grams of fat. A few examples of snacks and meals containing five 
grams of fat were discussed with participants. Verbal confirmation of tomato juice 
consumption was obtained on the next radiation therapy day. 
Data are reported as group means ± standard error of the mean. We 
utilized the Wilcoxon rank sum test to detect between-group differences for 
performance status and side-effects of treatment, and repeated measures were 
used to detect within-group differences at different time points. Chi-square was 
used to detect differences in proportions. We also conducted Spearman’s rho 
correlation to evaluate the association of performance status scores and 
treatment side effects with select lifestyle characteristics. Differences were 
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considered statistically significant at one-sided p ≤ 0.05, and a trend towards 
significance was observed with p between 0.051-0.10. 
Results 
Participants in our study were between 61 and 77 years of age, with no 
statistically significant differences in age distribution among participants in the 
four groups. Majority (71%) of our participants were Caucasian, 82% of 
participants were married, and 71% had at least a high school education. The 
TNM staging ranged from t1cn0m0 to t2cn0m0, with 71% of participant tumors in the 
t1cn0m0 stage. Treatment radiation dose ranged from 7250-7920 cgy and 
treatment days varied between 29 (18%), 38 (41%), 39 (12%) and 44 (29%). 
Overall 88% participants had a diagnosis of HTN and hyperlipidema, 35% were 
diagnosed with CAD and DM. Ninety-four percent of participants reported either 
never smoking or quitting some time ago and 65% of reported currently 
consuming alcohol. Seventy-one percent of participants reported using one or 
more over-the-counter herbal/nutritional supplements prior to entering the study 
but agreed to stop taking them for the duration of the study (Table 5.1). No 
statistically significant between-group differences were detected for any of these 
variables. 
Control group participants had higher ECOG scores with increasing 
cumulative doses of radiation. A consistent peak was observed at weeks 3-5 
followed by a slight decline at week 6, as a result of one participant in this group 
completing therapy. No change in performance status was reported by 
154 
 
participants in the 12 oz group, while a slightly increased group mean was noted 
in the 8 oz group beginning week 6. However, no statistically significant between-
group or within-group differences were detected (Table 5.2). 
 Utilizing the CTCAE measurement criteria, urinary frequency and urgency 
were evaluated using participant reported baseline or pretreatment levels. 
Statistically significant differences (p = 0.039) in urinary frequency were detected 
at week 5 between 4 and 8 oz groups. A significant trend was observed at week 
5 between control group and 8 oz group participants (p = 0.059) and between 8 
and 12 oz groups (p = 0.089). Urinary urgency was statistically significant at 
weeks 2 (p = 0.008) and 5 (p = 0.048) between control and 4 oz groups, and at 
weeks 5 (p = 0.004) and 7 (p = 0.029) between control and 8 oz groups.  A 
significant trend was observed at week 2 between control group and 8 oz group 
participants (p = 0.083) (Table 5.3). No within-group differences were detected in 
control, 4 or 12 oz groups, but a trend towards significance was observed, in the 
8 oz group for urinary frequency (p = 0.099) and urinary urgency (p = 0.069).  
 Statistically significant differences were observed in the reported incidence 
of diarrhea at weeks 6 and 7 (p = 0.029) between control and 8 oz groups. 
Participants in the 12 oz group reported a very minimal increase in stool 
frequency.  While no within-group differences were observed in control and 12 oz 
groups for diarrhea, we observed a trend towards significance (p= 0.065) in 4 oz 
group and statistical significance (p = 0.000) in the 8 oz group.  No incidence of 
proctitis was reported among participants in the 12 oz group. Despite reported 
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proctitis in the other three groups, no statistically significant differences were 
detected between or within-groups. Overall it appears that tomato juice 
supplementation exhibited a protective effect on reported diarrhea incidence 
during the first three weeks of treatment (Table 5.4). 
The relationship between certain lifestyle factors (supplement usage, 
diagnosis of HTN, CAD, DM), tomato juice supplementation and symptoms was 
investigated using the Spearman’s correlation. There was a positive correlation 
between ECOG score and alcohol intake (beginning week 3) and hypertension 
(baseline to week 7) and ECOG scores (Table 5.5). Prior dietary supplement use 
showed a statistically significant association with ECOG score at week 1 (r = 
0.555, p = 0.010, n = 17) and 2 (r = 0.433, p = 0.041, n = 17), and a significant 
trend at baseline and weeks 3-5 (Data not shown). No significant correlation was 
observed between ECOG score and DM. 
Discussion 
The primary objective of this paper was to examine the impact of three 
different doses of tomato juice on the performance status and selected radiation 
therapy related side effects in men with localized prostate cancer compared with 
participants in the control group. We did not measure fatigue in our participants, 
but nursing staff observed higher fatigue in control group participants, which may 
be reflected in the higher ECOG scores observed in control group participants. 
While not statistically significant, these results are clinically relevant and have 
implications beyond our study population, if these results can be replicated in 
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larger trials.  If consumption of tomato products can alleviate radiation therapy 
induced fatigue in patients, there is considerable potential for improved quality of 
life during treatment with daily consumption of at least 8-12 oz of tomato juice. 
Overall no significant differences in urinary frequency and urgency were 
observed between control and intervention group participants. While some 
between-group differences were detected for both urinary frequency and 
urgency, these may not be good outcome measures. Recommendations to 
increase fluid intake during treatment, personal tolerance and individual level of 
discomfort would greatly impact the subjective assessment of these variables.  
Tomato juice supplementation appears to have a GI protective effect for 
the first three weeks of treatment. While the incidence of diarrhea throughout 
radiation therapy appears to be lower in the control group, one participant 
reported taking Imodium® to manage his diarrhea, which resulted in a lower 
group mean for diarrhea (Table 5.4), but a higher weekly participant score 
(Grade 2: increased stool frequency, bleeding mucus discharge or rectal 
discomfort requiring medication; anal fissure) and group mean for proctitis (Table 
5.4). Despite consistency in treatment planning and delivery, significant variability 
in the incidence and severity of side effects is not uncommon (Bentzen, 2006). 
Radiation therapy may induce new microscopic colitis or exacerbate preexisting 
GI conditions causing diarrhea observed during therapy. Such effects may 
account for the increase in the incidence of diarrhea observed in the 4 and 8 oz 
tomato juice groups. Participants in the 12 oz group demonstrated the best GI 
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protective response. No proctitis was observed in this group and the incidence of 
diarrhea was minimal.  Only one participant in the 12 oz group reported higher 
stool frequency (change from every other day to daily bowel movement). 
Researchers have reported decreased severity of diarrhea and acute GI toxicity 
in rats that were supplemented with lycopene and underwent pelvic radiation 
(Andic, et al., 2009).  Our small sample size may have precluded us from 
detecting statistical significance. We did detect a significant positive association 
between performance status (ECOG score) and the diagnosis of hypertension or 
consumption of alcohol and but not serum or total dietary lycopene, DM or CAD.  
Chon and Loeffler have also reported lower radiation tolerance in patients with a 
diagnosis of diabetes or hypertension (Chon & Loeffler, 2002).  
  To our knowledge, this is the very first study evaluating the tolerance of 
lycopene supplementation (from processed tomato juice) during radiation therapy 
in prostate cancer patients. We assessed the tolerance of three doses of tomato 
juice during radiotherapy and evaluated their impact on performance status as 
well as both GI and GU symptoms during radiotherapy. While we did not observe 
any GU protective effect, we did observe a GI protective effect in the intervention 
groups. Tomato juice was well tolerated by the participants of this study, with no 
reported incidence of nausea, vomiting or heartburn. This study also expands the 
scope of lycopene research from preventive to an effective adjunct during 
radiation therapy. 
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  This study has several limitations. We used validated clinical assessment 
tools to monitor participant side effects of treatment and performance status. 
However, we did not find the criteria to be sensitive enough for the purposes of 
our study. For instance, when evaluating the incidence of diarrhea, participants 
with increased daily stool frequency of 1-3 stools were all classified on the 
CTCAE scale as grade 1 toxicity. Some of our participants reported no more than 
an additional stool per day over baseline, while other participants reported an 
increase of 2-3 stools per day. However, by using the CTCAE criteria, both 
groups of participants were classified as grade 1. More objective criteria to 
evaluate treatment toxicities need to be investigated for future clinical trials.  
Additionally, the small sample size of this study limits generalization of these 
results and also may have prevented us from detecting consistent statistically 
significant differences between groups. 
Conclusions 
Tomato juice supplementation had no effect on acute GU side effects of 
radiation treatment, but appeared to offer a GI protective effect in men with 
prostate cancer receiving at least 8-12 oz of tomato juice daily during radiation 
therapy.  Larger clinical trials are needed to validate these results.  
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Table 5.1. Frequency of lifestyle characteristics of study participants.  
 Control 
(n = 5) 
4 Oz 
(n = 4) 
8 Oz 
(n = 5) 
12 Oz 
(n = 3) 
Diabetes     
Yes 2 (40) 2 (50) 1 (20) 1 (33) 
No 3 (60) 2 (50) 4 (80) 2 (67) 
Hypertension     
Yes 5 (100) 4 (100) 4 (80) 2 (67) 
No 0 0 1 (20) 1 (33) 
Cardiovascular Disease     
Yes 2 (40) 3 (75) 1 (20) 0 
No 3 (60) 1 (25) 4 (80) 3 (100) 
Hypercholesterolemia     
Yes 4 (80) 4 (100) 4 (80) 3 (100) 
No 1 (20) 0 1 (20) 0 
Smoker     
Yes 0 1 (25) 0 0 
No 5 (100) 3 (75) 5 (100) 3 (100) 
Alcohol Consumption     
Yes 3 (60) 1 (25) 5 (100) 2 (67) 
No 2 (40) 3 (75) 0 1 (33) 
Routine use of 
supplements 
    
Yes 4 (80) 3 (75) 4 (80) 1 (33) 
No 1 (20) 1 (25) 1 (20) 2 (67) 
p<0.05 (one-sided).  No statistical significance detected. 
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Table 5.2. Reported weekly Eastern Cooperative Oncology Group performance 
status ("Eastern Cooperative Oncology Group Performance Status," 1982). Data 
are reported as mean ± standard error of the mean. 
 Control 
(n = 5) 
4 Oz 
(n = 4) 
8 Oz 
(n = 5) 
12 Oz 
(n = 3) 
Week 1 0.20±0.20 0.25±0.25 0.20±0.20 0.33±0.33 
Week 2 0.40±0.25 0.25±0.25 0.20±0.20 0.33±0.33 
Week 3 0.60±0.25 0.25±0.25 0.20±0.20 0.33±0.33 
Week 4 0.60±0.25 0.25±0.25 0.20±0.20 0.33±0.33 
Week 5 0.60±0.25 0.25±0.25 0.20±0.20 0.33±0.33 
Week 6 0.33±0.33 0.25±0.25 0.25±0.25 0.33±0.33 
Week 7 0.67±0.67 0.25±0.25 0.25±0.25 0.33±0.33 
p<0.05 (one-sided). No statistical significance detected. 
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Table 5.3. Reported weekly incidence of acute genitourinary side effects. Data 
are reported as mean ± standard error of the mean. 
Urinary 
frequency 
Control 
(n = 5) 
4 Oz 
(n = 4) 
8 Oz 
(n = 5) 
12 Oz 
(n = 3) 
Week 1 0.60±0.60 0.25±0.25 0.40±0.25 0.00±0.00 
Week 2 0.40±0.25 0.75±0.25 0.60±0.25 0.00±0.00 
Week 3 0.40±0.25 0.75±0.25 0.40±0.25 0.33±0.33 
Week 4 0.40±0.25 0.50±0.29 0.60±0.25 0.33±0.33 
Week 5 0.40±0.25 0.25±0.25a 1.20±0.20a 0.33±0.33 
Week 6 0.33±0.33 0.50±0.29 1.00±0.41 0.00±0.00 
Week 7 0.00±0.00 0.75±0.25 1.00±0.41 0.67±0.33 
Urinary Urgency     
Week 1 0.00±0.00 0.50±0.29 0.40±0.25 0.33±0.33 
Week 2 0.00±0.00b 1.00±0.00b 0.60±0.25 0.33±0.33 
Week 3 0.40±0.25 0.50±0.29 0.80±0.20 0.67±0.33 
Week 4 0.40±0.25 0.75±0.25 0.80±0.20 0.33±0.33 
Week 5 0.00±0.00cd 0.75±0.25d 1.00±0.00c 0.33±0.33 
Week 6 0.00±0.00 0.75±0.25 0.75±0.25 0.67±0.33 
Week 7 0.00±0.00e 0.75±0.25 1.00±0.00e 0.33±0.33 
Level of significance (p≤0.05). 
  
bcp ≤ 0.01 adep ≤ 0.05 
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Table 5.4. Reported weekly incidence of acute gastrointestinal side effects.  Data 
are reported as mean ± standard error of the mean.  
Diarrhea Control 
(n = 5) 
4 Oz 
(n = 4) 
8 Oz 
(n = 5) 
12 Oz 
(n = 3) 
Week 1 0.20±0.20 0.00±0.00 0.20±0.20 0.00±0.00 
Week 2 0.60±0.25 0.00±0.00 0.40±0.25 0.00±0.00 
Week 3 0.20±0.20 0.50±0.29 0.60±0.25 0.00±0.00 
Week 4 0.40±0.25 0.75±0.25 0.80±0.20 0.33±0.33 
Week 5 0.20±0.20 0.50±0.29 0.80±0.20 0.33±0.33 
Week 6 0.00±0.00a 0.75±0.25 1.25±0.00a 0.33±0.33 
Week 7 0.00±0.00a 0.75±0.25 1.00±0.00a 0.33±0.33 
Proctitis     
Week 1 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
Week 2 0.00±0.00 0.00±0.00 0.20±0.20 0.00±0.00 
Week 3 0.00±0.00 0.00±0.00 0.40±0.25 0.00±0.00 
Week 4 0.00±0.00 0.00±0.00 0.20±0.20 0.00±0.00 
Week 5 0.60±0.40 0.50±0.50 0.20±0.20 0.00±0.00 
Week 6 0.67±0.67 0.50±0.50 0.50±0.50 0.00±0.00 
Week 7 0.67±0.67 0.50±0.50 0.50±0.50 0.00±0.00 
Week 8 1.00±1.00 0.00±0.00 0.67±0.67 0.00±0.00 
p≤0.05, one-sided 
ap ≤ 0.05   
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Table 5.5: Spearman’s rho correlations for ECOG score ("Eastern Cooperative 
Oncology Group Performance Status," 1982)  
ECOG Score  
 
Baseline Wk1 Wk2 Wk3 Wk4 Wk5 Wk6 Wk7 
 N=17 N=17 N=17 N=17 N=17 N=17 N=14 N=14 
Alcohol 0.304 0.171 0.334 .485* .485* .485* .519* .536* 
Hypertension .789** .658** .566** .494* .494* .494* .645** .575* 
Correlation is significant at  
**p≤0.01 level (1-tailed) 
* p≤0.05 level (1-tailed) 
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CHAPTER VI 
 
EPILOGUE 
 
 
Nutrition care of the oncology patient has always been a passion of mine. 
This interest was sparked while I was doing my dietetic internship at the All India 
Institute of Medical Sciences in New Delhi, India. Patients were housed in cubicle 
like compartments in a large hall with glass partitions, sequestered from the 
outside world including friends and family. The diagnosis of cancer was a certain 
death sentence in the 1990’s, and this, along with social isolation and ravages of 
the disease and treatment, led to poor nutritional intake and progressive weight 
loss.  It boggles my mind to this day why the health care providers were 
surprised when they observed weight loss in these patients. While working as a 
dietitian in the US, the majority of the consults received for Medical Nutrition 
Therapy (MNT) were for “weight loss. Poor PO intake.” However, I have 
observed more intensive monitoring of cancer patients receiving chemotherapy 
due to obvious impediments to intake such as nausea, vomiting and diarrhea. 
Radiation therapy patients, more specifically patients with head and neck cancer, 
were referred for MNT only after extensive weight loss. We are now more aware 
of the effects of treatment on normal tissue, cytokine milieu created as a result of 
treatment, and a host of other factors that contribute to decreased intake and the 
common outcomes of weight loss and overall treatment tolerance. Proactive 
nutrition care in cancer patients can help improve treatment tolerance and quality 
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of life. Researchers are now beginning to explore nutrients as radiosensitizers to 
enhance the effect of radiation therapy on tumors while protecting normal tissue 
and reducing potential side effects of treatment. 
My dissertation examined the effect of tomato juice, a rich source of 
lycopene, in prostate cancer patients undergoing radiation therapy. The overall 
goals of this project were to evaluate whether dietary lycopene increases serum 
lycopene levels, delays onset of some of the most common side effects of 
radiation therapy and consequently improves performance status during therapy.  
So why lycopene?  
My interest in lycopene was piqued while researching the link between 
carotenoids and lung cancer for NTR 673:Research Methodology, in Spring 
2007. Lycopene, a potent antioxidant, has been a source of fascination to 
researchers for several decades. Researchers as early as the1950s have been 
utilizing lycopene to mitigate the effects of radiation (Forssberg, Lingen, Ernster, 
& Lindberg, 1959). Several epidemiological studies (Gann et al., 1999; 
Giovannucci, 1999, 2005; Vogt et al., 2002) have documented an inverse 
relationship between intake of lycopene rich foods and the development of 
prostate cancer. Using cell and animal studies as well as retrospective and 
prospective trials in humans, researchers have evaluated the impact of lycopene 
in patients with benign prostate hypertrophy (Edinger & Koff, 2006; Schwarz et 
al., 2008), high grade prostatic intraepithelial neoplasia (Mohanty, Saxena, 
Singh, Goyal, & Arora, 2005) and prostate cancer patients prior to initiating 
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treatment (Bowen et al., 2002; Chen et al., 2001; Jatoi et al., 2007; Kim et al., 
2003; Kucuk et al., 2001; Rao, Fleshner, & Agarwal, 1999)  or after treatment 
failure (Clark et al., 2006).  However, there is paucity of research investigating 
the impact of lycopene/tomato products supplementation in prostate cancer 
patients undergoing treatment. Researchers have demonstrated several 
mechanisms of action for lycopene’s effectiveness. Some of the mechanisms of 
action that are relevant to this project include inhibition of IL-6 expression and 
modulation of the cyclooxygenase pathway. Therefore, this research project was 
developed from research gaps identified in the areas of vulnerable populations, 
exposures, mechanisms and biomarkers (Davis et al., 2005).  
Due to the exploratory nature of this research, we encountered several 
challenges. The primary challenge was lack of sufficient funding to approach 
multiple cancer centers for patient recruitment, compensating a professional 
laboratory for blood sample assessment, and providing compensation to 
participants. We also had to limit the number of inflammatory mediators that we 
could test due to limited funding. However, this project could not have been 
conducted without the funding support we did receive from the University of 
North Carolina at Greensboro’s Faculty Grant. 
Initially, when participant recruitment commenced, we had some 
challenges with potential participant appointment notifications. Since the 
lycopene study was outside the routine job responsibilities of the cancer center 
staff, I had to work with them to insure I was notified about patient appointment 
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times and any subsequent changes in their appointment schedule, in order not to 
miss meeting with the participants. After making a few repeat trips to the cancer 
center, and missing a few screening appointments, we devised a system of 
notification that overcame this obstacle. 
We did not achieve our intended target of recruiting 40 total participants. 
This may have prevented us from observing statistical significance where 
statistical differences did exist. The possibility of reduced side effects from a food 
product consumed during radiation therapy did appear to be an incentive for at 
least some of the participants who volunteered for our study, as evidenced by 
participant enthusiasm and enrollment. It was a fascinating, educational 
experience working with the participants of this study.  When asked during the 
exit interviews, 65% of participants reported enrolling in the study to reduce their 
side effects of treatment, and 47% of participants also reported participating for 
purely altruistic reasons. These men were extremely motivated and inquisitive 
about the impact of nutrition and nutritional supplements on prostate health and 
were further intrigued by the possibility of something as simple as a tomato 
making them “feel better” along with the possibility of “chemicals” in the blood 
that could predict their radiation response!  Several participants requested 
additional information on risk vs benefits of supplements, and lowering sodium 
intake in their diet. Since the information requested would not have influenced 
the study results, information was provided to the participants when requested.  
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Due to the number of blood variables being tested, we had to insure that 
blood collection and processing procedures could be standardized.  All collected 
blood samples were treated the same, thus, we did not add indomethacin to the 
blood samples to halt synthesis of prostaglandins as stipulated in the PGE2 
ELISA kit. Omitting this step may result in higher PGE2 expression. Also 
considering the labile nature of the cytokines, blood processing methodology 
needs to be carefully considered, specifically the temperature at which blood 
samples should be processed. Since lycopene is affected by heat and light, we 
covered the collection tubes containing participant blood immediately with 
aluminum foil and placed them on ice post collection for transportation to the 
UNCG laboratory.  
Based on the results of this study, participant comments and researcher 
observations, tomato juice was well tolerated by men over 60 years of age, 
diagnosed with prostate cancer, undergoing radiation therapy. Only two 
participants withdrew from the study due to inability to consume the assigned 
volume of tomato juice. We recognize that tomato juice may not be acceptable to 
all men as a vehicle for the delivery of dietary lycopene. Consequently, other 
tomato products providing similar amounts of lycopene may need to be 
substituted. 
Participants in our study did demonstrate high systemic inflammation, 
which was not unexpected. We did not observe a significant correlation between 
inflammatory markers and side effects of treatment. The most noteworthy 
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difference that we did observe was performance status in the intervention 
groups. Control group participants reported higher fatigue than the intervention 
group participants and this was reflected in the reported performance status 
responses from week to week. Another challenge observed during the study was 
the measurement of urinary frequency and urgency. Considering the age of the 
participants and frequent complaints of difficulty urinating with this prostate 
pathology, and also since all participants in the study were instructed by the 
Radiation Oncologist to increase their fluid intake, it was difficult to truly assess if 
the urinary frequency and urgency complaints by participants were radiation 
therapy related. Consequently this may not be an appropriate endpoint for 
lycopene intervention trials. We observed weight loss in the control group and a 
protective/delayed gastrointestinal response with lycopene supplementation, 
confirming results from an animal study (Andic, Garipagaoglu, Yurdakonar, 
Tuncel, & Kucuk, 2009). Overall, the results of this study may help expand the 
role of lycopene research from preventive to therapeutic. 
Strengths and Limitations 
Strengths  
1. To our knowledge, this is the first study evaluating serum lycopene levels 
and the impact of food-based lycopene supplementation during 
radiotherapy in prostate cancer patients. 
2. Lycopene intake was assessed using a validated food frequency 
questionnaire, the National Cancer Institute’s (NCI) diet history 
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questionnaire (DHQ) which has been validated with older adults. 
Additionally, since the DHQ calculates average intake over a 12 month 
period, day-to-day or seasonal variations in intake are not reflected. 
3.  The DHQ was also selected for estimating lycopene rich foods over other 
available methods (food diary) mainly because it would require less work 
for the patients as compared to maintaining a food diary during their 
treatment regimen. 
4. Tolerance of food-based lycopene supplementation during radiotherapy 
was assessed using the NCI Cancer Therapy Evaluation Program: 
Common Toxicity Criteria (CTC) v 2.0. 
5. Impact of lycopene supplementation on both performance status and 
select side effects during radiotherapy was assessed. 
6. Impact of total lycopene on key inflammatory markers was evaluated. 
7. This study expands the scope of lycopene research from preventive to an 
effective adjunct during radiation therapy in patients with localized prostate 
cancer. 
Limitations  
1. In order to minimize disruption of daily activities among the study 
participants, blood draws were scheduled around the time of their 
prescheduled radiation treatment appointment. Consequently, patients 
were not in a fasted state for the blood draws. Several researchers have 
demonstrated that the serum concentration of carotenoids do not change 
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significantly for up to four hours after a meal (Brown, Rose, Craft, Seidel, 
& Smith, 1989; Mejia & Arroyave, 1983; Mejia, Pineda, Noriega, Benitez, 
& Falla, 1984). However, the impact of non-fasted state on the other test 
parameters remains unknown. 
2. We were unable to use food records to monitor intake of lycopene rich 
foods during study duration.  
3. While the DHQ require less work for the patients as compared to 
maintaining a food diary, it relies heavily on patient memory in its 
reporting.  
4. Efficacy of lycopene supplementation was only evaluated in men with 
localized prostate cancer during radiotherapy. It also needs to be 
evaluated in prostate cancer patients receiving other treatments such as 
hormone therapy. 
5. We only measured total serum lycopene levels in our participants. Role of 
specific lycopene isomers (cis vs trans) should also be evaluated in future 
trials. 
6. Small sample size of this study limits generalization of these results. 
Future Work 
Based on the results of this research study, a phase II trial utilizing 8-12 oz 
of tomato juice or equivalent quantity of tomato product should be conducted. 
Participants in the 12 oz group demonstrated the least side effects of treatment 
and a progressive decline in CRP and PGE2 expression between the three time 
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points. Despite a small increase in IL-6 expression at midpoint, the endpoint 
results were lower than the baseline results in the 12 oz group. While participants 
in the 4 oz group demonstrated a progressive decline in IL-6 between the three 
time points, some participants did demonstrate other side effects of treatment. 
Lower fatigue was observed among all intervention group participants but not in 
the control group. This was an unexpected finding. While we did not measure 
fatigue scores, we speculate that it impacted the performance status scores 
observed. Since we excluded patients who concurrently received hormone 
therapy or were treated with brachytherapy, or received radiation to the whole 
pelvic bed, the impact of lycopene supplementation in these groups also needs 
to be investigated. Additionally, no information exists on the impact of this 
supplementation in reducing long term complications of radiation therapy and in 
survivors. A retrospective review of long-term side effects in our study 
participants should also be conducted to identify the impact of lycopene on these 
side effects. 
Overall, patients who volunteered to participate in our study appeared to 
have a desire for more “natural” alternatives to manage side effects of radiation 
therapy. This research also provides valuable data on the impact of tomato juice 
as a source of the carotenoid lycopene on select markers of inflammation. Links 
exploring the relationship between cytokine expression, radiation side-effects and 
lycopene need to be explored further in larger clinical trials. We hope that the 
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results of this study will allow us to secure funding in the future to conduct trials 
with a larger sample of patients to validate these results. 
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HIGH POINT REGIONAL HEALTH SYSTEM 
INSTITUTIONAL REVIEW BOARD 
 
HIPAA – AUTHORIZATION FOR RESEARCH 
For the Use and/or Disclosure of 
Protected Health Information 
 
You may qualify for participation in a research study.  This “HIPAA Authorization 
for Research” form gives you information about how health information collected 
about you for a research study would be used by researchers and disclosed to others 
involved in the research study.  Your signature on this form permits High Point 
Regional to give your information to the research team. 
Study Title:  Food-based lycopene supplementation in prostate cancer patients 
undergoing radiotherapy 
Principal Investigator:  __Martha Taylor, PhD_________________________________ 
 
I authorize the use and/or disclosure of my protected health information as described 
below: 
1. The following entity/person(s) is authorized to use or disclose my information: 
 High Point Regional Health System 
601 North Elm Street 
 High Point, NC  27262 
(336) 878-6000 
2. The following entity/person(s) is authorized to receive my information: 
 The Researchers (members, agents or successors of the research team, such as 
the Principal Investigator, Co-Investigators and members of their research 
staff) 
 The sponsor of the research study, and its agents and contractors 
 Representatives of government organizations, review boards, and other 
persons who are required to watch over the safety and effectiveness of 
medical products and therapies and the conduct of research 
 
3. Description of the information that may be used or disclosed: 
 Health information in my medical records that is relevant to the study 
(Taking part in this research study may involve collecting and disclosing health 
information that you consider confidential or private that directly identifies you.  
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Information in your medical record may include results of tests, procedures, 
interventions, interactions, questionnaires or surveys.  All information may be 
used and possibly disclosed and re-disclosed to monitor your health status, to 
measure the effects of drugs/devices/procedures /interventions as stated in this 
study, to determine research results and outcomes, and possibly develop new 
drugs/devices/tests/procedures and commercial products.) 
 
4. My information will be used or disclosed for the following purposes: 
• By the Researchers, among themselves and with other participating 
researchers to conduct the Research; 
• By the research Sponsor, as will be described in the Informed Consent Form; 
• By the representatives of government organizations, review boards, and other 
persons to watch over the safety and effectiveness of medical products and 
therapies and the conduct of research. 
 
(Your health information may be used by, disclosed to and re-disclosed for: research, 
quality assurance, or regulatory purposes, by: members, agents or successors of the 
research team, such as the Principal Investigator, Co-Investigators and members of 
their research staff (“Researchers”); other researchers and their staff involved with 
this study at other medical centers, institutions, hospitals, central data centers, the 
U.S. Food and Drug Administration, the Department of Health and Human Services, 
the Federal Office of Human Research Protection, High Point Regional Health 
System and/or the sponsor of this research study.) 
5. Study data that does not directly identify you may be published in medical journals or 
shared with others as part of scientific discussions. 
 
6. You have the right to see and copy your personal health information related to the 
research study for as long as this information is held by the Investigator or a research 
institution.  However, to ensure the scientific integrity of the study, you will not be 
able to review some of the study information until after the study has been complete. 
 
7. This authorization will expire when the last component of this research study is 
completed.  (Some research studies include more than one component, each of which 
may span a different time period; therefore, this authorization extends to the time 
when the last component is completed.) 
 
8. I understand that I may revoke this authorization at any time.  My revocation must be 
in writing and contain my signature.  I am aware that my revocation is not effective to 
the extent that the entity/person(s) I have authorized to use or disclose my 
information have acted in reliance upon this authorization.  To revoke my 
authorization, I understand that I need to contact the IRB Office at the address and 
phone number listed above in item #1 above and complete the appropriate paperwork. 
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9. I have been advised, and I understand, that this authorization is voluntary.  I do not 
have to sign this authorization and my refusal to sign will not affect my abilities to 
obtain treatment from High Point Regional Health System, nor will it affect my 
eligibility for benefits.  However, I understand that I will be required to sign this 
authorization form prior to receiving research-related treatment. 
 
10. I understand that if my information is disclosed to someone who is not required to 
comply with the federal privacy protection regulations, then such information may be 
re-disclosed and would no longer be protected. 
 
11. I certify that I have received a copy of this authorization. 
 
 
 
             
Signature of Patient     Date 
 
 
        
Print Name 
In the event this form is completed by someone other than the patient, please indicate 
below: 
             
Signature      Date 
 
 
 
             
Print Name      Relationship to Patient 
 
 
03-03; revised: 12-18-03; revised 01-09-06 
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APPENDIX C. HEALTH INFORMATION PORTABILITY AND 
ACCOUNTABILITY ACT (HIPAA) FORM – SPANISH 
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High Point Regional Health System 
Comité de Ética de Investigación Clínica 
 
Autorización para Investigación-HIPAA 
Para el Uso y/o Divulgación de  
Información Médica Protegida 
 
Usted puede calificar para participar en un estudio de investigación.  Este formulario  
“Autorización para Investigación de HIPPA” le da información acerca de cómo su información 
medica colectada para el estudio de investigación será usada por los investigadores y será 
divulgada a otros envueltos en el estudio de investigación.  Su firma en este formulario permite 
a High Point Regional dar su información al equipo de investigación. 
Título del Estudio:   
Investigador Principal: ____Martha Taylor, PhD_________________________________ 
Yo autorizo el uso y/o divulgación de mi información médica protegida como se describe abajo: 
1.  La siguiente entidad/persona(s) son autorizadas para usar o divulgar mi información: 
 High Point Regional Health System 
601 North Elm Street 
High Point, NC  27262 
(336) 878-6000 
 
2.  La siguiente entidad/persona(s) esta autorizada para recibir mi información: 
 Los investigadores (miembros, agentes o sucesores del equipo de investigación, tales 
como el Investigador Principal, Co-Investigadores y miembros del personal de 
investigación) 
 El patrocinador del estudio de investigación y sus agentes y contratistas 
 Representantes de organizaciones gubernamentales, comités de ética, y otras personas 
que les es requerido vigilar la seguridad y la efectividad de los productos médicos y 
terapias y el conducto de la investigación.    
 
3.  Descripción de la información que puede ser usada y divulgada: 
 Información médica en mis expedientes médicos que sea pertinente al estudio 
 
(El tomar parte en este estudio puede envolver el colectar y divulgar información 
médica que usted considera confidencial o privada que directamente lo identifica.  
Información médica en su expediente médico puede incluir los resultados de exámenes, 
procedimientos, intervenciones, interacciones, cuestionarios o encuestas.  Toda la 
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información puede ser usada y posiblemente divulgada y revelada para monitorear su 
estado de salud para medir los efectos de los 
medicamentos/aparatos/procedimientos/intervenciones como se ha expuesto en este 
estudio, para determinar los resultados y consecuencias y posiblemente desarrollar 
nuevos medicamentos/aparatos/exámenes/procedimientos y productos comerciales.) 
 
4. Mi información será usada o divulgada con los siguientes propósitos: 
 
 Por los Investigadores, entre ellos y con otros investigadores participantes para 
conducir la Investigación. 
 Por el investigador Patrocinador, como será descrito en el Consentimiento 
Informado; 
 Por los representantes de organizaciones gubernamentales, comités de ética y otras 
personas que vigilan la seguridad y la efectividad de los productos médicos y 
terapias y el conducto de la investigación. 
 
(Su información puedes ser usada, divulgada y revelada para: investigación, control 
de calidad o propósitos reguladores, por: miembros, agentes o sucesores de el 
equipo de investigación, tal como el Investigador Principal, Co-Investigadores y 
miembros del personal de investigación (“Investigadores”); otros investigadores y su 
personal envueltos con este estudio en sus centros médicos, instituciones, 
hospitales, centro de datos central, Administración de Alimentos y Fármacos de EE. 
UU., el Departamento de Salud y Servicios Humanos, La Oficina Federal para la 
Protección de los Seres Humanos en la Investigación, High Point Regional Health 
System y/o el patrocinador de este estudio de investigación.   
 
5. Información del estudio que no lo identifique directamente puede se publicada en 
diarios médicos o compartida con otros en discusiones científicas. 
 
6. Usted tiene el derecho de ver y copiar su información personal médica relacionada con 
la investigación mientras que el Investigador o la institución de investigación tenga esta 
información.  Sin embargo, para asegurar la integridad científica de la investigación 
usted no podrá repasar alguna de la información de la investigación hasta después de 
que se haya completado la investigación.   
7. Esta autorización se vence cuando el ultimó componente de esta investigación se 
complete.  (Algunos estudios de  investigación incluyen más de un componente, lo cual 
cada uno tiene un lapso de un período de tiempo diferente; por consiguiente, esta 
autorización se extiende al tiempo cuando el ultimó componente es completado.)  
8. Yo entiendo que puedo revocar esta autorización en cualquier momento.  Mi revocación 
debe ser por escrito y debe contener mi firma.  Estoy al tanto de que mi revocación no 
es efectiva a la entidad/persona(s) que he autorizado y han actuado según esta 
autorización para usar y divulgar mi información.  Para revocar mi autorización, yo 
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entiendo que necesito contactar la oficina del IRB a la dirección y número de teléfono 
indicado arriba en el artículo #1 arriba y completar el papeleo apropiado.   
9. Se me ha aconsejado y entiendo que esta autorización es voluntaria.  No tengo que 
firmar esta autorización y mi rechazo a firmar no afectará mis habilidades a obtener 
tratamiento de High Point Regional Health System, ni tampoco afectará mi elegibilidad 
para beneficios.  Sin embargo, yo entiendo que se requiere que firme esta autorización 
antes de recibir tratamiento relacionado a la investigación. 
10. Yo entiendo que si mi información es divulgada a alguien que no se le requiera cumplir 
con las regulaciones federales de privacidad, después la información puede ser revelada 
y ya no seria protegida. 
11. Yo certifico que he recibido una copia de esta autorización. 
 
________________________________  ___________________________ 
Firma del paciente    Fecha 
  
 
 __________________________________ 
Escriba su nombre en letra de molde 
 
En el caso de que este formulario sea completado por alguien que no es el paciente, por 
favor indíquelo abajo: 
 
________________________________  ___________________________ 
Firma      Fecha 
 
________________________________  ______________________________ 
Escriba su nombre en letra de molde  Relación al paciente 
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HIGH POINT REGIONAL HEALTH SYSTEM 
INSTITUTIONAL REVIEW BOARD 
INFORMED CONSENT 
 
What is a research study? 
You are invited to be in a research study. Research studies are designed to gain scientific 
knowledge that may help other people in the future. You may or may not receive any 
benefit from being part of the study. There may also be risks associated with being part of 
research studies. You are being asked to take part in this study because you have been 
diagnosed with prostate cancer and are about to begin radiation therapy for it. Your 
participation in this study is voluntary. Please take your time to make your decision and 
ask your study doctor or the study staff to explain any words or information that you do 
not understand. You may also discuss the study with your friends and family. 
Who is sponsoring the study? 
The researchers do not hold a direct financial interest in the sponsor or the product being 
studied. 
Why is the study being done? 
This study is being done to test if lycopene, a natural substance found in tomatoes, 
tomato products and some other foods helps reduce radiation therapy related side effects 
in men with prostate cancer, receiving external beam radiation therapy. 
In this study, the effect of three different amounts of tomato juice is being evaluated. In 
this study, you will receive 4 ounces, 8 ounces or 12 ounces of tomato juice. 
How many people will take part in the study? 
Forty men with prostate cancer about to initiate radiation therapy for treatment will be 
invited to participate in this study. 
What is involved in the study? 
If you agree to participate, we will need to check your blood work to make sure your 
kidneys and liver are functioning adequately and check your bloods lycopene level and 
other immune function related labs. This will require a blood sample (about 2 tablespoons 
of blood) to be drawn at the beginning of the study. These tests will be repeated at the 
end of three weeks of treatment and on the last day you receive your radiation treatment. 
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We will ask you to drink your assigned amount of tomato juice daily while you are 
receiving your radiation treatment, starting at least 2 days before you begin your 
treatment. On Friday of each week (during treatment), you will be provided with two 
additional doses of the beverage to take home with you. One dose of the beverage should 
be consumed on Saturday and the other on Sunday. 
You will be asked to complete the National Cancer Institute’s Diet History 
Questionnaire. This will help us estimate your usual intake of lycopene rich foods. There 
is no right or wrong answer, and you do not need to change your eating habits just 
because you are participating in this study. Please answer the questions honestly about 
how frequently you have been consuming specific foods. 
At the end of each week, you receive treatment we will also ask you to report your level 
of fatigue and ability to carry out your daily activities and any symptoms you may be 
experiencing. 
How long will I be in the study? 
You will be in the study for the entire time you are receiving radiation therapy. 
The researcher may decide to take you off the study if: 1) continued participation is not in 
your best medical interest, 2) health conditions occur which would make your 
participation possibly dangerous, or 3) new information becomes available. 
While we encourage you to continue till the end of the study, you may of course, 
withdraw from the study at any time. This will not comprise or affect the quality of your 
care that you may receive from this institution. If you decide to stop participating at any 
time, we encourage you to talk with the investigator or study staff first to learn about any 
potential health or safety consequences. 
What are the risks of the study? 
Being in this study may or may not involve any risk to you. You should discuss the risk 
of being in this study with the study staff. 
Blood draw: You may experience discomfort, bruising, and/or bleeding where the needle 
is inserted. There may be bruising at the puncture site when blood is drawn and 
occasionally some redness and swelling. Occasionally some people become dizzy, 
lightheaded or feel faint. Infection may occur on rare occasions. 
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Risks and side effects related to the study treatments: 
Study supplement: Lycopene is a naturally substance found in tomatoes, tomato products 
and some other foods. Processed tomato juice, which is the chosen food to provide 
lycopene in this study, may potentially cause some of the following side effects: 
• heartburn 
• abdominal distention  
• flatulence (gas)(Jatoi et al., 2007) 
• nausea  
• vomiting 
• diarrhea 
 
There may be other side effects that we cannot predict or are unexpected. If you have any 
unusual symptoms, report them immediately to your doctor and the study staff. You 
should also tell the research staff about all medications, vitamins and supplements you 
take and any medical conditions you have. This may help avoid side effects, interactions 
and other risks. 
Will I benefit from taking part in the study? 
You may or may not receive any benefit from taking part in this research study. We hope 
the information learned from this study will benefit other patients in the future. The 
benefit of participating in this study may be a decrease in radiation therapy related side 
effects. 
Will my medical information be kept private? 
We will do our best to make sure that the personal information in your medical record 
will be kept private. However, we cannot guarantee total privacy. Your personal 
information may be given out if required by law. If information from this study is 
published or presented at scientific meetings, your name and other personal information 
will not be used. 
A record of your progress will be kept in a confidential file at the hospital or doctor’s 
office where you receive treatment. Organizations that may inspect and/or copy your 
research and medical records (blood samples etc.) for quality assurance, research, and 
data analysis include groups such as: 
Comprehensive cancer center at Wake Forest University (CCCWFU) 
National Cancer Institute (NCI) and its representative 
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Food and Drug Administration (FDA) 
Office of Human Research protections (OHRP) 
Department of Health and Human Services (DHHS) 
Institutional Review Board (IRB) at High Point Regional Health System 
Possible other federal or state government agencies 
If your record is used out given out for governmental purposes, it will be done under 
conditions that will protect your privacy to the fullest extent possible consistent with the 
laws relating to public disclosure of information and law-enforcement responsibilities of 
the agency. These agencies may review the research to see that it is being done safely and 
correctly. 
You authorize the use of clinical information contained in your records, but any 
publication that includes such information or data shall not reveal your name, show  
your picture or contain any other personally identifying information, except as otherwise 
required by law. 
What are the costs of taking part in this study? 
There are no costs to you for taking part in this study. All the study costs, including any 
study medications and procedures directly related to the study, will be paid for by the 
study. Costs or your regular medical care/treatment, which are not related to this study, 
will be your own responsibility. 
You will not be paid to participate in this study. 
What happens if I am injured because I took part in this study? 
It is important that you tell your study doctor, Bart Frizzell, M.D. if you feel that you 
have been injured because if taking part in this study. You can tell the doctor in person or 
call him at 336-878-6036. 
You will get medical treatment if you are injured as a result of taking part in this study. 
You and/or your health plan will be charged for this treatment. This study will not pay for 
medical treatment. Although no funds or monies have been set aside to compensate you 
in the event of injury or illness related to the study treatment or procedures, you do not 
waive any of your legal rights for compensation by signing this form. 
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You or your insurance company will be charged for continuing medical care and/or 
hospitalization. 
What are my rights if I take part in this study? 
Taking part in this study is voluntary. You may choose to take part, not to take part or 
may leave the study at any time. No matter what decision you make, there will be no 
penalty for you and you will not lose any of your regular benefits. Leaving the study will 
not affect your medical care or result in any penalty or loss of benefits to which you are 
entitled. 
Even after you agree to take part in this study, you may withdraw at anytime. Before you 
withdraw, you should talk to one of the researchers. This will allow them to inform you 
of any medical problems that could result from stopping your treatment. Your decision to 
stop taking part in this study will not affect your medical treatment or your relationship 
with those treating you or with this institution. If you withdraw from the study, you will 
still be offered all available care that meets your medical condition. You are free to seek 
care from a doctor of your choice at any time. The investigators also have the right to 
stop your participation in the study at any time. This could happen if you lose too much 
weight or have side effects from either the radiation therapy or the beverage that prevents 
you from continuing in the study. 
We will tell you about new information that may affect your health, welfare or 
willingness to stay in the study. You may be asked to sign another consent form in 
response to new information. 
Who can answer my questions about the study? 
For questions about the study or a research-related injury, contact your doctor, Bart 
Frizzell, M.D. at 336-878-6036. 
You can contact the study coordinator, Mri Datta at 336-307-9020 if you have further 
questions. 
For questions about your rights as a research participant, contact the High Point Regional 
health System Institutional Review Board (which is a group of people at the hospital 
where you receive treatment, who review the research to protect your rights) at 336-878-
6207. 
Participant Contract  
I have been offered the opportunity to ask questions about this study and all questions 
have been answered to my satisfaction. The contents of this form have been explained to 
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me and I understand them. I agree to allow the research personnel specified above the 
access to my medical records. 
It may be necessary for my doctor to contact me at a future date regarding new 
information about the treatment I received; therefore, I agree to notify my doctor of any 
change of address and/or telephone number. 
My signature below means that I have voluntarily agreed to participate in this research 
study. I will be given a copy of all 6 pages of this consent. I have read it or it has been 
read to me, I may also request a copy of the study (complete study plan) 
 
_____________________  _________________          _________ 
(Participant Name)   (Participant Signature)         (Date) 
I certify that I have explained to the above individual the nature and purpose, the 
potential benefits, and possible risks associated with participation in the research study 
and have answered any questions that have been raised. 
 ______________________     _________________  _________ 
Name of person obtaining consent)      (Signature)         (Date) 
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I, _________________________________, withdraw my consent to participate in this 
study and refuse to have clinical data collected from my medical record (s). 
 
Participant name _____________________________  study ID#___________ 
   (please print name clearly) 
 
Participant signature ___________________________ Date____________ 
 
Witness signature ____________________________ Date____________ 
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APPENDIX E. CONSENT FORM – SPANISH 
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HIGH POINT REGIONAL HEALTH SYSTEM 
COMITÉ DE ÉTICA DE INVESTIGACIÓN CLÍNICA 
 
CONSENTIMIENTO INFORMADO 
¿Qué es un estudio de investigación? 
Usted es invitado a participar en un estudio de investigación.  Los estudios de investigación son 
diseñados para obtener conocimiento científico que pueda ayudar a otras personas en el futuro.  
Quizá reciba o no beneficios por ser parte del estudio.  También pueden existir riesgos asociados 
por ser parte de los estudios de investigación.  Se le ha pedido ser parte de este estudio porque 
usted ha sido diagnosticado con cáncer de la próstata y está a punto de recibir radio terapia 
para ella.  Su participación en este estudio es voluntaria.  Por favor de tomarse el tiempo para 
tomar su decisión y pregúntele a su doctor o a el personal del estudio que le expliquen cualquier 
palabra o información que no entienda.  También puede hablar con su familia y amistades 
acerca del estudio. 
¿Quién esta patrocinando el estudio? 
Los investigadores no tienen ningún interés financiero al patrocinar el producto que se está 
estudiando. 
¿Por qué se está haciendo este estudio? 
Este estudio se esta haciendo para probar si el licopeno, una sustancia natural que se halla en 
tomates, productos de tomates y otros alimentos, puede ayudar a reducir los efectos 
secundarios relacionados con la radioterapia en hombres con cáncer de la próstata que reciben 
radioterapia. 
En este estudio, se está evaluando el efecto de tres diferentes cantidades de jugo de tomate.  En 
este estudio usted recibirá 4 onzas, 8 onzas y 12 onzas de jugo de tomate. 
¿Cuántas personas participarán en el estudio? 
Cuarenta hombres con cáncer de la próstata que están por iniciar la radioterapia serán invitados 
a participar en este estudio. 
¿Qué envuelve el estudio? 
Si usted está de acuerdo en participar, necesitamos revisar sus análisis de sangre para 
asegurarnos de que sus riñones e hígado estén funcionando adecuadamente y analizaremos en 
su sangre su nivel de licopeno y otras funciones inmunes.  Esto requiere que tomemos una 
muestra de su sangre (como 2 cucharadas de sangre) al principio del estudio.  Estos exámenes 
se repetirán al final de tres semanas de tratamiento y al último día que reciba la radioterapia. 
Le pediremos que tome a diario su bebida de jugo de tomate con la cantidad asignada mientras 
esté recibiendo su radioterapia, comenzando por lo menos 2 días antes de empezar su 
tratamiento.  El viernes de cada semana (durante el tratamiento) se le proveerá con dos dosis 
adicionales de la bebida para que la lleve a casa.  Debe consumir una dosis de la bebida el 
sábado y la otra el domingo. 
Se le pedirá que llene el Cuestionario de Historial Alimenticio del Instituto Nacional de Cáncer.  
Esto nos ayudará a estimar su consumo de alimentos ricos en licopeno.  No hay ninguna 
contestación correcta o incorrecta y no tiene que cambiar sus hábitos de alimentación solo 
porque va a participar en este estudio.  Por favor de contestar todas las preguntas lo más 
honesto posible, de que tan frecuente ha estado consumiendo alimentos específicos.   
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Al final de cada semana que reciba tratamiento también le pediremos que reporte su nivel de 
fatiga y habilidad de llevar a cabo sus actividades diarias y cualquier síntoma que experimente. 
¿Cuánto tiempo participaré en el estudio? 
Usted participará en el estudio todo el tiempo que reciba la radioterapia. 
El investigador puede decidir removerlo del estudio si: 1) su participación no es lo más 
conveniente para su salud 2) ocurren condiciones de salud que harían su participación 
posiblemente peligrosa  o 3) sale disponible información nueva. 
Aunque le animamos a que continué hasta el final, usted puede retirarse del estudio en 
cualquier momento.  Esto no comprometerá o afectará la calidad de cuidado que recibe de esta 
institución.  Si decide no participar en cualquier momento le animamos a que hable con el 
investigador o personal del estudio primero para ver si hay alguna consecuencia potencial en su 
salud o seguridad. 
¿Cuáles son los riesgos del estudio? 
El participar en este estudio puede o no envolver riesgos a usted.  Hable con el personal del 
estudio acerca de los riesgos por participar en el. 
 
Extracción de sangre: Puede experimentar incomodidad, moretón y/o sangrado donde 
introducen la aguja.  Pueden obtener un moretón en el sitio de la punción cuando extraigan la 
sangre y ocasionalmente enrojecimiento e hinchazón.  Ocasionalmente algunas personas se 
marean o sienten que van a desmayar.  En raras ocasiones puede producirse una infección.   
 
Riesgos y efectos secundarios relacionados a los tratamientos del estudio: 
Suplemento del estudio: Licopeno es una sustancia natural que se encuentra en tomates, 
productos de tomates y otros alimentos.  El jugo de tomate procesado, el alimento escogido 
para proveer licopeno en este estudio, puede potencialmente causar los siguientes efectos 
secundarios: 
• acidez/agruras 
• distensión abdominal 
• flatulencia (gas)  
• náusea 
• vomito 
• diarrea 
 
Puede haber otros efectos secundarios que no podemos predecir o que son inesperados.  Si 
tiene algún síntoma inusual repórtelos de inmediato a su doctor o al el personal del estudio.  
También déjele saber a el personal de investigación sobre todo medicamento, vitaminas o 
suplementos que toma y cualquier condición de salud que tenga.  Esto puede ayudar a 
evitar efectos secundarios, interacciones y otros riesgos. 
¿Me beneficiaré por participar en el estudio? 
Puede que si o que no reciba ningún beneficio al participar en el estudio de investigación.  
Esperamos que la información que obtengamos del estudio le podrá beneficiar a otros 
pacientes en el futuro.  El beneficio de participar en este estudio puede ser una disminución 
en los efectos secundarios relacionados con la radioterapia. 
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¿Se mantendrá privada mi información médica? 
Haremos lo mejor para asegurarnos de que su información personal en su expediente 
médico se mantenga privada.  Sin embargo, no le podemos garantizar privacidad total.  Su 
información personal puede ser divulgada si es requerido por la ley.  Si la información de 
este estudio es publicada o presentada en juntas científicas, no se usará su nombre o alguna 
otra información personal. 
El expediente de su progreso se mantendrá en un archivo confidencial en el hospital o la 
oficina del doctor donde usted recibe el tratamiento.  Las organizaciones que quizá 
inspeccionen y/o copien su estudio o expediente médico (muestras de sangre, etc.) para 
garantía de calidad, investigación y análisis de datos incluyen los grupos como: 
Centro exhaustivo de cáncer en La Universidad Wake Forest (CCCWFU) 
Instituto Nacional de Cáncer (NCI) y sus representantes  
Administración de Alimentos y Fármacos (FDA) 
Oficina para la Protección de los Seres Humanos en la Investigación (OHRP) 
Departamento de Salud y Servicios Humanos (DHHS) 
Comité de Ética de Investigación Clínica en High Point Regional Health System 
Posiblemente otras agencias gubernamentales federales o estatales 
Si su expediente se libera con propósitos gubernamentales, será bajo condiciones que 
proteja su privacidad hasta donde las leyes relacionadas a la divulgación pública de 
información y las responsabilidades de la agencia a ejecutar la ley lo permitan.  Estas 
agencias pueden examinar la investigación para ver si se esta haciendo de una manera 
segura y correcta. 
Usted autoriza el uso de información clínica que contiene su expediente, pero cualquier 
publicación que incluya tal información o datos no deben revelar su nombre, mostrar su 
fotografía o contener cualquier otra información que lo identifique, a menos que se requiera 
por ley. 
¿Cuáles con los costos por participar en este estudio? 
No hay ningún costo a usted por participar en este estudio.  Todos los costos del estudio, 
incluyendo cualquier medicamento o procedimientos directamente relacionados con el 
estudio, serán pagados por el estudio.  Los costos de su tratamiento/cuidado médico 
regular, que no están relacionados con el este estudio, serán su responsabilidad. 
No se le pagará por participar en este estudio. 
¿Qué pasa si me lastimo por participar en este estudio? 
Es importante que le diga a su doctor, Bart Frizzell, , M.D. si siente que ha sido lastimado al 
participar en este estudio.  Puede decírselo al doctor en persona o llamarlo al 336-878-6036. 
Usted recibirá tratamiento médico si es lastimado como resultado de participar en este 
estudio.  Se le cobrará a usted y/o plan de salud por este tratamiento.  Este estudio no 
pagará por tratamiento médico.  Aunque no se ha reservado fondos o dinero para 
compensarlo en evento de ser lastimado o por enfermedad relacionada con el tratamiento o 
procedimientos del estudio, al firmar este formulario usted no esta renunciando sus 
derechos legales por compensación.   
Se le cobrará a usted o su compañía de seguro por cuidado médico continuo y/o por ser 
hospitalizado. 
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¿Cuáles son mis derechos si participo en este estudio? 
El participar en este estudio es voluntario.  Puede optar por participar, no participar o por dejar 
el estudio en cualquier momento.  No importa cual sea su decisión, no habrá ninguna 
penalización y no perderá ninguno de sus beneficios regulares.  El que deje el estudio no 
afectará su cuidado médico o resultará en ninguna penalización o pérdida de beneficios a los 
cuales tenga derecho. 
Aun si concuerda en participar en este estudio, usted puede retirarse en cualquier momento.  
Antes de retirarse debe hablar con los investigadores.  Esto les permitirá informarle de cualquier 
problema que pueda surgir como resultado por dejar el tratamiento.  Su decisión de dejar de 
participar en el estudio no afectará su tratamiento médico o su relación con quienes lo atienden 
o con esta institución.  Si se retira del estudio, aún se le ofrecerá todo cuidado disponible que 
reúna los requisitos a su condición médica.   Tiene el derecho de buscar cuidado de cualquier 
doctor en cualquier momento.  Los investigadores también tienen el derecho de detener su 
participación en este estudio en cualquier momento.  Esto ocurre si baja demasiado de peso o 
tiene efectos secundarios, ya sea de la radioterapia o la bebida, que prevenga a que continúe en 
el estudio. 
Le informaremos acerca de nueva información que pueda afectar su salud, bienestar o 
disposición de permanecer en el estudio.  Puede que se le pida firmar otro consentimiento en 
reacción a la nueva información. 
¿Quién puede contestar mis preguntas acerca del estudio? 
Para preguntas acerca del estudio o herida/lesión relacionado con el estudio, contacte a su 
doctor, Bart Frizzell, M.D. al 336878-6036. 
 
Puede contactar a la coordinadora del estudio, Mri Datta al 336-307-9020 si tiene más 
preguntas. 
 
Para preguntas sobre sus derechos como participante de la investigación, contacte a el Comité 
de Ética de Investigación Clínica de High Point Regional Health System (lo cual es un grupo de 
personas en el hospital donde recibe tratamiento, quienes revisan el proyecto de investigación 
para proteger sus derechos: al 336-878-6207. 
Contrato del Participante 
Se me ha ofrecido la oportunidad de hacer preguntas acerca del estudio y todas las preguntas 
han sido contestadas a mi satisfacción.  Se me ha explicado el contenido de este formulario y lo 
entiendo.  Estoy de acuerdo en permitir el personal de la investigación especificado arriba a 
tener acceso a mi expediente médico. 
Quizá sea necesario que mi doctor me contacte en el futuro sobre nueva información acerca del 
tratamiento que recibí; por lo tanto yo concuerdo en notificar a mi doctor con cualquier cambio 
de dirección y/o número de teléfono. 
Mi firma abajo significa que yo voluntariamente concuerdo en participar en esta investigación.  
Se me dará una copia de las 5 páginas de este consentimiento.  Yo lo he leído o se me ha leído, 
también puedo pedir una copia del estudio (plan completo del estudio) 
 
_____________________________ ______________________          ___________________ 
(Nombre del Participante)  (Firma del Participante)        (Fecha) 
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Yo certifico que he explicado al individuo mencionado arriba la naturaleza y el propósito, los 
beneficios potenciales y posibles riesgos asociados con la participación en la investigación y he 
contestado cualquier pregunta que ha surgido. 
 
 
_______________________________________ _______________________        ____________ 
(Nombre de la persona obteniendo el consentimiento) (Firma)     (Fecha) 
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Yo, ____________________________________________________________, retiro mi 
consentimiento a participar en este estudio y me rehúso a que colecten datos de mi 
expediente(s) médico. 
 
 
 
 
 
Nombre del participante ________________________________________ # de identificación de 
estudio 
                 
 
 
 
 (por favor escriba claramente su nombre en letra de molde) 
 
 
 
 
Firma del participante __________________________________ Fecha _______________ 
 
 
 
 
 
Firma del testigo ______________________________________ Fecha ________________ 
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APPENDIX F. SCREENING FORM 
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Participant Information/Screening 
Name:____________________________________  Age:____________ 
Ethnicity:  African American       Caucasian          Other________________ 
Height:________   reported wt:__________   how long ago:_________________ 
Weight change:  loss (#/time)_____________  gain (#/time)______________ 
Marital Status:   married widowed  divorced  never married 
Highest level of Education:    < high school     high school       > high school   
Other significant information:_______________________________________ 
 
Group Assignment:  Participant ID: 
 
No. Of treatments prescribed: _______    Gy, over   _______ days 
Labs 
Results 
Date: Date: 
PSA   
Na   
K    
Gluc   
BUN   
Cr.   
Ca   
albumin   
SGOT   
SGPT   
LDH   
Alk. Phos   
   
   
   
   
Medical History 
 HTN  
 DM  
 CAD  
 Hyper chol  
 
Meds & Supplements: Prescription 
& OTC 
Medications Supplements 
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 Yes No 
ECOG performance score 0 or 1   
Are you allergic to tomatoes or red food coloring?   
Are you allergic to any other foods? If yes, please specify foods allergic to__   
Have you ever been diagnosed with    
Problems with your immune function   
liver disease   
kidney disease   
malabsorption disorders/ Irritable bowel/ Celiac disease   
Uncontrolled gastro-esophageal reflux disease   
Are you currently taking any fiber supplements/pills: Metamucil, Citrucel, Fibercon, Benefiber   
Do you exercise? If yes, how often?_________________________________   
Do you smoke? If yes how many packs a day___________________   
Do you drink alcohol? If yes, please specify how many drinks   
Daily ___ drinks a day of ________ 
Weekly____ drinks a week of _____ 
Monthly ___drinks per month of __ 
Socially ___ drink_____________ 
Since being diagnosed with cancer, have you made any changes in (specify)   
Activity   
Diet   
Lifestyle   
Are you currently taking any of the following supplements    
Multivitamin supplement with lycopene   
Saw Palmetto   
Lycopene   
Vitamin A   
Vitamin C   
Vitamin E   
Beta-carotene   
Omega-3 Fatty acids   
Fish oil   
Flax seeds   
Flaxseed oil   
EPA/DHA   
________________________________Other Supplements (please specify)   
Are you willing to stop taking these supplements for the duration of the study?   
Would you be willing to sign an informed consent form?   
Notes: 
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APPENDIX G. INSTRUCTIONS FOR STUDY PARTICIPANTS – ENGLISH 
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Instructions for tomato juice and prostate cancer study participants 
1. Please continue with your normal eating habits and meal patterns. Do not make 
any changes in your diet just because you are participating in this study. 
2. During your participation in the study, each Friday you will be provided with two 
beverage containers. Please consume the beverage in one container on Saturday and 
the other on Sunday.   
3. Consume beverage within 30 minutes of eating a meal to aid in the digestion of the 
beverage. 
4. Do not consume any of the following supplements for the duration of your 
treatment/study participation as these may change how your body handles the 
treatment you are receiving. 
 
a. Multivitamin 
b. Saw Palmetto 
c. Lycopene 
d. Beta-Carotene 
e. Vitamin A 
f. Vitamin C 
g. Vitamin E 
h. Omega-3 
i. Fish Oil 
j. EPA/DHA 
k. Flaxseeds 
l. Flaxseed oil 
 
5. Before taking any other nutritional supplement or vitamins, please check with your 
radiation doctor and the study coordinator. Some of these supplements may decrease 
the benefits of the radiation treatment you are receiving. 
6. You will be asked to complete a food frequency questionnaire at the beginning of 
the study. This should take you about an hour to complete. Please answer all 
questions as accurately as you can and return the questionnaire to the study 
coordinator, one week before your last treatment. There is no right or wrong answer. 
7. Please let your radiation doctor and study coordinator know if there are any changes in 
your bowel movements, bladder problems or you experience other problems such as 
nausea, vomiting, or heartburn. 
 
You can reach the study coordinator Mri Datta at 307-9020 
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APPENDIX H. INSTRUCTIONS FOR STUDY PARTICIPANTS – SPANISH 
  
 
214 
 
Instrucciones para los participantes en el estudio de cáncer de la próstata y jugo de tomate 
 
1. Por favor continúe con sus hábitos y patrones normales de alimentación.  No haga 
ningún cambio en su dieta solo porque esta participando en este estudio. 
 
2. Durante su participación en el estudio, cada viernes se le proveerá con dos envases de 
bebidas.  Por favor de consumir la bebida de un envase el sábado y la otra el domingo. 
 
3. Consuma la bebida dentro de 30 minutos de haber comido para ayudar con la digestión 
de la bebida. 
 
4. No consuma ninguno de los siguientes suplementos por la duración de su participación 
en el tratamiento/estudio, ya que estos pueden cambiar la manera como su cuerpo 
maneja el tratamiento que esta recibiendo. 
 
a. Multivitamínico   e. Vitamina A  i. Aceite de pescado 
b. Palma enana americana  f.  Vitamina C  j. EPA/DHA  
c. Licopeno   g. Vitamina E  k. Linaza 
d. Beta Caroteno   h. Omega-3  l.  Aceite de linaza 
 
 
5. Antes de tomar algún otro suplemento o vitaminas, por favor revise con su doctor de 
radiación y el coordinador del estudio.  Algunos de estos suplementos pueden disminuir 
los beneficios del tratamiento de radiación que está recibiendo. 
 
6. Se le pedirá completar un cuestionario de frecuencia de alimentos al principio del 
estudio.  Le tomará una hora completarlo.  Por favor de contestar todas las preguntas lo 
más preciso posible y entréguelo al coordinador del estudio, una semana antes de su 
último tratamiento.   No hay ninguna contestación correcta o incorrecta. 
 
7. Por favor déjele saber a su doctor de radiación y al coordinador del estudio si hay algún 
cambio en sus defecaciones, problemas de la vejiga o si experimenta otros problemas 
como náusea, vomito o ardor de estómago. 
 
 
 
 
 
Se puede comunicar con la coordinadora del estudio Mri Datta al 307-9020 
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APPENDIX I. NATIONAL CANCER INSTITUTE DIET HISTORY 
QUESTIONNAIRE 
NATIONAL INSTITUTES OF HEALTH 
 
Diet History Questionnaire 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Today's date: 
 
MONTH DAY YEAR 
|___|___| 
0 0 
1 1 
2 2 
3 3 
 4 
 5 
 6 
 7 
 8 
   Jan  
   Fe b 
   Mar 
   Ap r 
   May  
   J un 
   Ju l 
   Au g 
   Sep 
   Oct 
   No v 
   Dec  9 
 2007 
 2008 
 2009 
 2010 
 2011 
 
 
 
 
 
 
 
In what month were 
you born? 
 
   Jan  
   Fe b 
   Mar 
   Ap r 
   May  
   J un 
   Ju l 
   Au g 
   Sep 
   Oct 
   No v 
   Dec 
 
 
 
 
 
In what year were 
you born? 
 
 19 |___|___| 
0 0
1 1
2 2
3 3
4 4
5 5
6 6
7 7
8 8
9 9
 
 
 
 
 
Are you male or 
female? 
 
 Male 
 Female 
GENERAL INSTRUCTIONS 
• Answer each question as best you can.  Estimate if you are not sure.  A guess is 
better than leaving a blank. 
• Use only a black ball-point pen.  Do not use a pencil or felt-tip pen.  Do n ot fold, 
staple, or tear the pages. 
• Put an X in the box next to your answer.  
• If you make any changes, cross out the incorrect answer and put an X in the box 
next to the correct answer.  Also draw a circle around the correct answer. 
• If you mark NEVER, NO, or DON’T KNOW for a question, please follow any 
arrows or instructions that direct you to the next question. 
 
BEFORE TURNING THE PAGE, PLEASE COMPLETE THE FOLLOWING QUESTIONS. 
 
BAR CODE LABEL OR SUBJECT ID 
HERE  
 
|___|___|___|___|___|___|___|___| 
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1. Over the past 12 months, how often did you drink 
tomato juice or vegetable juice? 
 
 NEVER (GO TO QUESTION 2) 
 
 1 time per month or less  1 time per day 
 2–3 times per month  2–3 times per day 
 1–2 times per week  4–5 times per day 
 3–4 times per week  6 or more times per day 
 5–6 times per week  
 
1a. Each time you drank tomato juice or 
vegetable juice, how much did you usually 
drink? 
 
 Less than ¾ cup (6 ounces) 
 ¾ to 1¼  cups (6 to 10 ounces) 
 More than 1¼  cups (10 ounces) 
 
2. Over the past 12 months, how often did you drink 
orange juice or grapefruit juice? 
 
 NEVER (GO TO QUESTION 3) 
 
 1 time per month or less  1 time per day 
 2–3 times per month  2–3 times per day 
 1–2 times per week  4–5 times per day 
 3–4 times per week  6 or more times per day 
 5–6 times per week  
 
2a. Each time you drank orange juice or 
grapefruit juice, how much did you usually 
drink? 
 
 Less than ¾ cup (6 ounces) 
 ¾ to 1¼  cups (6 to 10 ounces) 
 More than 1¼  cups (10 ounces) 
 
3. Over the past 12 months, how often did you drink 
other 100% fruit juice or 100% fruit juice 
mixtures (such as apple, grape, pineapple, or 
others)? 
 
 NEVER (GO TO QUESTION 4) 
 
 1 time per month or less  1 time per day 
 2–3 times per month  2–3 times per day 
 1–2 times per week  4–5 times per day 
 3–4 times per week  6 or more times per day 
 5–6 times per week  
 
3a. Each time you drank other fruit juice or fruit 
juice mixtures, how much did you usually 
drink? 
 
 Less than ¾ cup (6 ounces) 
 ¾ to 1½ cups (6 to 12 ounces) 
 More than 1½  cups (12 ounces) 
Over the past 12 months… 
 
4. How often did you drink other fruit drinks (such 
as cranberry cocktail, Hi-C, lemonade, or Kool-
Aid, diet or regular)? 
 
 NEVER (GO TO QUESTION 5) 
 
 1 time per month or less  1 time per day 
 2–3 times per month  2–3 times per day 
 1–2 times per week  4–5 times per day 
 3–4 times per week  6 or more times per day 
 5–6 times per week  
 
4a. Each time you drank fruit drinks, how much 
did you usually drink? 
 
 Less than 1 cup (8 ounces) 
 1 to 2 cups (8 to 16 ounces) 
 More than 2 cups (16 ounces) 
 
4b. How often were your fruit drinks diet or 
sugar-free drinks? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
5. How often did you drink milk as a beverage 
(NOT in coffee, NOT in cereal)?  (Please include 
chocolate milk and hot chocolate.) 
 
 NEVER (GO TO QUESTION 6) 
 
 1 time per month or less  1 time per day 
 2–3 times per month  2–3 times per day 
 1–2 times per week  4–5 times per day 
 3–4 times per week  6 or more times per day 
 5–6 times per week  
 
5a. Each time you drank milk as a beverage, 
how much did you usually drink? 
 
 Less than 1 cup (8 ounces) 
 1 to 1½ cups (8 to 12 ounces) 
 More than 1½ cups (12 ounces)  
 
5b. What kind of milk did you usually drink? 
 
 Whole milk 
 2% fat milk 
 1 % fat milk 
 Skim, nonfat, or ½% fat milk 
 Soy milk 
 Rice milk 
 Other 
 
Question 4 appears in the next column Question 6 appears on the next page 
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Over the past 12 months… 
 
6. How often did you drink meal replacement, 
energy, or high-protein beverages such as 
Instant Breakfast, Ensure, Slimfast, Sustacal or 
others? 
 
 NEVER (GO TO QUESTION 7) 
 
 1 time per month or less  1 time per day 
 2–3 times per month  2–3 times per day 
 1–2 times per week  4–5 times per day 
 3–4 times per week  6 or more times per day 
 5–6 times per week  
 
6a. Each time you drank meal replacement 
beverages, how much did you usually drink? 
 
 Less than 1 cup (8 ounces) 
 1 to 1½ cups (8 to 12 ounces) 
 More than 1½ cups (12 ounces)  
 
7. Over the past 12 months, did you drink soft 
drinks, soda, or pop? 
 
 NO (GO TO QUESTION 8) 
 
 YES 
 
 
7a. How often did you drink soft drinks, soda, 
or pop IN THE SUMMER? 
 
 NEVER  
  
 1 time per month or less  1 time per day 
 2–3 times per month  2–3 times per day 
 1–2 times per week  4–5 times per day 
 3–4 times per week  6 or more times  
 5–6 times per week per day 
 
7b. How often did you drink soft drinks, soda, 
or pop DURING THE REST OF THE YEAR? 
  
 NEVER  
  
 1 time per month or less  1 time per day 
 2–3 times per month  2–3 times per day 
 1–2 times per week  4–5 times per day 
 3–4 times per week  6 or more times  
 5–6 times per week per day 
 
7c. Each time you drank soft drinks, soda, or 
pop, how much did you usually drink? 
 
 Less than 12 ounces or less than 1 can or bottle 
 12 to 16 ounces or 1 can or bottle 
 More than 16 ounces or more than 1 can or bottle 
 
7d. How often were these soft drinks, soda, or 
pop diet or sugar-free? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
7e. How often were these soft drinks, soda, or 
pop caffeine-free? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
8. Over the past 12 months, did you drink beer? 
 
 NO (GO TO QUESTION 9) 
 
 YES 
 
 
8a. How often did you drink beer IN THE 
SUMMER? 
 
 NEVER  
  
 1 time per month or less  1 time per day 
 2–3 times per month  2–3 times per day 
 1–2 times per week  4–5 times per day 
 3–4 times per week  6 or more times  
 5–6 times per week per day 
 
8b. How often did you drink beer DURING THE 
REST OF THE YEAR? 
 
 NEVER  
  
 1 time per month or less  1 time per day 
 2–3 times per month  2–3 times per day 
 1–2 times per week  4–5 times per day 
 3–4 times per week  6 or more times  
 5–6 times per week per day 
 
8c. Each time you drank beer, how much did you 
usually drink? 
 
 Less than a 12-ounce can or bottle 
 1 to 3 12-ounce cans or bottles 
 More than 3 12-ounce cans or bottles 
 
 
                          
 
Question 9 appears on the next page Question 8 appears in the next column 
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Over the past 12 months… 
 
9. How often did you drink wine or wine coolers? 
 
 NEVER (GO TO QUESTION 10) 
 
 1 time per month or less  1 time per day 
 2–3 times per month  2–3 times per day 
 1–2 times per week  4–5 times per day 
 3–4 times per week  6 or more times per day 
 5–6 times per week  
 
9a. Each time you drank wine or wine coolers, 
how much did you usually drink? 
  
 Less than 5 ounces or less than 1 glass 
 5 to 12 ounces or 1 to 2 glasses 
 More than 12 ounces or more than 2 glasses 
 
10. How often did you drink liquor or mixed drinks? 
 
 NEVER (GO TO QUESTION 11) 
 
 1 time per month or less  1 time per day 
 2–3 times per month  2–3 times per day 
 1–2 times per week  4–5 times per day 
 3–4 times per week  6 or more times per day 
 5–6 times per week  
 
10a. Each time you drank liquor or mixed drinks, 
how much did you usually drink? 
 
 Less than 1 shot of liquor 
1 to 3 shots of liquor 
 More than 3 shots of liquor 
 
 
11. Over the past 12 months, did you eat oatmeal, 
grits, or other cooked cereal? 
 
 NO (GO TO QUESTION 12) 
 
 YES 
 
 
11a. How often did you eat oatmeal, grits, or 
other cooked cereal IN THE WINTER? 
 
 NEVER  
  
 1–6 times per winter  2 times per week 
 7–11 times per winter  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
 
 
11b. How often did you eat oatmeal, grits, or 
other cooked cereal DURING THE REST 
OF THE YEAR? 
  
 NEVER  
  
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
11c. Each time you ate oatmeal, grits, or other 
cooked cereal, how much did you usually 
eat? 
 
 Less than ¾ cup  
 ¾ to 1¼  cups  
 More than 1¼  cups  
 
12. How often did you eat cold cereal? 
 
 NEVER (GO TO QUESTION 13) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
12a. Each time you ate cold cereal, how much 
did you usually eat? 
 
 Less than 1 cup 
 1 to 2½ cups 
 More than 2½ cups 
 
12b. How often was the cold cereal you ate Total, 
Product 19, or Right Start? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
12c. How often was the cold cereal you ate All 
Bran, Fiber One, 100% Bran, or Bran 
Buds? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
Question 12 appears in the next column Question 13 appears on the next page 
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Over the past 12 months… 
 
12d. How often was the cold cereal you ate some 
other bran or fiber cereal (such as 
Cheerios, Shredded Wheat, Raisin Bran, 
Bran Flakes, Grape-Nuts, Granola, 
Wheaties, or Healthy Choice)? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
12e. How often was the cold cereal you ate any 
other type of cold cereal (such as Corn 
Flakes, Rice Krispies, Frosted Flakes, 
Special K, Froot Loops, Cap'n Crunch, or 
others)? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
12f. Was milk added to your cold cereal? 
 
 NO (GO TO QUESTION 13) 
 
 YES 
 
12g. What kind of milk was usually added? 
 
 Whole milk 
 2% fat milk 
 1% fat milk 
 Skim, nonfat, or ½% fat milk 
 Soy milk 
 Rice milk 
 Other 
 
12h. Each time milk was added to your cold 
cereal, how much was usually added? 
 
 Less than ½ cup 
 ½ to 1 cup 
 More than 1 cup 
 
13. How often did you eat applesauce? 
 
 NEVER (GO TO QUESTION 14) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
13a. Each time you ate applesauce, how much 
did you usually eat? 
 
 Less than ½ cup 
 ½ to 1 cup 
 More than 1 cup 
 
14. How often did you eat apples? 
 
 NEVER (GO TO QUESTION 15) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
14a. Each time you ate apples, how many did you 
usually eat? 
 
 Less than 1 apple 
 1 apple 
 More than 1 apple 
 
15. How often did you eat pears (fresh, canned, or 
frozen)? 
 
 NEVER (GO TO QUESTION 16) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
15a. Each time you ate pears, how many did you 
usually eat? 
 
 Less than 1 pear 
 1 pear 
 More than 1 pear 
 
16. How often did you eat bananas? 
 
 NEVER (GO TO QUESTION 17) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
 
                              
 
Question 14 appears in the next column Question 17 appears on the next page 
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Over the past 12 months… 
 
16a. Each time you ate bananas, how many did 
you usually eat? 
 
 Less than 1 banana 
 1 banana 
 More than 1 banana  
 
17. How often did you eat dried fruit, such as prunes 
or raisins (not including dried apricots)? 
 
 NEVER (GO TO QUESTION 18) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
17a. Each time you ate dried fruit, how much did 
you usually eat (not including dried apricots)? 
 
 Less than 2 tablespoons 
 2 to 5 tablespoons 
 More than 5 tablespoons 
 
18. Over the past 12 months, did you eat peaches, 
nectarines, or plums? 
 
 NO (GO TO QUESTION 19) 
 
 YES 
 
 
18a. How often did you eat fresh peaches, 
nectarines, or plums WHEN IN SEASON? 
 
  NEVER  
  
 1–6 times per season  2 times per week 
 7–11 times per season  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
18b. How often did you eat peaches, nectarines, 
or plums (fresh, canned, or frozen) DURING 
THE REST OF THE YEAR? 
 
  NEVER  
  
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
18c. Each time you ate peaches, nectarines, or 
plums, how much did you usually eat? 
 
 Less than 1 fruit or less than ½ cup 
 1 to 2 fruits or ½ to ¾ cup 
 More than 2 fruits or more than ¾ cup 
 
19. How often did you eat grapes? 
 
  NEVER (GO TO QUESTION 20) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
19a. Each time you ate grapes, how much did 
you usually eat? 
 
 Less than ½ cup or less than 10 grapes 
 ½ to 1 cup or 10 to 30 grapes 
 More than 1 cup or more than 30 grapes 
 
20. Over the past 12 months, did you eat 
cantaloupe? 
 
 NO (GO TO QUESTION 21) 
 
 YES 
 
 
20a. How often did you eat fresh cantaloupe 
WHEN IN SEASON? 
 
  NEVER  
  
 1–6 times per season  2 times per week 
 7–11 times per season  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
20b. How often did you eat fresh or frozen cantaloupe 
DURING THE REST OF THE YEAR? 
 
  NEVER  
  
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
 
 
 
Question 19 appears in the next column Question 21 appears on the next page 
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Over the past 12 months… 
 
20c. Each time you ate cantaloupe, how much 
did you usually eat? 
 
 Less than ¼ melon or less than ½ cup 
 ¼ melon or ½ to 1 cup 
 More than ¼ melon or more than 1 cup  
 
21. Over the past 12 months, did you eat melon, 
other than cantaloupe (such as watermelon or 
honeydew)? 
 
 NO (GO TO QUESTION 22) 
 
 YES 
 
 
21a. How often did you eat fresh melon, other 
than cantaloupe (such as watermelon or 
honeydew) WHEN IN SEASON? 
 
  NEVER  
  
 1–6 times per season  2 times per week 
 7–11 times per season  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
21b. How often did you eat fresh or frozen 
melon, other than cantaloupe (such as 
watermelon or honeydew) DURING THE 
REST OF THE YEAR? 
 
  NEVER  
  
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
21c. Each time you ate melon other than 
cantaloupe, how much did you usually eat? 
 
 Less than ½ cup or 1 small wedge 
 ½ to 2 cups or 1 medium wedge 
 More than 2 cups or 1 large wedge 
 
 
    
22. Over the past 12 months, did you eat 
strawberries? 
 
 NO (GO TO QUESTION 23) 
 
 YES  
 
 
22a. How often did you eat fresh strawberries 
WHEN IN SEASON? 
 
  NEVER  
  
 1–6 times per season  2 times per week 
 7–11 times per season  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
22b. How often did you eat fresh or frozen 
strawberries DURING THE REST OF THE YEAR? 
 
  NEVER  
  
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
22c. Each time you ate strawberries, how much 
did you usually eat? 
 
 Less than ¼ cup or less than 3 berries 
 ¼ to ¾ cup or 3 to 8 berries 
 More than ¾ cup or more than 8 berries 
 
23. Over the past 12 months, did you eat oranges, 
tangerines, or tangelos? 
 
 NO (GO TO QUESTION 24) 
 
 YES 
 
 
23a. How often did you eat fresh oranges, tangerines, 
or tangelos WHEN IN SEASON? 
 
  NEVER  
  
 1–6 times per season  2 times per week 
 7–11 times per season  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
Question 22 appears in the next column Question 24 appears on the next page 
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Over the past 12 months… 
 
23b. How often did you eat oranges, tangerines, 
or tangelos (fresh or canned) DURING THE 
REST OF THE YEAR? 
 
  NEVER  
  
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
23c. Each time you ate oranges, tangerines, or 
tangelos, how many did you usually eat? 
 
 Less than 1 fruit 
 1 fruit 
 More than 1 fruit 
 
24. Over the past 12 months, did you eat grapefruit? 
 
 NO (GO TO QUESTION 25) 
 
 YES 
 
 
24a. How often did you eat fresh grapefruit 
WHEN IN SEASON? 
 
  NEVER  
  
 1–6 times per season  2 times per week 
 7–11 times per season  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
24b. How often did you eat grapefruit (fresh or 
canned) DURING THE REST OF THE YEAR? 
 
  NEVER  
  
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
24c. Each time you ate grapefruit, how much did 
you usually eat? 
 
 Less than ½ grapefruit 
 ½ grapefruit 
 More than ½ grapefruit 
 
25. How often did you eat other kinds of fruit? 
 
 NEVER (GO TO QUESTION 26) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
25a. Each time you ate other kinds of fruit, how 
much did you usually eat? 
 
 Less than ¼ cup 
 ¼  to ¾ cup 
 More than ¾ cup 
 
26. How often did you eat COOKED greens (such as 
spinach, turnip, collard, mustard, chard, or kale)? 
 
 NEVER (GO TO QUESTION 27) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
26a. Each time you ate COOKED greens, how 
much did you usually eat? 
 
 Less than ½ cup 
 ½ to 1 cup 
 More than 1 cup 
 
27. How often did you eat RAW greens (such as 
spinach, turnip, collard, mustard, chard, or kale)?  
(We will ask about lettuce later.) 
 
 NEVER (GO TO QUESTION 28) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
27a. Each time you ate RAW greens, how much 
did you usually eat? 
 
 Less than ½ cup 
 ½ to 1 cup 
 More than 1 cup 
 
 
 
 
 
 
 
Question 28 appears on the next page Question 25 appears in the next column 
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Over the past 12 months… 
 
28. How often did you eat coleslaw? 
 
 NEVER (GO TO QUESTION 29) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
28a. Each time you ate coleslaw, how much did 
you usually eat? 
 
 Less than ¼ cup 
 ¼  to ¾ cup 
 More than ¾ cup 
 
29. How often did you eat sauerkraut or cabbage 
(other than coleslaw)? 
 
 NEVER (GO TO QUESTION 30) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
29a. Each time you ate sauerkraut or cabbage, 
how much did you usually eat? 
 
 Less than ¼ cup 
 ¼ to 1 cup 
 More than 1 cup 
 
30. How often did you eat carrots (fresh, canned, or 
frozen)? 
 
 NEVER (GO TO QUESTION 31) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
30a. Each time you ate carrots, how much did 
you usually eat? 
 
 Less than ¼ cup or less than 2 baby carrots 
 ¼ to ½ cup or 2 to 5 baby carrots 
 More than ½ cup or more than 5 baby carrots 
 
 
 
31. How often did you eat string beans or green 
beans (fresh, canned, or frozen)? 
 
 NEVER (GO TO QUESTION 32) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
31a. Each time you ate string beans or green 
beans, how much did you usually eat? 
 
 Less than ½ cup 
 ½ to 1 cup 
 More than 1 cup 
 
32. How often did you eat peas (fresh, canned, or 
frozen)? 
 
 NEVER (GO TO QUESTION 33) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
32a. Each time you ate peas, how much did you 
usually eat? 
 
 Less than ¼ cup 
 ¼ to ¾ cup 
 More than ¾ cup 
 
33. Over the past 12 months, did you eat corn? 
 
 NO (GO TO QUESTION 34) 
 
 YES 
 
 
33a. How often did you eat fresh corn WHEN IN 
SEASON? 
 
  NEVER  
  
 1–6 times per season  2 times per week 
 7–11 times per season  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
                                     
Question 31 appears in the next column Question 34 appears on the next page 
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Over the past 12 months… 
 
33b. How often did you eat corn (fresh, canned, or 
frozen) DURING THE REST OF THE YEAR? 
 
  NEVER  
  
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
33c. Each time you ate corn, how much did you 
usually eat? 
 
 Less than 1 ear or less than ½ cup 
 1 ear or ½ to 1 cup 
 More than 1 ear or more than 1 cup 
 
 
34. Over the past 12 months, how often did you eat 
broccoli (fresh or frozen)? 
 
 NEVER (GO TO QUESTION 35) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
34a. Each time you ate broccoli, how much did 
you usually eat? 
 
 Less than ¼ cup 
 ¼ to 1 cup 
 More than 1 cup 
 
35. How often did you eat cauliflower or Brussels 
sprouts (fresh or frozen)? 
 
 NEVER (GO TO QUESTION 36) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
35a. Each time you ate cauliflower or Brussels 
sprouts, how much did you usually eat? 
 
 Less than ¼ cup 
 ¼ to ½ cup 
 More than ½ cup 
 
 
36. How often did you eat mixed vegetables? 
 
 NEVER (GO TO QUESTION 37) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
36a. Each time you ate mixed vegetables, how 
much did you usually eat? 
 
 Less than ½ cup 
 ½ to 1 cup 
 More than 1 cup 
 
37. How often did you eat onions? 
 
 NEVER (GO TO QUESTION 38) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
37a. Each time you ate onions, how much did 
you usually eat? 
 
 Less than 1 slice or less than 1 tablespoon 
 1 slice or 1 to 4 tablespoons 
 More than 1 slice or more than 4 tablespoons 
 
38. Now think about all the cooked vegetables you 
ate in the past 12 months and how they were 
prepared.  How often were your vegetables 
COOKED WITH some sort of fat, including oil 
spray?  (Please do not include potatoes.) 
 
 NEVER (GO TO QUESTION 39) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
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38a. Which fats were usually added to your 
vegetables DURING COOKING?  (Please do 
not include potatoes.  Mark all that apply.) 
 
 Margarine 
(including low-fat) 
 Corn oil 
 Canola or rapeseed oil 
 Butter (including 
low-fat) 
 Oil spray, such as Pam 
or others 
 Lard, fatback, or 
bacon fat 
 Other kinds of oils 
 None of the above 
 Olive oil  
 
39. Now, thinking again about all the cooked 
vegetables you ate in the past 12 months, how 
often was some sort of fat, sauce, or dressing 
added AFTER COOKING OR AT THE TABLE?  
(Please do not include potatoes.) 
 
 NEVER (GO TO QUESTION 40) 
 
 1–6 times per year  3–4 times per week 
 7–11 times per year  5–6 times per week 
 1 time per month  1 time per day 
 2–3 times per month  2 times per day  
 1–2 times per week  3 or more times per day 
 
39a. Which fats, sauces, or dressings were 
usually added AFTER COOKING OR AT 
THE TABLE?  (Please do not include 
potatoes.  Mark all that apply.) 
 
 Margarine 
(including low-fat) 
 Salad dressing 
 Cheese sauce 
 Butter (including 
low-fat) 
 White sauce 
 Other 
 Lard, fatback, or 
bacon fat 
 
 
39b. If margarine, butter, lard, fatback, or bacon 
fat was added to your cooked vegetables 
AFTER COOKING OR AT THE TABLE, how 
much did you usually add? 
 
 Did not usually add these 
 Less than 1 teaspoon 
 1 to 3 teaspoons 
 More than 3 teaspoons 
 
39c. If salad dressing, cheese sauce, or white 
sauce was added to your cooked vegetables 
AFTER COOKING OR AT THE TABLE, how 
much did you usually add? 
 
 Did not usually add these 
 Less than 1 tablespoon 
 1 to 3 tablespoons 
 More than 3 tablespoons 
40. Over the past 12 months, how often did you eat 
sweet peppers (green, red, or yellow)? 
 
 NEVER (GO TO QUESTION 41) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
40a. Each time you ate sweet peppers, how 
much did you usually eat? 
 
 Less than ⅛  pepper 
 ⅛  to ¼ pepper 
 More than ¼ pepper 
 
41. Over the past 12 months, did you eat fresh 
tomatoes (including those in salads)? 
 
 NO (GO TO QUESTION 42) 
 
 YES 
 
 
41a. How often did you eat fresh tomatoes 
(including those in salads) WHEN IN 
SEASON? 
 
  NEVER  
  
 1–6 times per season  2 times per week 
 7–11 times per season  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
41b. How often did you eat fresh tomatoes 
(including those in salads) DURING THE 
REST OF THE YEAR? 
 
  NEVER  
  
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
41c. Each time you ate fresh tomatoes, how 
much did you usually eat? 
 
 Less than ¼ tomato 
 ¼ to ½ tomato 
 More than ½ tomato 
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42. How often did you eat lettuce salads (with or 
without other vegetables)? 
 
 NEVER (GO TO QUESTION 43) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
42a. Each time you ate lettuce salads, how much 
did you usually eat? 
 
 Less than ¼ cup 
 ¼ to 1¼  cups  
 More than 1¼  cups 
 
43. How often did you eat salad dressing (including 
low-fat) on salads? 
 
 NEVER (GO TO QUESTION 44) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
43a. Each time you ate salad dressing on salads, 
how much did you usually eat? 
 
 Less than 2 tablespoons 
 2 to 4 tablespoons 
 More than 4 tablespoons 
 
44. How often did you eat sweet potatoes or yams? 
 
 NEVER (GO TO QUESTION 45) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
44a. Each time you ate sweet potatoes or yams, 
how much did you usually eat? 
 
 1 small potato or less than ¼ cup 
 1 medium potato or ¼ to ¾ cup 
 1 large potato or more than ¾ cup 
 
 
45. How often did you eat French fries, home fries, 
hash browned potatoes, or tater tots? 
 
 NEVER (GO TO QUESTION 46) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
45a. Each time you ate French fries, home fries, 
hash browned potatoes, or tater tots how 
much did you usually eat? 
 
 Less than 10 fries or less than ½ cup 
 10 to 25 fries or ½ to 1 cup 
 More than 25 fries or more than 1 cup 
 
46. How often did you eat potato salad? 
 
 NEVER (GO TO QUESTION 47) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
46a. Each time you ate potato salad, how much 
did you usually eat? 
 
 Less than ½ cup 
 ½ to 1 cup 
 More than 1 cup 
 
47. How often did you eat baked, boiled, or mashed 
potatoes? 
 
 NEVER (GO TO QUESTION 48) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
47a. Each time you ate baked, boiled, or 
mashed potatoes, how much did you 
usually eat? 
 
 1 small potato or less than ½ cup 
 1 medium potato or ½ to 1 cup 
 1 large potato or more than 1 cup 
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47b. How often was sour cream (including low-
fat) added to your potatoes, EITHER IN 
COOKING OR AT THE TABLE? 
 
 Almost never or never (GO TO QUESTION 47d) 
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
47c. Each time sour cream was added to your 
potatoes, how much was usually added? 
 
 Less than 1 tablespoon 
 1 to 3 tablespoons 
 More than 3 tablespoons 
 
47d. How often was margarine (including low-fat) 
added to your potatoes, EITHER IN 
COOKING OR AT THE TABLE? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
47e. How often was butter (including low-fat) 
added to your potatoes, EITHER IN 
COOKING OR AT THE TABLE? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
47f. Each time margarine or butter was added to 
your potatoes, how much was usually 
added? 
 
 Never added 
 Less than 1 teaspoon 
 1 to 3 teaspoons 
 More than 3 teaspoons 
 
47g. How often was cheese or cheese sauce 
added to your potatoes, EITHER IN 
COOKING OR AT THE TABLE? 
 
 Almost never or never (GO TO QUESTION 48) 
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
47h. Each time cheese or cheese sauce was 
added to your potatoes, how much was 
usually added? 
 
 Less than 1 tablespoon 
 1 to 3 tablespoons 
 More than 3 tablespoons 
 
48. How often did you eat salsa? 
 
 NEVER (GO TO QUESTION 49) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
48a. Each time you ate salsa, how much did you 
usually eat? 
 
 Less than 1 tablespoon 
 1 to 5 tablespoons 
 More than 5 tablespoons 
 
49. How often did you eat catsup? 
 
 NEVER (GO TO QUESTION 50) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
49a. Each time you ate catsup, how much did you 
usually eat? 
 
 Less than 1 teaspoon 
 1 to 6 teaspoons 
 More than 6 teaspoons 
 
50. How often did you eat stuffing, dressing, or 
dumplings? 
 
 NEVER (GO TO QUESTION 51) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
50a. Each time you ate stuffing, dressing, or 
dumplings, how much did you usually eat? 
 
 Less than ½ cup 
 ½ to 1 cup 
 More than 1 cup 
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51. How often did you eat chili? 
 
 NEVER (GO TO QUESTION 52) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
51a. Each time you ate chili, how much did you 
usually eat? 
 
 Less than ½ cup 
 ½ to 1¾ cups 
 More than 1¾ cups 
 
52. How often did you eat Mexican foods (such as 
tacos, tostados, burritos, tamales, fajitas, 
enchiladas, quesadillas, and chimichangas)? 
 
 NEVER (GO TO QUESTION 53) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
52a. Each time you ate Mexican foods, how 
much did you usually eat? 
 
 Less than 1 taco, burrito, etc. 
 1 to 2 tacos, burritos, etc. 
 More than 2 tacos, burritos, etc. 
 
53. How often did you eat cooked dried beans 
(such as baked beans, pintos, kidney, blackeyed 
peas, lima, lentils, soybeans, or refried beans)?  
(Please don't include bean soups or chili.) 
 
 NEVER (GO TO QUESTION 54) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
53a. Each time you ate beans, how much did you 
usually eat? 
 
 Less than ½ cup 
 ½ to 1 cup 
 More than 1 cup 
 
 
53b. How often were the beans you ate refried 
beans, beans prepared with any type of 
fat, or with meat added? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
54. How often did you eat other kinds of 
vegetables? 
 
 NEVER (GO TO QUESTION 55) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
54a. Each time you ate other kinds of 
vegetables, how much did you usually eat? 
 
 Less than ¼ cup 
 ¼ to ½ cup 
 More than ½ cup 
 
55. How often did you eat rice or other cooked 
grains (such as bulgur, cracked wheat, or 
millet)? 
 
 NEVER (GO TO QUESTION 56) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
55a. Each time you ate rice or other cooked 
grains, how much did you usually eat? 
 
 Less than ½ cup 
 ½ to 1½  cups 
 More than 1½  cups 
 
55b. How often was butter, margarine, or oil 
added to your rice IN COOKING OR AT THE 
TABLE? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
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56. How often did you eat pancakes, waffles, or 
French toast? 
 
 NEVER (GO TO QUESTION 57) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
56a. Each time you ate pancakes, waffles, or 
French toast, how much did you usually 
eat? 
 
 Less than 1 medium piece 
 1 to 3 medium pieces 
 More than 3 medium pieces 
 
56b. How often was margarine (including low-fat) 
added to your pancakes, waffles, or French 
toast AFTER COOKING OR AT THE 
TABLE? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
56c. How often was butter (including low-fat) 
added to your pancakes, waffles, or French 
toast AFTER COOKING OR AT THE 
TABLE? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
56d. Each time margarine or butter was added to 
your pancakes, waffles, or French toast, how 
much was usually added? 
 
 Never added 
 Less than 1 teaspoon 
 1 to 3 teaspoons 
 More than 3 teaspoons 
 
56e. How often was syrup added to your 
pancakes, waffles, or French toast? 
 
 Almost never or never (GO TO QUESTION 57) 
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
56f. Each time syrup was added to your 
pancakes, waffles, or French toast, how 
much was usually added? 
 
 Less than 1 tablespoon 
 1 to 4 tablespoons 
 More than 4 tablespoons 
 
57. How often did you eat lasagna, stuffed shells, 
stuffed manicotti, ravioli, or tortellini?  (Please 
do not include spaghetti or other pasta.) 
 
 NEVER (GO TO QUESTION 58) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
57a. Each time you ate lasagna, stuffed shells, 
stuffed manicotti, ravioli, or tortellini, how 
much did you usually eat? 
 
 Less than 1 cup 
 1 to 2 cups 
 More than 2 cups 
 
58. How often did you eat macaroni and cheese? 
 
 NEVER (GO TO QUESTION 59) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
58a. Each time you ate macaroni and cheese, 
how much did you usually eat? 
 
 Less than 1 cup 
 1 to 1½  cups 
 More than 1½  cups 
 
59. How often did you eat pasta salad or macaroni 
salad? 
 
 NEVER (GO TO QUESTION 60) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
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59a. Each time you ate pasta salad or macaroni 
salad, how much did you usually eat? 
 
 Less than ½ cup 
 ½ to 1 cup 
 More than 1 cup 
 
60. Other than the pastas listed in Questions 57, 58, 
and 59, how often did you eat pasta, spaghetti, 
or other noodles? 
 
 NEVER (GO TO QUESTION 61) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
60a. Each time you ate pasta, spaghetti, or 
other noodles, how much did you usually 
eat? 
 
 Less than 1 cup 
 1 to 3 cups 
 More than 3 cups 
 
60b. How often did you eat your pasta, spaghetti, 
or other noodles with tomato sauce or 
spaghetti sauce made WITH meat? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
60c. How often did you eat your pasta, spaghetti, 
or other noodles with tomato sauce or 
spaghetti sauce made WITHOUT meat? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
60d. How often did you eat your pasta, spaghetti, 
or other noodles with margarine, butter, oil, 
or cream sauce? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
61. How often did you eat bagels or English 
muffins? 
 
 NEVER  (GO TO INTRODUCTION TO QUESTION 62) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
61a. Each time you ate bagels or English 
muffins, how many did you usually eat? 
 
 Less than 1 bagel or English muffin 
 1 bagel or English muffin 
 More than 1 bagel or English muffin 
 
61b. How often was margarine (including low-fat) 
added to your bagels or English muffins? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
61c. How often was butter (including low-fat) 
added to your bagels or English muffins? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
61d. Each time margarine or butter was added to 
your bagels or English muffins, how much 
was usually added? 
 
 Never added 
 Less than 1 teaspoon 
 1 to 2 teaspoons 
 More than 2 teaspoons 
 
61e. How often was cream cheese (including low-
fat) spread on your bagels or English 
muffins? 
 
 Almost never or never (GO TO INTRODUCTION 
TO QUESTION 62) 
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
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61f. Each time cream cheese was added to your 
bagels or English muffins, how much was 
usually added? 
 
 Less than 1 tablespoon 
 1 to 2 tablespoons 
 More than 2 tablespoons 
 
 
The next questions ask about your intake of 
breads other than bagels or English muffins.  First, 
we will ask about bread you ate as part of 
sandwiches only.  Then we will ask about all other 
bread you ate. 
 
62. How often did you eat breads or rolls AS PART 
OF SANDWICHES (including burger and hot dog 
rolls)? 
 
 NEVER (GO TO QUESTION 63) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
62a. Each time you ate breads or rolls AS PART 
OF SANDWICHES, how many did you 
usually eat? 
 
 1 slice or ½ roll 
 2 slices or 1 roll 
 More than 2 slices or more than 1 roll 
 
62b. How often were the breads or rolls that you 
used for your sandwiches white bread 
(including burger and hot dog rolls)? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
62c. How often was mayonnaise or 
mayonnaise-type dressing (including low-
fat) added to your sandwich bread or rolls? 
 
 Almost never or never (GO TO QUESTION 62e) 
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
 
62d. Each time mayonnaise or mayonnaise-type 
dressing was added to your sandwich 
breads or rolls, how much was usually 
added? 
 
 Less than 1 teaspoon 
 1 to 3 teaspoons 
 More than 3 teaspoons 
 
62e. How often was margarine (including low-fat) 
added to your sandwich bread or rolls? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
62f. How often was butter (including low-fat) 
added to your sandwich bread or rolls? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
62g. Each time margarine or butter was added to 
your sandwich breads or rolls, how much 
was usually added? 
 
 Never added 
 Less than 1 teaspoon 
 1 to 2 teaspoons 
 More than 2 teaspoons 
 
63. How often did you eat breads or dinner rolls, 
NOT AS PART OF SANDWICHES? 
 
 NEVER (GO TO QUESTION 64) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
63a. Each time you ate breads or dinner rolls, 
NOT AS PART OF SANDWICHES, how 
much did you usually eat? 
 
 1 slice or 1 dinner roll 
 2 slices or 2 dinner rolls 
 More than 2 slices or 2 dinner rolls 
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63b. How often were the breads or rolls you ate 
white bread? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
63c. How often was margarine (including low-fat) 
added to your breads or rolls? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
63d. How often was butter (including low-fat) 
added to your breads or rolls? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
63e. Each time margarine or butter was added to 
your breads or rolls, how much was usually 
added? 
 
 Never added 
 Less than 1 teaspoon 
 1 to 2 teaspoons 
 More than 2 teaspoons 
 
63f. How often was cream cheese (including low-
fat) added to your breads or rolls? 
 
 Almost never or never (GO TO QUESTION 64) 
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
63g. Each time cream cheese was added to your 
breads or rolls, how much was usually 
added? 
 
 Less than 1 tablespoon 
 1 to 2 tablespoons 
 More than 2 tablespoons 
 
                       
64. How often did you eat jam, jelly, or honey on 
bagels, muffins, bread, rolls, or crackers? 
 
 NEVER (GO TO QUESTION 65) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
64a. Each time you ate jam, jelly, or honey, how 
much did you usually eat? 
 
 Less than 1 teaspoon 
 1 to 3 teaspoons 
 More than 3 teaspoons 
 
65. How often did you eat peanut butter or other 
nut butter? 
 
 NEVER (GO TO QUESTION 66) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
 
65a. Each time you ate peanut butter or other 
nut butter, how much did you usually eat? 
 
 Less than 1 tablespoon 
 1 to 2 tablespoons 
 More than 2 tablespoons 
 
 
66. How often did you eat roast beef or steak IN 
SANDWICHES? 
 
 NEVER (GO TO QUESTION 67) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
66a. Each time you ate roast beef or steak IN 
SANDWICHES, how much did you usually 
eat? 
 
 Less than 1 slice or less than 2 ounces 
 1 to 2 slices or 2 to 4 ounces 
 More than 2 slices or more than 4 ounces 
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67. How often did you eat turkey or chicken COLD 
CUTS (such as loaf, luncheon meat, turkey ham, 
turkey salami, or turkey pastrami)?  (We will ask 
about other turkey or chicken later.) 
 
 NEVER (GO TO QUESTION 68) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
67a. Each time you ate turkey or chicken COLD 
CUTS, how much did you usually eat? 
 
 Less than 1 slice 
 1 to 3 slices  
 More than 3 slices  
 
 
68. How often did you eat luncheon or deli-style 
ham?  (We will ask about other ham later.) 
 
 NEVER (GO TO QUESTION 69) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
68a. Each time you ate luncheon or deli-style 
ham, how much did you usually eat? 
 
 Less than 1 slice  
 1 to 3 slices  
 More than 3 slices  
 
68b. How often was the luncheon or deli-style 
ham you ate light, low-fat, or fat-free? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
 
                      
69. How often did you eat other cold cuts or 
luncheon meats (such as bologna, salami, 
corned beef, pastrami, or others, including low-
fat)?  (Please do not include ham, turkey, or 
chicken cold cuts.) 
 
 NEVER (GO TO QUESTION 70) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
69a. Each time you ate other cold cuts or 
luncheon meats, how much did you usually 
eat? 
 
 Less than 1 slice 
 1 to 3 slices 
 More than 3 slices 
 
69b. How often were the other cold cuts or 
luncheon meats you ate light, low-fat, or fat-
free cold cuts or luncheon meats?  (Please 
do not include ham, turkey, or chicken cold 
cuts.)  
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
70. How often did you eat canned tuna (including in 
salads, sandwiches, or casseroles)? 
 
 NEVER (GO TO QUESTION 71) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
70a. Each time you ate canned tuna, how much 
did you usually eat? 
 
 Less than ¼ cup or less than 2 ounces 
 ¼ to ½ cup or 2 to 3 ounces 
 More than ½ cup or more than 3 ounces 
 
70b. How often was the canned tuna you ate 
water-packed tuna? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
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70c. How often was the canned tuna you ate 
prepared with mayonnaise or other 
dressing (including low-fat)? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
71. How often did you eat GROUND chicken or 
turkey?  (We will ask about other chicken and 
turkey later.) 
 
 NEVER (GO TO QUESTION 72) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
 
71a. Each time you ate GROUND chicken or 
turkey, how much did you usually eat? 
 
 Less than 2 ounces or less than ½ cup  
 2 to 4 ounces or ½ to 1 cup 
 More than 4 ounces or more than 1 cup 
 
72. How often did you eat beef hamburgers or 
cheeseburgers? 
 
 NEVER (GO TO QUESTION 73) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
72a. Each time you ate beef hamburgers or 
cheeseburgers, how much did you usually 
eat? 
 
 Less than 1 patty or less than 2 ounces 
 1 patty or 2 to 4 ounces 
 More than 1 patty or more than 4 ounces 
 
72b. How often were the beef hamburgers or 
cheeseburgers you ate made with lean 
ground beef? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
73. How often did you eat ground beef in mixtures 
(such as meatballs, casseroles, chili, or 
meatloaf)? 
 
 NEVER (GO TO QUESTION 74) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
73a. Each time you ate ground beef in mixtures, 
how much did you usually eat? 
 
 Less than 3 ounces or less than ½ cup  
 3 to 8 ounces or ½ to 1 cup  
 More than 8 ounces or more than 1 cup  
 
74. How often did you eat hot dogs or frankfurters?  
(Please do not include sausages or vegetarian 
hot dogs.) 
 
 NEVER (GO TO QUESTION 75) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
74a. Each time you ate hot dogs or frankfurters, 
how many did you usually eat? 
 
 Less than 1 hot dog 
 1 to 2 hot dogs 
 More than 2 hot dogs 
 
 
74b. How often were the hot dogs or frankfurters 
you ate light or low-fat hot dogs? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
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75. How often did you eat beef mixtures such as 
beef stew, beef pot pie, beef and noodles, or 
beef and vegetables? 
 
 NEVER (GO TO QUESTION 76) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
75a. Each time you ate beef stew, beef pot pie, 
beef and noodles, or beef and vegetables, 
how much did you usually eat? 
 
 Less than 1 cup 
 1 to 2 cups 
 More than 2 cups 
 
76. How often did you eat roast beef or pot roast?  
(Please do not include roast beef or pot roast in 
sandwiches.) 
 
 NEVER (GO TO QUESTION 77) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
76a. Each time you ate roast beef or pot roast 
(including in mixtures), how much did you 
usually eat? 
 
 Less than 2 ounces 
 2 to 5 ounces 
 More than 5 ounces  
 
77. How often did you eat steak (beef)?  (Do not 
include steak in sandwiches) 
 
 NEVER (GO TO QUESTION 78) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
77a. Each time you ate steak (beef), how much 
did you usually eat? 
 
 Less than 3 ounces 
 3 to 7 ounces 
 More than 7 ounces 
77b. How often was the steak you ate lean steak? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
78. How often did you eat pork or beef spareribs? 
 
 NEVER (GO TO QUESTION 79) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
78a. Each time you ate pork or beef spareribs, 
how much did you usually eat? 
 
 Less than 4 ribs 
 4 to 12 ribs 
 More than 12 ribs 
 
79. How often did you eat roast turkey, turkey 
cutlets, or turkey nuggets (including in 
sandwiches)? 
 
 NEVER (GO TO QUESTION 80) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
79a. Each time you ate roast turkey, turkey 
cutlets, or turkey nuggets, how much did 
you usually eat?  (Please note: 4 to 8 turkey 
nuggets = 3 ounces.) 
 
 Less than 2 ounces 
 2 to 4 ounces 
 More than 4 ounces 
 
80. How often did you eat chicken as part of salads, 
sandwiches, casseroles, stews, or other 
mixtures? 
 
 NEVER (GO TO QUESTION 81) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
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80a. Each time you ate chicken as part of salads, 
sandwiches, casseroles, stews, or other 
mixtures, how much did you usually eat? 
 
 Less than ½ cup 
 ½ to 1½  cups 
 More than 1½  cups 
 
81. How often did you eat baked, broiled, roasted, 
stewed, or fried chicken (including nuggets)?  
(Please do not include chicken in mixtures.) 
 
 NEVER (GO TO QUESTION 82) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
81a. Each time you ate baked, broiled, roasted, 
stewed, or fried chicken (including 
nuggets), how much did you usually eat? 
 
 Less than 2 drumsticks or wings, less than 
1 breast or thigh, or less than 4 nuggets 
 2 drumsticks or wings, 1 breast or thigh, or 4 to 
8 nuggets 
 More than 2 drumsticks or wings, more than 
1 breast or thigh, or more than 8 nuggets 
 
 
81b. How often was the chicken you ate fried 
chicken (including deep fried) or chicken 
nuggets? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
81c. How often was the chicken you ate WHITE 
meat? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
81d. How often did you eat chicken WITH skin? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
82. How often did you eat baked ham or ham 
steak? 
 
 NEVER (GO TO QUESTION 83) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
82a. Each time you ate baked ham or ham steak, 
how much did you usually eat? 
 
 Less than 1 ounce 
 1 to 3 ounces 
 More than 3 ounces 
 
83. How often did you eat pork (including chops, 
roasts, and in mixed dishes)?  (Please do not 
include ham, ham steak, or sausage.) 
 
 NEVER (GO TO QUESTION 84) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
83a. Each time you ate pork, how much did you 
usually eat? 
 
 Less than 2 ounces or less than 1 chop 
 2 to 5 ounces or 1 chop 
 More than 5 ounces or more than 1 chop 
 
84. How often did you eat gravy on meat, chicken, 
potatoes, rice, etc.? 
 
 NEVER (GO TO QUESTION 85) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
84a. Each time you ate gravy on meat, chicken, 
potatoes, rice, etc., how much did you 
usually eat? 
 
 Less than ⅛ cup 
 ⅛ to ½ cup 
 More than ½ cup 
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85. How often did you eat liver (all kinds) or 
liverwurst? 
 
 NEVER (GO TO QUESTION 86) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
85a. Each time you ate liver or liverwurst, how 
much did you usually eat? 
 
 Less than 1 ounce 
 1 to 4 ounces 
 More than 4 ounces 
 
86. How often did you eat bacon (including low-fat)? 
 
 NEVER (GO TO QUESTION 87) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
86a. Each time you ate bacon, how much did you 
usually eat? 
 
 Fewer than 2 slices 
 2 to 3 slices 
 More than 3 slices 
 
86b. How often was the bacon you ate light, low-
fat, or lean bacon? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
87. How often did you eat sausage (including low-
fat)? 
 
 NEVER (GO TO QUESTION 88) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
 
87a. Each time you ate sausage, how much did 
you usually eat? 
 
 Less than 1 patty or 2 links 
 1 to 3 patties or 2 to 5 links 
 More than 3 patties or 5 links 
 
87b. How often was the sausage you ate light, 
low-fat, or lean sausage? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
88. How often did you eat fish sticks or fried fish 
(including fried seafood or shellfish)? 
 
 NEVER (GO TO QUESTION 89) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
88a. Each time you ate fish sticks or fried fish, 
how much did you usually eat? 
 
 Less than 2 ounces or less than 1 fillet 
 2 to 7 ounces or 1 fillet 
 More than 7 ounces or more than 1 fillet 
 
89. How often did you eat fish or seafood that was 
NOT FRIED (including shellfish)? 
 
 NEVER (GO TO INTRODUCTION TO QUESTION 90) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
89a. Each time you ate eat fish or seafood that 
was NOT FRIED, how much did you usually 
eat? 
 
 Less than 2 ounces or less than 1 fillet 
 2 to 5 ounces or 1 fillet 
 More than 5 ounces or more than 1 fillet 
 
                       
Question 88 appears in the next column Introduction to Question 90 appears on the next page 
 
239 
Over the past 12 months… 
 
Now think about all the meat, poultry, and fish 
you ate in the past 12 months and how they were 
prepared. 
 
90. How often was oil, butter, margarine, or other 
fat used to FRY, SAUTE, BASTE, OR 
MARINATE any meat, poultry, or fish you ate?  
(Please do not include deep frying.) 
 
 NEVER (GO TO QUESTION 91) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
90a. Which of the following fats were regularly 
used to prepare your meat, poultry, or fish?  
(Mark all that apply.) 
 
 Margarine (including 
low-fat) 
 Corn oil 
 Canola or rapeseed oil 
 Butter (including 
low-fat) 
 Oil spray, such as Pam 
or others 
 Lard, fatback, or 
bacon fat 
 Other kinds of oils 
 None of the above 
 Olive oil  
 
91. How often did you eat tofu, soy burgers, or soy 
meat-substitutes? 
 
 NEVER (GO TO QUESTION 92) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
91a. Each time you ate tofu, soy burgers, or soy 
meat-substitutes, how much did you usually 
eat? 
 
  Less than ¼ cup or less than 2 ounces 
  ¼ to ½ cup or 2 to 4 ounces 
  More than ½ cup or more than 4 ounces 
 
92. Over the past 12 months, did you eat soups? 
 
 NO (GO TO QUESTION 93) 
 
 YES 
 
 
92a. How often did you eat soup DURING THE 
WINTER? 
 
 NEVER  
  
 1–6 times per winter  2 times per week 
 7–11 times per winter  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
92b. How often did you eat soup DURING THE 
REST OF THE YEAR? 
 
 NEVER  
  
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
92c. Each time you ate soup, how much did you 
usually eat? 
 
 Less than 1 cup 
 1 to 2 cups 
 More than 2 cups 
 
92d. How often were the soups you ate bean 
soups? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
92e. How often were the soups you ate cream 
soups (including chowders)? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
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92f. How often were the soups you ate tomato or 
vegetable soups? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
92g.  How often were the soups you ate broth 
soups (including chicken) with or without 
noodles or rice? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
93. How often did you eat pizza? 
 
 NEVER (GO TO QUESTION 94) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
93a. Each time you ate pizza, how much did you 
usually eat? 
 
 Less than 1 slice or less than 1 mini pizza 
 1 to 3 slices or 1 mini pizza 
 More than 3 slices or more than 1 mini pizza 
 
93b. How often did you eat pizza with pepperoni, 
sausage, or other meat?  
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
94. How often did you eat crackers? 
 
 NEVER (GO TO QUESTION 95) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
94a. Each time you ate crackers, how many did 
you usually eat? 
 
 Fewer than 4 crackers 
 4 to 10 crackers 
 More than 10 crackers 
 
95. How often did you eat corn bread or corn 
muffins? 
 
 NEVER (GO TO QUESTION 96) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
95a. Each time you ate corn bread or corn 
muffins, how much did you usually eat? 
 
 Less than 1 piece or muffin 
 1 to 2 pieces or muffins 
 More than 2 pieces or muffins 
 
96. How often did you eat biscuits? 
 
 NEVER (GO TO QUESTION 97) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
96a. Each time you ate biscuits, how many did 
you usually eat? 
 
 Fewer than 1 biscuit 
 1 to 2 biscuits 
 More than 2 biscuits 
 
97. How often did you eat potato chips, tortilla 
chips, or corn chips (including low-fat, fat-free, 
or low-salt)? 
 
 NEVER (GO TO QUESTION 98) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
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97a. Each time you ate potato chips, tortilla 
chips, or corn chips, how much did you 
usually eat? 
 
 Fewer than 10 chips or less than 1 cup 
 10 to 25 chips or 1 to 2 cups 
 More than 25 chips or more than 2 cups  
 
97b. How often were the chips you ate Wow 
chips or other chips made with fat 
substitute (Olean or Olestra)? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
97c. How often were the chips you ate other low-
fat or fat-free chips? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
98. How often did you eat popcorn (including low-
fat)? 
 
 NEVER (GO TO QUESTION 99) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
98a. Each time you ate popcorn, how much did 
you usually eat? 
 
 Less than 2 cups, popped 
 2 to 5 cups, popped 
 More than 5 cups, popped 
 
99. How often did you eat pretzels? 
 
 NEVER (GO TO QUESTION 100) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
99a. Each time you ate pretzels, how many did 
you usually eat? 
 
 Fewer than 5 average twists 
 5 to 20 average twists 
 More than 20 average twists 
 
100. How often did you eat peanuts, walnuts, 
seeds, or other nuts?  
 
 NEVER (GO TO QUESTION 101) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
100a. Each time you ate peanuts, walnuts, seeds, 
or other nuts, how much did you usually eat? 
 
 Less than ¼ cup 
 ¼ to ½ cup 
 More than ½ cup 
 
101. How often did you eat energy, high-protein, or 
breakfast bars such as Power Bars, Balance, 
Clif, or others? 
 
 NEVER (GO TO QUESTION 102) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
101a. Each time you ate energy, high-protein, or 
breakfast bars, how much did you usually 
eat? 
 
 Less than 1 bar  
 1 bar  
 More than 1 bar  
 
102. How often did you eat yogurt (NOT including 
frozen yogurt)? 
 
 NEVER (GO TO QUESTION 103) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
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102a. Each time you ate yogurt, how much did 
you usually eat? 
 
 Less than ½ cup or less than 1 container 
 ½ to 1 cup or 1 container 
 More than 1 cup or more than 1 container  
 
103. How often did you eat cottage cheese 
(including low-fat)? 
 
 NEVER (GO TO QUESTION 104) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
103a. Each time you ate cottage cheese, how 
much did you usually eat? 
 
 Less than ¼ cup 
 ¼ to 1 cup 
 More than 1 cup 
 
104. How often did you eat cheese (including low-fat; 
including on cheeseburgers or in sandwiches or 
subs)? 
 
 NEVER (GO TO QUESTION 105) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
104a. Each time you ate cheese, how much did 
you usually eat? 
 
 Less than ½ ounce or less than 1 slice 
 ½ to 1½  ounces or 1 slice 
 More than 1½  ounces or more than 1 slice 
 
104b. How often was the cheese you ate light or 
low-fat cheese? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
104c. How often was the cheese you ate fat-free 
cheese? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
 
105. How often did you eat frozen yogurt, sorbet, or 
ices  (including low-fat or fat-free)? 
 
 NEVER (GO TO QUESTION 106) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
 
105a. Each time you ate frozen yogurt, sorbet, or 
ices, how much did you usually eat? 
 
 Less than ½ cup or less than 1 scoop 
 ½ to 1 cup or 1 to 2 scoops 
 More than 1 cup or more than 2 scoops 
 
106. How often did you eat ice cream, ice cream 
bars, or sherbet (including low-fat or fat-free)? 
 
 NEVER (GO TO QUESTION 107) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
 
106a. Each time you ate ice cream, ice cream 
bars, or sherbet, how much did you usually 
eat? 
 
 Less than ½ cup or less than 1 scoop 
 ½ to 1½  cups or 1 to 2 scoops 
 More than 1½  cups or more than 2 scoops 
 
106b. How often was the ice cream you ate light, 
low-fat, or fat-free ice cream or sherbet? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
Question 105 appears in the next column Question 107 appears on the next page 
 
243 
Over the past 12 months… 
 
107. How often did you eat cake (including low-fat or 
fat-free)? 
 
 NEVER (GO TO QUESTION 108) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
107a. Each time you ate cake, how much did you 
usually eat? 
 
 Less than 1 medium piece 
 1 medium piece 
 More than 1 medium piece 
 
107b. How often was the cake you ate light, low-
fat, or fat-free cake? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
108. How often did you eat cookies or brownies 
(including low-fat or fat-free)? 
 
 NEVER (GO TO QUESTION 109) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
 
108a. Each time you ate cookies or brownies, 
how much did you usually eat? 
 
 Less than 2 cookies or 1 small brownie 
 2 to 4 cookies or 1 medium brownie 
 More than 4 cookies or 1 large brownie 
 
 
108b. How often were the cookies or brownies you 
ate light, low-fat, or fat-free cookies or 
brownies? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
109. How often did you eat doughnuts, sweet rolls, 
Danish, or pop-tarts?  
 
 NEVER (GO TO QUESTION 110) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
109a. Each time you ate doughnuts, sweet rolls, 
Danish, or pop-tarts, how much did you 
usually eat? 
 
 Less than 1 piece 
 1 to 2 pieces 
 More than 2 pieces 
 
110. How often did you eat sweet muffins or 
dessert breads (including low-fat or fat-free)? 
 
 NEVER (GO TO QUESTION 111) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
110a. Each time you ate sweet muffins or dessert 
breads, how much did you usually eat? 
 
 Less than 1 medium piece 
 1 medium piece 
 More than 1 medium piece 
 
 
110b. How often were the sweet muffins or 
dessert breads you ate light, low-fat, or fat-
free sweet muffins or dessert breads? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
111. How often did you eat fruit crisp, cobbler, or 
strudel? 
 
 NEVER (GO TO QUESTION 112) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
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111a. Each time you ate fruit crisp, cobbler, or 
strudel, how much did you usually eat? 
 
 Less than ½ cup 
 ½ to 1 cup 
 More than 1 cup 
 
112. How often did you eat pie?  
 
 NEVER (GO TO QUESTION 113) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
112a. Each time you ate pie, how much did you 
usually eat? 
 
 Less than  ⅛ of a pie 
 About ⅛ of a pie 
 More than ⅛ of a pie 
 
The next four questions ask about the kinds of 
pie you ate.  Please read all four questions 
before answering. 
 
112b. How often were the pies you ate fruit pie 
(such as apple, blueberry, others)? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
112c. How often were the pies you ate cream, 
pudding, custard, or meringue pie? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
112d. How often were the pies you ate pumpkin or 
sweet potato pie? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
 
112e. How often were the pies you ate pecan pie? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
113. How often did you eat chocolate candy?  
 
 NEVER (GO TO QUESTION 114) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
113a. Each time you ate chocolate candy, how 
much did you usually eat? 
 
 Less than 1 average bar or less than 1 ounce 
 1 average bar or 1 to 2 ounces 
 More than 1 average bar or more than 2 ounces 
 
114. How often did you eat other candy? 
 
 NEVER (GO TO QUESTION 115) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
 
114a. Each time you ate other candy, how much 
did you usually eat? 
 
 Fewer than 2 pieces 
 2 to 9 pieces 
 More than 9 pieces 
 
115. How often did you eat eggs, egg whites, or egg 
substitutes (NOT counting eggs in baked 
goods and desserts)?  (Please include eggs in 
salads, quiche, and soufflés.) 
 
 NEVER (GO TO QUESTION 116) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week   2 or more times per day 
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115a. Each time you ate eggs, how many did you 
usually eat? 
 
 1 egg 
 2 eggs 
 3 or more eggs 
 
115b. How often were the eggs you ate egg 
substitutes? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
115c. How often were the eggs you ate egg 
whites only? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
115d. How often were the eggs you ate regular 
whole eggs? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
 
115e. How often were the eggs you ate cooked in 
oil, butter, or margarine? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
115f.  How often were the eggs you ate part of 
egg salad? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
                      
116. How many cups of coffee, caffeinated or 
decaffeinated, did you drink? 
 
 NEVER (GO TO QUESTION 117) 
 
 Less than 1 cup per   5–6 cups per week 
month  1 cup per day 
 1–3 cups per month  2–3 cups per day 
 1 cup per week  4–5 cups per day 
 2–4 cups per week  6 or more cups per day 
 
116a. How often was the coffee you drank 
decaffeinated? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
117. How many glasses of ICED tea, caffeinated or 
decaffeinated, did you drink? 
 
 NEVER (GO TO QUESTION 118) 
 
 Less than 1 cup per   5–6 cups per week 
month  1 cup per day 
 1–3 cups per month  2–3 cups per day 
 1 cup per week  4–5 cups per day 
 2–4 cups per week  6 or more cups per day 
 
117a.  How often was the iced tea you drank 
decaffeinated or herbal tea? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
118. How many cups of HOT tea, caffeinated or 
decaffeinated, did you drink? 
 
 NEVER (GO TO QUESTION 119) 
 
 Less than 1 cup per   5–6 cups per week 
month  1 cup per day 
 1–3 cups per month  2–3 cups per day 
 1 cup per week  4–5 cups per day 
 2–4 cups per week  6 or more cups per day 
 
118a. How often was the hot tea you drank 
decaffeinated or herbal tea? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
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119. How often did you add sugar or honey to your 
coffee or tea? 
 
 NEVER (GO TO QUESTION 120) 
 
 Less than 1 time per   5–6 times per week 
month  1 time per day 
 1–3 times per month  2–3 times per day 
 1 time per week  4–5 times per day 
 2–4 times per week  6 or more times per day 
 
119a. Each time sugar or honey was added to 
your coffee or tea, how much was usually 
added? 
 
 Less than 1 teaspoon 
 1 to 3 teaspoons 
 More than 3 teaspoons 
 
120. How often did you add artificial sweetener to 
your coffee or tea? 
 
 NEVER (GO TO QUESTION 121) 
 
 Less than 1 time per  5–6 times per week 
month  1 time per day 
 1–3 times per month  2–3 times per day 
 1 time per week  4–5 times per day 
 2–4 times per week  6 or more times per day 
 
120a. What kind of artificial sweetener did you 
usually use? 
 
 Equal or aspartame 
 Sweet N Low or saccharin 
 
121. How often was non-dairy creamer added to 
your coffee or tea? 
 
 NEVER (GO TO QUESTION 122) 
 
 Less than 1 time per  5–6 times per week 
month  1 time per day 
 1–3 times per month  2–3 times per day 
 1 time per week  4–5 times per day 
 2–4 times per week  6 or more times per day 
 
121a. Each time non-dairy creamer was added to 
your coffee or tea, how much was usually 
used? 
 
 Less than 1 teaspoon 
 1 to 3 teaspoons 
 More than 3 teaspoons 
 
121b. What kind of non-dairy creamer did you 
usually use? 
 
 Regular powdered 
 Low-fat or fat-free powdered 
 Regular liquid 
 Low-fat or fat-free liquid 
 
122. How often was cream or half and half added to 
        your coffee or tea? 
 
 NEVER (GO TO QUESTION 123) 
 
 Less than 1 time per  5–6 times per week 
month  1 time per day 
 1–3 times per month  2–3 times per day 
 1 time per week  4–5 times per day 
 2–4 times per week  6 or more times per day 
 
122a. Each time cream or half and half was 
added to your coffee or tea, how much was 
usually added? 
 
 Less than 1 tablespoon 
 1 to 2 tablespoons 
 More than 2 tablespoons 
 
123. How often was milk added to your coffee or 
tea? 
 
 NEVER (GO TO QUESTION 124) 
 
 Less than 1 time per  5–6 times per week 
month  1 time per day 
 1–3 times per month  2–3 times per day 
 1 time per week  4–5 times per day 
 2–4 times per week  6 or more times per day 
 
123a. Each time milk was added to your coffee or 
tea, how much was usually added? 
 
 Less than 1 tablespoon 
 1 to 3 tablespoons 
 More than 3 tablespoons 
 
123b.  What kind of milk was usually added to your 
coffee or tea? 
 
 Whole milk 
 2% milk 
 1% milk 
 Skim, nonfat, or ½% milk 
 Evaporated or condensed (canned) milk 
 Soy milk 
 Rice milk 
 Other 
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124. How often was sugar or honey added to foods 
you ate?  (Please do not include sugar in coffee, 
tea, other beverages, or baked goods.) 
 
 NEVER (GO TO INTRODUCTION TO  
QUESTION 125) 
 
 1–6 times per year  2 times per week 
 7–11 times per year  3–4 times per week 
 1 time per month  5–6 times per week 
 2–3 times per month  1 time per day  
 1 time per week  2 or more times  
 per day 
 
124a. Each time sugar or honey was added to 
foods you ate, how much was usually 
added? 
 
 Less than 1 teaspoon 
 1 to 3 teaspoons 
 More than 3 teaspoons 
 
The following questions are about the kinds of 
margarine, mayonnaise, sour cream, cream 
cheese, and salad dressing that you eat.  If 
possible, please check the labels of these foods 
to help you answer. 
 
125. Over the past 12 months, did you eat 
margarine? 
 
 NO (GO TO QUESTION 126) 
 
 YES 
 
 
125a. How often was the margarine you ate 
regular-fat margarine (stick or tub)? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
125b. How often was the margarine you ate light 
or low-fat margarine (stick or tub)? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
 
125c. How often was the margarine you ate fat-
free margarine? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
126.  Over the past 12 months, did you eat butter? 
 
 NO (GO TO QUESTION 127) 
 
 YES 
 
 
126a. How often was the butter you ate light or 
low-fat butter? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
127. Over the past 12 months, did you eat 
mayonnaise or mayonnaise-type dressing? 
 
 NO (GO TO QUESTION 128) 
 
 YES 
 
 
127a. How often was the mayonnaise you ate 
regular-fat mayonnaise? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
127b. How often was the mayonnaise you ate light 
or low-fat mayonnaise? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
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127c. How often was the mayonnaise you ate fat-
free mayonnaise? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
128. Over the past 12 months, did you eat sour 
cream? 
 
 NO (GO TO QUESTION 129) 
 
 YES 
 
 
128a. How often was the sour cream you ate 
regular-fat sour cream? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
128b. How often was the sour cream you ate light, 
low-fat, or fat-free sour cream? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
129. Over the past 12 months, did you eat cream 
cheese? 
 
 NO (GO TO QUESTION 130) 
 
 YES 
 
 
129a. How often was the cream cheese you ate 
regular-fat cream cheese? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
129b. How often was the cream cheese you ate 
light, low-fat, or fat-free cream cheese? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
130. Over the past 12 months, did you eat salad 
dressing? 
 
 NO (GO TO INTRODUCTION TO QUESTION 131) 
 
 YES 
 
 
130a. How often was the salad dressing you ate 
regular-fat salad dressing (including oil 
and vinegar dressing)? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
130b. How often was the salad dressing you ate 
light or low-fat salad dressing? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
130c. How often was the salad dressing you ate 
fat-free salad dressing? 
 
 Almost never or never  
 About ¼ of the time 
 About ½ of the time 
 About ¾ of the time 
 Almost always or always 
 
The following two questions ask you to 
summarize your usual intake of vegetables and 
fruits.  Please do not include salads, potatoes, or 
juices. 
 
131. Over the past 12 months, how many servings of 
vegetables (not including salad or potatoes) did 
you eat per week or per day? 
 
 Less than 1 per week  2 per day 
 1–2 per week  3 per day 
 3–4 per week  4 per day 
 5–6 per week  5 or more per day 
 1 per day  
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132. Over the past 12 months, how many servings of 
fruit (not including juices) did you eat per week 
or per day? 
 
 Less than 1 per week  2 per day 
 1–2 per week  3 per day 
 3–4 per week  4 per day 
 5–6 per week  5 or more per day 
 1 per day  
 
133. Over the past month, which of the following 
foods did you eat AT LEAST THREE TIMES?  
(Mark all that apply.) 
 
 Avocado, guacamole  Olives 
 Cheesecake  Oysters 
 Chocolate, fudge, or  Pickles or pickled 
butterscotch toppings vegetables or fruit 
or syrups  Plantains 
 Chow mein noodles  Pork neckbones, hock, 
 Croissants head, feet 
 Dried apricots  Pudding or custard 
 Egg rolls  Veal, venison, lamb 
 Granola bars  Whipped cream, regular 
 Hot peppers  Whipped cream,  
 Jello, gelatin substitute 
 Milkshakes or   
ice-cream sodas  NONE 
 
134. For ALL of the past 12 months, have you 
followed any type of vegetarian diet? 
 
 NO (GO TO INTRODUCTION TO QUESTION 135) 
 
 YES 
 
 
134a. Which of the following foods did you 
TOTALLY EXCLUDE from your diet?  
(Mark all that apply.) 
 
 Meat (beef, pork, lamb, etc.) 
 Poultry (chicken, turkey, duck) 
 Fish and seafood 
 Eggs 
 Dairy products (milk, cheese, etc.) 
 
                     
The next questions are about your use of fiber 
supplements or vitamin pills. 
 
135. Over the past 12 months, did you take any of the 
following types of fiber or fiber supplements 
on a regular basis (more than once per week for 
at least 6 of the last 12 months)?   
 (Mark all that apply.) 
 
 NO, didn't take any fiber supplements on a regular 
basis (GO TO QUESTION 136) 
 YES, psyllium products (such as Metamucil, 
Fiberall, Serutan, Perdiem, Correctol) 
 YES, methylcellulose/cellulose products (such as 
Citrucel, Unifiber) 
 YES, Fibercon 
 YES, Bran (such as wheat bran, oat bran, or bran 
wafers) 
 
136. Over the past 12 months, did you take any 
multivitamins, such as One-a-Day-, Theragran-, 
or Centrum-type multivitamins (as pills, liquids, or 
packets)? 
 
 NO (GO TO INTRODUCTION TO QUESTION 138) 
 
 YES 
 
 
137. How often did you take One-a-day-, Theragran-, 
or Centrum-type multivitamins? 
 
 Less than 1 day per month 
 1–3 days per month 
 1–3 days per week 
 4–6 days per week 
 Every day 
 
137a. Does your multivitamin usually contain 
minerals (such as iron, zinc, etc.)? 
 
 NO 
 YES 
 Don't know 
 
137b. For how many years have you taken 
multivitamins? 
 
 Less than 1 year 
 1–4 years 
 5–9 years 
 10 or more years 
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137c. Over the past 12 months, did you take any 
vitamins, minerals, or other herbal 
supplements other than your multivitamin? 
 
 NO 
 
 
Thank you very much for completing this 
questionnaire!  Because we want to be able to 
use all the information you have provided, we 
would greatly appreciate it if you would please 
take a moment to review each page making sure 
that you: 
 
• Did not skip any pages and 
• Crossed out the incorrect answer and circled 
the correct answer if you made any changes. 
 
 YES (GO TO INTRODUCTION TO 
QUESTION 138) 
 
These last questions are about the vitamins, 
minerals, or herbal supplements you took that are 
NOT part of a One-a-day-, Theragran-, or 
Centrum-type of multivitamin. 
 
Please include vitamins taken as part of an 
antioxidant supplement. 
 
138. How often did you take Beta-carotene (NOT as 
part of a multivitamin in Question 137)? 
 
 NEVER (GO TO QUESTION 139) 
 
 Less than 1 day per month 
 1–3 days per month 
 1–3 days per week 
 4–6 days per week 
 Every day 
 
138a. When you took Beta-carotene, about how 
much did you take in one day? 
 
 Less than 10,000 IU 
 10,000–14,999 IU 
 15,000–19,999 IU 
 20,000–24,999 IU 
 25,000 IU or more 
 Don't know 
 
138b. For how many years have you taken Beta-
carotene? 
 
 Less than 1 year 
 1–4 years 
 5–9 years 
 10 or more years 
139. How often did you take Vitamin A (NOT as part 
of a multivitamin in Question 137)? 
 
 NEVER (GO TO QUESTION 140) 
 
 Less than 1 day per month 
 1–3 days per month 
 1–3 days per week 
 4–6 days per week 
 Every day 
 
139a.  When you took Vitamin A, about how much 
did you take in one day? 
 
 Less than 8,000 IU 
 8,000–9,999 IU 
 10,000–14,999 IU 
 15,000–24,999 IU 
 25,000 IU or more 
 Don't know 
 
139b. For how many years have you taken 
Vitamin A? 
 
 Less than 1 year 
 1–4 years 
 5–9 years 
 10 or more years 
 
140. How often did you take Vitamin C (NOT as part 
of a multivitamin in Question 137)? 
 
 NEVER (GO TO QUESTION 141) 
 
 Less than 1 day per month 
 1–3 days per month 
 1–3 days per week 
 4–6 days per week 
 Every day 
 
140a. When you took Vitamin C, about how much 
did you take in one day? 
 
 Less than 500 mg 
 500–999 mg 
 1,000–1,499 mg 
 1,500–1,999 mg 
 2,000 mg or more 
 Don't know 
 
140b. For how many years have you taken 
Vitamin C? 
 
 Less than 1 year 
 1–4 years 
 5–9 years 
 10 or more years 
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141. How often did you take Vitamin E (NOT as part 
of a multivitamin in Question 137)?  
 
 NEVER (GO TO QUESTION 142) 
 
 Less than 1 day per month 
 1–3 days per month 
 1–3 days per week 
 4–6 days per week 
 Every day 
 
141a.  When you took Vitamin E, about how much 
did you take in one day? 
 
 Less than 400 IU 
 400–799 IU 
 800–999 IU 
 1,000 IU or more 
 Don't know 
 
141b. For how many years have you taken 
Vitamin E? 
 
 Less than 1 year 
 1–4 years 
 5–9 years 
 10 or more years 
 
142. How often did you take Calcium or Calcium- 
containing antacids (NOT as part of a 
multivitamin in Question 137)?  
 
 NEVER (GO TO QUESTION 143) 
 
 Less than 1 day per month 
 1–3 days per month 
 1–3 days per week 
 4–6 days per week 
 Every day 
 
142a. When you took Calcium or Calcium- 
containing antacids, about how much 
elemental calcium did you take in one day? 
  (If possible, please check the label for 
elemental calcium.) 
 
 Less than 500 mg 
 500–599 mg 
 600–999 mg 
 1,000 mg or more 
 Don't know 
 
 
 
142b. For how many years have you taken 
Calcium or Calcium-containing antacids? 
 
 Less than 1 year 
 1–4 years 
 5–9 years 
 10 or more years 
 
The last two questions ask you about other 
supplements you took more than once per week. 
 
143. Please mark any of the following single 
supplements you took more than once per 
week (NOT as part of a multivitamin in Question 
137): 
 
 B-6 
 B-complex 
 Brewer's yeast 
 Cod liver oil 
 Coenzyme Q 
 Fish oil 
 (Omega-3 fatty acids) 
  Folic acid/folate 
  Glucosamine 
  Hydroxytryptophan (HTP) 
  Iron 
  Niacin 
  Selenium 
  Zinc 
 
144. Please mark any of the following herbal or 
botanical supplements you took more than 
once per week. 
 
 Aloe Vera 
 Astragalus 
 Bilberry 
 Cascara sagrada 
 Cat's claw 
 Cayenne 
 Cranberry 
 Dong Kuai (Tangkwei) 
 Echinacea 
 Evening primrose oil 
 Feverfew 
 Garlic 
 
  Ginger 
  Ginkgo biloba  
  Ginseng (American or 
Asian) 
  Goldenseal 
  Grapeseed extract 
  Kava, kava 
  Milk thistle 
  Saw palmetto 
  Siberian ginseng 
  St. John's wort 
  Valerian 
  Other 
 
 
Thank you very much for completing this 
questionnaire!  Because we want to be able to use 
all the information you have provided, we would 
greatly appreciate it if you would please take a 
moment to review each page making sure that you: 
 
• Did not skip any pages and 
• Crossed out the incorrect answer and circled the 
correct answer if you made any changes.
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Enrollment ID:    NCI Symptom and Toxicity Evaluation     Date: 
Criteria Pt 
response 
Grade 
0 
Grade 1 Grade 2 Grade 3 Grade 4 
Weight 
loss 
 None 
(<5%) 
5-<10% of baseline, 
intervention not 
indicated 
10-<20% of baseline; 
nutrition support 
indicated 
> 20% of baseline; TF or 
TPN indicated 
--- 
Nausea  None Able to eat 
reasonable intake 
Intake significantly 
decreased but can eat 
No significant intake ----- 
Vomiting  None 1 episode in 24 
hours over 
pretreatment 
2-5 episodes in 24 
hours; IV fluids 
indicated < 24 hrs 
≥ 6 episodes in 24 hours,  
IV fluids or TPN indicated 
> 24 hrs 
Life threatening 
consequences 
Heartburn  None  Mild  Moderate Severe - 
Urinary 
frequency/
urgency 
 None Increase in 
frequency or  
nocturia upto 2 x 
normal  
Increase in frequency 
or  nocturia more 
than 2 x normal but 
less frequent than 
every hr 
frequency of urination 
hourly or with more 
urgency, requiring catheter 
---- 
Diarrhea 
(patients 
without 
colostomy
) 
 None Increase of < 4 
stools/day over pre-
treatment 
Increase of 4 – 6 
stools/day or 
nocturnal stools  
Increase of ≥ 7 stools/day 
or incontinence; or need 
for parenteral support for 
dehydration  
Physiologic 
consequences 
requiring intensive 
care;or hemodynamic 
collapse 
Proctitis  
None 
increased stool 
frequency, 
occasional blood 
streaked stools or 
rectal discomfort 
(including 
hemorrhoids not 
requiring meds 
increased stool 
frequency, bleeding 
mucus discharge or 
rectal discomfort 
requiring medication; 
anal fissure 
increased stool 
frequency/diarrhea 
requiring parenteral 
support; rectal bleeding 
requiring transfusions or 
persistent mucus discharge, 
necessitating pads 
perforation, bleeding 
or necrosis or other 
life threatening 
complication 
requiring surgical 
intervention (eg 
colostomy) 
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Grade Patient 
response 
ECOG Criteria 
0  Fully active, able to carry on all pre-disease performance without 
restriction 
1  Restricted in physically strenuous activity but ambulatory and 
able to carry out work of a light or sedentary nature, e.g., light 
house work, office work 
2  Ambulatory and capable of all selfcare but unable to carry out any 
work activities. Up and about more than 50% of waking hours 
3  Capable of only limited selfcare, confined to bed or chair more 
than 50% of waking hours 
4  Completely disabled. Cannot carry on any selfcare. Totally 
confined to bed or chair 
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Tomato Juice study participant evaluation 
 
Please tell us why you chose to participate in this study (please select all 
that apply). 
 Liked the idea of tomato juice helping with radiation therapy side 
effects 
 Wanted to participate in a research study 
 Wanted to help student research 
 Other (please specify)______________________________________ 
________________________________________________________ 
________________________________________________________ 
 
Are you glad you participated in this study? (Please select only one 
response). 
 Yes 
 Maybe, not sure 
 No (please elaborate why not________________________________) 
 
 
Based on your experience participating in this study, what changes (if any) 
would you recommend the researchers make to improve participation in this 
study for other men with prostate cancer undergoing radiation therapy? 
 No changes 
 Recommend the following changes 
a. ___________________________________________________ 
b. ___________________________________________________ 
c. ___________________________________________________ 
 
Thank you for your valuable participation in this research 
study. 
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APPENDIX L.  SUPPLEMENTAL FIGURES 
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Figure 1. Serum lycopene levels at baseline among study [participants based on Gleason sum. 
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Figure 2. Serum log c-reactive protein levels at baseline based on Gleason Sum 
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Figure 3. Serum log c-reactive protein levels among study groups at three time points. 
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Figure 4. Serum interleukin-6 levels at baseline based on Gleason Sum 
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Figure 5. Serum Interleukin-6 levels among study groups at three time points. 
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Figure 6. Serum prostaglandin E2 levels at baseline based on Gleason Sum 
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Figure 7. Serum prostaglandin E2 levels among study groups at three time points. 
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Figure 8. Scatter plot of serum lycopene plotted against total lycopene intake 
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Figure 9. Scatter plot of serum lycopene plotted against total lycopene intake 
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Figure 10. Scatter plot of serum CRP log transformed plotted against serum interleukin-6 
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Figure 11. Weight change during treatment in control and all treatment groups 
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Figure 12. Weight change during treatment in all groups 
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Figure 13. ECOG score incidence during treatment in all groups 
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Figure 14. ECOG scores during treatment in all groups 
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Figure 15. Urinary frequency during treatment in control and all treatment groups  
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Figure 16. Urinary frequency incidence during treatment in all groups 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
wk1 wk2 wk3 wk4 wk5* wk6 wk7
Sc
or
e
0 4 8 12
*P=0.039
+P=0.059
#P=0.089
*+#
+
*
#
 
273 
 
Figure 17. Urinary urgency during treatment in control and all treatment groups 
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Figure 18. Urinary urgency incidence during treatment in all groups 
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Figure 19. Diarrhea incidence during treatment in control and all treatment groups 
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Figure 20. Diarrhea incidence during treatment in all groups 
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Figure 21. Proctitis incidence during treatment in control and all treatment groups 
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Figure 22. Proctitis incidence during treatment in all groups 
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